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Abstract 
Over 200,000 cases of breast cancer are diagnosed every year. Nearly 20% of 
these patients supplement their diets with some form of vitamin D. This high frequency of 
vitamin D supplement use may be due in part to research suggesting that cancer patients 
with higher serum vitamin D3 levels have better prognoses than patients with low serum 
vitamin D3. However, double-blind clinical trials on the efficacy of vitamin D3 
supplementation in breast cancer have been inconclusive. A recent meta-analysis 
showed evidence of reduced cancer recurrence in patients taking vitamin D3 supplements 
who had ‘estrogen receptor positive’ (ERα66+) breast cancer, but not those who had 
estrogen receptor negative’ (ERα66-) breast cancer.  
Once ingested, vitamin D3 is metabolized in the liver into the circulating pre-
hormone 25(OH)D3, which is then further metabolized into 1,25(OH)2D3 and 
24R,25(OH)2D3. 24R,25(OH)2D3 has been shown to activate a number of membrane 
signaling pathways, some of which overlap with 17-estradiol (E2) signaling through 
ERα36, a membrane isoform of ERα66. The central hypothesis of this thesis was that 
24R,25(OH)2D3 is tumorigenic in certain cancers and that this tumorigenicity is mediated 
in part by ER isoforms. 
E2 signaling through ER36 has been described in the ER66-, ER36+ breast 
cancer cell line HCC381. Specific aim 1 determined whether E2 signaling through ER36 
was tumorigenic other cancers with different ER profiles. Specific aim 2 determined 
how 24R,25(OH)2D3 affected tumorigenicity in breast cancer using the common breast 
cancer cell line MCF7 (ER66+, ER36+) as a model. Specific aim 3 investigated the 
role of ER isoforms in 24R,25(OH)2D3 signaling in breast cancer cell lines by comparing 
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the tumorigenic effects of 24R,25(OH)2D3 in MCF7 cells (ER66+, ER36+) and HCC38 
cells (ER66-, ER36+). To determine whether ER66 regulates the effects of 
24R,25(OH)2D3, ER66 was expressed in two ERα66- cell lines. The effect of 
24R,25(OH)2D3 on apoptosis was assessed in wild-type and ER-expressing cell lines.  
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Chapter 1.  
Introduction 
Nearly 1 in 8 women will be diagnosed with breast cancer in her lifetime2. 
Approximately 20% of these women will supplement their diets with some form of vitamin 
D3,4. This high frequency of vitamin D3 supplement use may be due in part to reports that 
suggest that cancer patients with higher serum 25-hydroxyvitamin D3 (25(OH)D3) levels 
have better prognoses and increased survival rates than patients with low 25(OH)D35. 
However, double-blind clinical trials and some pre-clinical studies investigating the 
efficacy of vitamin D3 supplementation on cancer patient outcomes have been 
inconclusive, and recent large-scale studies do not show any correlation between vitamin 
D3 supplement use and cancer incidence6,7. One reason for this may be that most double-
blind clinical trials do not account for the heterogeneous nature of breast cancer in their 
analyses. A recent meta-analysis of vitamin D3 serum levels in breast cancer patients 
showed that elevated serum vitamin D3 is associated 
with a reduced risk of tumor recurrence in patients with 
‘estrogen receptor positive’ (ER+) disease, but did not 
show a similar association between vitamin D3 status 
and cancer recurrence in patients with ‘estrogen 
receptor negative’ (ER-) tumors8 (Figure 1.1). This 
suggests that estrogen receptor status may be a factor 
in the efficacy of vitamin D supplementation in cancer. 
Breast cancer is a multifaceted, heterogeneous 
disease with numerous molecular subtypes that 
Figure 1.1 Effect of vitamin D 
supplementation on breast 
cancer recurrence in ER- and 
ER+ breast cancer.7 
*indicates significance against 
a no-treatment control (-- line, 
hazard ratio of 1). 
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influence disease severity. These molecular subtypes can be demarcated by the 
expression of hormone receptors, such as the estrogen receptor. Estrogen receptor 
status is a discrete identification paradigm that allows clinicians to divide patients into 
meaningful groups for personalized treatment regimens. Patients with ER+ tumors  
generally have better outcomes than patients with ER- tumors9. This is in part because 
ER+ breast cancer responds favorably to treatment with anti-estrogen drugs10. However, 
the mechanisms governing the more aggressive pathology of ER- tumors compared to 
their less aggressive ER+ counterparts have not been fully elucidated.  
One reason for this may lie in the intrinsically misleading histological classifications 
assigned to ‘ER+’ and ‘ER-’ tumors. In actuality, ER+ and ER- tumor classification denote 
the intra-tumoral expression of only one estrogen receptor – the transcriptionally active 
steroid hormone receptor ER66. Both ER+ and ER- tumors express many other 
estrogen receptors, such as the membrane receptor ER36, an isoform of ER66; 
estrogen receptor  (ER), another transcriptionally active ER11; and G-protein coupled 
receptor 30 (GPR30), a membrane estrogen receptor12.  
Another reason for different serum vitamin D3 levels in ER+ vs. ER- patients may 
be because serum vitamin D3 is actually a measure of 25(OH)D3, which is in itself a 
precursor to the active steroid hormone metabolites 1,25(OH)2D3 and 24R,25(OH)2D3. 
Once ingested, vitamin D3 is metabolized in the liver into the circulating pre-hormone 
25(OH)D3, which is then further metabolized into 1,25(OH)2D3 and 24R,25(OH)2D313. 
Research has shown that 1,25(OH)2D3 has anti-tumorigenic effects in certain cancers, 
including both ER+ and ER- breast cancer14. However, little has been done to study the 
effects of 24R,25(OH)2D3 on cancer tumorigenicity.  
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The effect of 24R,25(OH)2D3 on ER+ vs. ER- breast cancer tumorigenicity is 
particularly interesting because 24R,25(OH)2D3 has been shown to activate a number of 
membrane signaling pathways, some of which overlap with 17-estradiol (E2) signaling 
through the membrane receptor ER36. In chondrocytes, 24R,25(OH)2D3 has been 
shown to rapidly increase the activity of phospholipase-D2 (PLD2)15 and subsequently 
activate protein kinase C (PKC)16. Studies with 24S,25(OH)2D3, the enantiomer of 
24R,25(OH)2D3, have shown that this rapid pathway is unique to the 24R,25(OH)2D3 
metabolite 17. Downstream of PKC, 24R,25(OH)2D3 promotes p53 ubiquitination and 
subsequent degradation, reduces the ratio of B cell lymphoma protein 2-associated X 
protein to B cell lymphoma protein 2 (BAX/BCL2), inhibits cytochrome C translocation, 
and blocks caspase-3 cleavage to prevent apoptosis18.  
The receptor that mediates the actions of 24R,25(OH)2D3 has not yet been 
definitively identified. However, three candidate receptors have been suggested: a 
membrane isoform of the vitamin D receptor (mVDR), which binds 24R,25(OH)2D3 and 
can be isolated from tibial chick fracture calluses19,20; catalase-1, an enzyme isolated from 
chick intestine cell membranes which binds 24R,25(OH)2D321; and family 57 b2 
(FAM47B2), a transmembrane protein in articular cartilage cells which synthesizes 
ceramide sphingolipids in cartilage and binds 24,25(OH)2D3 with a higher affinity than 
1,25(OH)2D322. All three of these receptors candidates are associated with membrane-
signaling complexes. This, coupled with the 24R,25(OH)2D3 pathway, suggests that 
24R,25(OH)2D3 is modulated by a membrane-associated protein signaling complex23. 
Many estrogen receptors act through membrane-associated pathways. GPR30, 
for example, is a G-protein coupled receptor (GPCR) estrogen receptor which signals 
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through the epidermal growth factor receptor (EGFR) to activate the phosphoinositol-3-
kinase (PI3K) pathway. Downstream of PI3K, GPR30 signaling prevents apoptosis and 
enhances metastasis 24. Similarly, ERβ has been described as a potent estrogen receptor 
with a high affinity for 17β-estradiol (E2). However, ERβ has primarily been described as 
a classical genomic nuclear receptor25 rather than a membrane receptor. It does have 
some extra-nuclear activity26, but this extra-nuclear activity has been most well-described 
in the mitochondria and cytoplasm or in conjunction with other estrogen receptors such 
as GPR30 at the membrane12. 
The membrane isoform of ERα (ERα36), on the other hand, has been shown to 
signal at the membrane through the second messengers PKC and PLD. Our lab has 
shown that in both ER+ and ER- cancers, rapid E2 signaling through ERα36 activates 
PKC, which subsequently activates PLD. This is a similar pathway to that described by 
24R,25(OH)2D3 in chondrocytes. However, as stated above, 24R,25(OH)2D3 activates 
PLD, then PKC; while the E2-ERα36 signaling cascade activates PKC before PLD. The 
similarity in these two pathways suggests crosstalk between the 24R,25(OH)2D3 pathway 
and E2-ERα36 pathway may be partially regulating the effects of 24R,25(OH)2D3 on ER+ 
and ER- breast cancer. 
It is important to note that while our work has shown that the rapid effects of E2 on 
PKC at the membrane are the result of ERα36 signaling, other labs have shown that 
ERα46 and ERα66, the nuclear and cytosolic classic isoforms of ERα, can be trafficked 
to the membrane via palmitoylation. Once at the membrane, signaling by E2-ERα66 may 
mimic E2-ERα36 signaling. Therefore, it is necessary to investigate both the ERα36 and 
ERα66 isoforms for the possibility of crosstalk between 24R,25(OH)2D3, and membrane-
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ERα signaling. The parallel mechanisms and potential crosstalk between the signaling 
mechanisms of 24R,25(OH)2D3 and ERα36 led us to investigate the role of 
24R,25(OH)2D3 in breast cancer. 
Our lab has shown that in both ER+ and ER- breast cancer, E2 binds to ER36 
and activates PKC-PLD mediated signaling pathways at the membrane that act 
downstream to prevent apoptosis and promote proliferation27. In chondrocytes, 
24R,25(OH)2D3 binds to a membrane receptor to initiate a similar signaling cascade that 
prevents apoptosis18. The overall goal of this thesis was to determine the effect of 
24R,25(OH)2D3 on tumorigenicity in breast cancer, and to determine whether those 
effects were modulated by ER isoforms. 
E2 signaling through ER36 has been described in the ER66-, ER36+ breast 
cancer cell line HCC381. Specific aim 1 determined whether E2 signaling through ER36 
was tumorigenic in other cancers that have different ER profiles. The tumorigenicity of 
E2 was assessed in two laryngeal squamous cell carcinoma (LSCC) cell lines with 
different ER isoform expression. Cancer stage and metastasis was correlated with ER 
isoform expression in primary LSCC tumor samples and matched normal controls to 
assess correlations between ER isoform expression and tumor aggression. 
Specific aim 2 determined how 24R,25(OH)2D3 affected tumorigenicity in breast 
cancer using the common breast cancer cell line MCF7 (ER66+, ER36+) as a model. 
The tumorigenicity of 24R,25(OH)2D3 was assessed in vitro by examining DNA synthesis 
and markers for apoptosis, epithelial-to-mesenchymal transition and metastasis, and in 
vivo in a xenograft mammary fat pad murine tumor model. The mechanism of 
24R,25(OH)2D3 signaling in MCF7 (ER66+, ER36+) was identified using chemical and 
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antibody inhibitors. Specific aim 3 investigated the role of ER isoforms in 
24R,25(OH)2D3 signaling in breast cancer cell lines by comparing the tumorigenic effects 
of 24R,25(OH)2D3 in two breast cancer cells: MCF7 (ER66+, ER36+) and HCC38 
(ER66-, ER36+). Tumorigenicity was assessed in vivo and in vitro, and the mechanism 
of 24R,25(OH)2D3 signaling in HCC38 (ER66-, ER36+) was elucidated using chemical 
and antibody inhibitors and enzyme activity assays. To determine which isoform of ER 
regulates the effects of 24R,25(OH)2D3 on apoptosis ER66 was overexpressed in 
HCC38 (ER66-, ER36+). To investigate whether ER66 was only tumorigenic in breast 
cancer cell lines, ER was overexpressed in an unrelated cell line, C2C12 (ER66-, 
ER36+). The effect of 24R,25(OH)2D3 on apoptosis was assessed in wild-type and ER-
overexpressed cell lines. The central hypothesis of these aims was that 24R,25(OH)2D3 
is tumorigenic in certain cancers and that this tumorigenicity is mediated in part by ER 
isoforms. 
 
Specific Aim 1: Determine the estrogen receptor profile and estrogen 
responsiveness in laryngeal cancer and clinical outcomes. 
There is growing evidence that laryngeal squamous cell carcinomas (LSCC) are 
responsive to sex hormones, specifically 17β-estradiol (E2), despite the controversy 
regarding the presence and characterization of E2 receptors (ER). Determination of sex 
hormone responsiveness impacts the prognosis of LSCC patients and the treatment 
modalities implemented by their clinicians. Discovery of membrane-associated steroid 
hormone receptors and rapid membrane signaling opened the possibility that cancers 
previously labeled ‘non-hormone dependent,’ and ‘ER negative’ might be susceptible to 
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the effects of E2 via these membrane receptors. The objective of this aim was to show 
that the expression of different membrane ERs in LSCC is not uniform, which may result 
in differential and antagonistic responses to E2. This aim hypothesized that E2 signaling 
through ER36 was tumorigenic, and that primary LSCC aggression was proportional to 
ER36 and inversely proportional to ER66 expression.  
  ER isoform expression was characterized in LSCC cell lines and primary clinical 
samples. Tumorigenicity of E2 in LSCC was assessed by examining the effects of E2 on 
proliferation and apoptosis in vitro and tumor burden in a mouse xenograft model in vivo. 
A possible E2 signaling mechanism was determined by using chemical signaling inhibitors 
and an ER36-blocking antibody. Associations between ERα expression and LSCC 
aggression were confirmed using data from the Total Cancer Genome Atlas. 
 
Specific Aim 2: Determine if 24R,25-Dihydroxyvitamin D3 regulates breast cancer 
cells in vitro and in vivo. 
Epidemiological studies indicate that high serum 25-hydroxyvitamin D3 [25(OH)D3] 
is associated with improved prognosis and survival in some breast cancer patients. Pre-
clinical studies attributed this to the anti-tumorigenic properties of its steroid hormone 
metabolite 1α,25(OH)2D3. However, 1,25(OH)2D3 is highly calcemic and thus has a 
narrow therapeutic window. Here we investigate the effects of another steroid hormone 
metabolites of 25(OH)2D3, 24R,25(OH)2D3, as an alternative non-calcemic vitamin D3 
supplement. The objective of this aim was to assess the effect of 24R,25(OH)2D3, a steroid 
hormone metabolite of vitamin D3, on tumorigenic markers in the MCF7 (ER66+, 
ER36+), an ER66+, ER36+ breast cancer cell line. We hypothesized that 
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24R,25(OH)2D3 would be anti-tumorigenic in MCF7 and that a rapid membrane-
associated mechanism would stimulate this effect. 
NOD-SCID-IL2R null female mice with MCF7 xenografts in the mammary fat pad 
were treated with 24R,25(OH)2D3 and changes in tumor burden and metastases were 
assessed in vivo. Breast cancer cell lines were treated in vitro with 24R,25(OH)2D3 to 
determine its effects on proliferation, apoptosis, migration, and metastatic markers. A 
possible 24R,25(OH)2D3 signaling mechanism was determined by using chemical 
signaling inhibitors and an ER36-blocking antibody to determine the dependence of ER  
isoforms on 24R,25(OH)2D3 signaling.   
 
Specific Aim 3: Determine if 24R,25(OH)2D3 differentially regulates tumorigenicity 
in estrogen receptor  dependent manner. 
Our lab has identified an understudied metabolite of vitamin D3, 24R,25(OH)2D3, 
which has anti-tumorigenic effects in the ER66+, ER36- breast cancer cell line MCF7. 
However, preliminary evidence suggests that ER66 and ER36 may modulate the anti-
tumorigenic effects of 24R,25(OH)2D3. The objective of this aim was to evaluate the effect 
of 24R,25(OH)2D3 in the breast cancer cell line HCC38  (ER66-, ER36+)  and 
determine the role of ER66 and ER36 on 24R,25(OH)2D3 tumorigenicity. We 
hypothesized that 24R,25(OH)2D3 would be pro-tumorigenic in HCC38 and that this effect 
would be modulated by ER66. 
NOD-SCID-IL2R null female mice with HCC38 xenografts in the mammary fat pad 
were treated with 24R,25(OH)2D3 and changes in tumor burden were assessed in vivo. 
Breast cancer cell lines were treated in vitro with 24R,25(OH)2D3 to determine its effects 
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on proliferation, apoptosis, migration, and metastatic markers. A possible 24R,25(OH)2D3 
signaling mechanism was determined by enzymatic activity assays and by using chemical 
signaling inhibitors and an ER36-blocking antibody to determine the dependence of ER  
isoforms on 24R,25(OH)2D3 signaling. To determine which isoform of ER regulates the 
effects of 24R,25(OH)2D3 on apoptosis ER66 was overexpressed in the ER66-negative 
HCC38. To investigate whether ER66 was only tumorigenic in breast cancer cell lines 
ER was also overexpressed in an unrelated cell line, C2C12. The effect of 
24R,25(OH)2D3 on apoptosis was assessed in wild-type and ER-overexpressed cell 
lines.  
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Chapter 2.  
Background and Literature Review 
Steroid hormones mediate a wide variety of vital developmental and physiological 
functions in different organs, such as the reproductive system, bone, brain, and fat 
differentiation and metabolism. When steroid hormones are deficient or abnormal, they 
have deleterious effects such as promoting the development and progression of 
hormone-responsive cancers28. Traditionally, steroid hormones signal by binding to 
receptors in the cytosol followed by either homodimerization or heterodimerization to form 
a complex, which is then translocated to the nucleus. In the nucleus, the complex 
functions as a transcription factor by binding to either specific response elements or to 
transcription initiation complexes on the DNA to either activating or repressing 
transcription29. 
This process occurs in a matter of hours to days30,31. In contrast, it is now well-
accepted that most steroid hormones induce a non-nuclear rapid signaling response that 
occurs in seconds to minutes, which is not delayed by inhibition of transcription or 
translation31–35. The signaling response is a result of steroid hormones binding to specific 
extra-nuclear receptors, which mainly reside in the cell membrane, particularly the 
caveolae. When activated, these receptors trigger signaling cascades that involve 
kinases, phospholipases, calcium flux, and other secondary messengers36,37. 
 
Nature of steroid-hormone membrane receptors  
Rapid signaling is mediated through receptors that reside in the cell membrane. 
Many of these receptors act as G protein-coupled receptors upon ligation, leading to 
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signaling cascades that regulate existing protein function and downstream gene 
expression 34,38. The nature of these receptors is a matter of controversy. Some have 
advocated that they are the traditional receptors residing in the cell membrane, 
particularly concerning receptors for estrogen, progesterone, androgen, and 
glucocorticoids, and the vitamin D receptor39–42.  Others have suggested that they are 
truncated isoforms of traditional nuclear membrane receptors43. For example, the well-
described membrane estrogen receptor ERα36 is a truncated isoform of the canonical 
estrogen receptor ERα66. However, others have identified novel orphan receptors that 
also mediate rapid membrane signaling44–47.  
 
Classical nuclear receptor trafficking 
Nuclear receptors for sex hormones have been found in the plasma membranes 
of hormone-responsive cancers where they activate rapid signaling pathways that 
enhance cancer cell survival and proliferation 27,48.  It is thought that the classical 
receptors exert their effects through transactivation of the epidermal-like growth factor 
(EGF) or insulin-like growth factor-1 (IGF-1) tyrosine kinase receptors to stimulate kinase 
cascades. Another theory suggests that classical receptors signal through collaboration 
with G-protein coupled receptors47,49,50.  
Trafficking of the classical receptors to the plasma membrane occurs through 
palmitoylation,35,51 which involves the attachment of palmitic acid to an internal cysteine 
residue. Palmitoylation promotes the association of the receptor with caveolin-1, a 
transporter protein, to caveolae rafts in the plasma membrane52. Palmitoylation occurs in 
a nine amino acid motif, which includes the cysteine palmitoylation site. This 
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palmitoylation motif is highly conserved in estrogen receptor (ER) isoforms α and β, 
progesterone receptor (PR) and androgen receptor (AR)35,40. Once the receptor is 
associated with the caveolae, it may interact with many signaling proteins associated with 
the caveolae rafts and activate various Gα and Gβ/γ proteins within seconds53,54.  
 
Estrogen Receptor α and its isoforms 
In the last ten years, several isoforms of ERα have come to light 43. The most widely 
studied of these alternative receptors are ERα46 and ERα36, a membrane-bound variant 
of the classical ERα, ERα66. Both ERα46 and ERα36 arise from alternative splicing of 
the ESR1 gene 42, with ERα36 including a novel exon of the gene, exon 9 42. ERα36 has 
been identified in many breast cancer cell lines that were previously characterized as ERα 
negative 1, such as HCC38 and MDA-MB-231 55. In breast cancer, the presence of ERα36 
has been associated with increased aggression and metastasis in vitro, in vivo, and in 
situ 56,57. In one study, a continuum of ERα66/ERα36 positive/negative cell line-derived 
xenografts was examined in vivo. ERα66+, ERα36- tumors found to be the least 
aggressive, ERα66+, ERα36+ slightly more aggressive, ERα66-, ERα36- second-most 
aggressive, and ERα66-, ERα36+ tumors the most aggressive of all four phenotypes. 
This suggests that the relative levels of ERα66 and ERα36 within a tumor are more 
important modulators of breast cancer aggression than the presence of each receptor 
individually. However, it should be noted that this study did not examine levels of ERα46, 
which could have further modulated tumor aggression. ERα46 has been found in some 
breast cancer cell lines, but little is known about its function as an estrogen receptor 
independent of ERα66 and ERα36 27,58.  
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In a sampling of breast cancer cells, MCF7, which is widely regarded as a less-aggressive 
breast cancer cell line 59, was found to have high levels of ERα66+, low levels of ERα46, 
and moderate levels of ERα36 (Figure 2.1). HCC38, a moderately aggressive breast 
cancer cell line 1, had no ERα66, moderate levels of ERα46, and moderate levels of 
ERα36 (Figure 2.1). MDA-MB-231, an aggressively metastatic breast cancer cell line 60, 
had no ERα66, high levels of ERα46, and moderate levels of ERα36 (Figure 2.1). It is not 
clear which of these isoforms or what combination of isoforms determines the relative 
levels of aggression or metastatic potential of each cell line; however, it is crucial to take 
the expression of each of the ERα isoforms into account when classifying them as ‘ER 
positive’ or ‘ER negative.’  
 
 
 
 
 
Figure 2.1 Western blot data of ERα isoforms in breast cancer cells. 
[A] ERα66, [B] ERα46, and [C] ERα36 normalized to GAPDH and expressed as mean 
normalized signal intensity ± standard error in MCF7, HCC38, and MDA-MB-231 breast 
cancer cell lines61.  
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Estrogen and estrogen receptors in laryngeal cancer 
Although the importance of estrogen and estrogen receptor signaling has been 
well-established in breast cancer, estrogen signaling is also important in other hormonally 
responsive cancers. The larynx is a secondary sex organ that undergoes trophic changes 
in response to hormonal shifts during puberty, the role of steroid hormones and steroid 
hormone receptors in laryngeal squamous cell carcinoma (LSCC) has been understudied. 
Researchers first began to describe functional estrogen receptors (ERs) in LSCC cell 
lines over three decades ago62,63. These studies led to a small clinical trial on the use of 
tamoxifen, a potent anti-estrogen, in the treatment of LSCC64,65. However, the trial failed 
within six months because there was no observed clinical response or reduction in tumor 
size. This largely ended investigations into ER and the use of anti-estrogens in the 
treatment of LSCC. 
ERα36 is present in both ER66 positive (ER66+) and ER66 negative    
(ER66-) LSCC samples66–68. However, unlike breast cancer27, ERα36 expression in 
LSCC is highly variable. This suggests that crosstalk between rapid and genomic 
signaling pathways mediated by multiple ERs may control the estrogen response in 
LSCC. This section highlights some of the rapid estrogen signaling pathways previously 
described in LSCC and suggests that clinical decisions regarding prognosis and 
treatment of LSCC may be informed by the ERα profiles of individual LSCC patients.  
Previous studies by our laboratory show that loss of nuclear ER staining, but not 
membrane ER staining (as measured by immunohistochemistry) is associated with 
reduced patient prognoses and increased lymph node metastases in LSCC66. This is 
similar to trends observed in ER- breast cancer66,67,69. A loss of estrogen receptor β 
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expression (ERβ) has been associated with increased aggression in LSCC70. Changes 
in the non-traditional transmembrane ER G-protein coupled estrogen receptor (GPER1) 
and ER36 have also been associated with malignancies observed in histology of human 
vocal fold tissue71 and in vitro experiments on human LSCC cells66,67.  
 
Estrogen receptor signaling 
Classical estrogen signaling is mediated by the nuclear receptors ER and ER. 
E2 binding to these receptors in the cytoplasm leads to hetero-or homo-dimerized ERs 
and the translocation of the E2-ER ligand-receptor complex to the nucleus. Here it acts 
as a transcription factor for genes associated with proliferation, cell survival, metastasis, 
invasion, migration, and others68,72. Simultaneously, membrane-associated E2-ER 
binding triggers many rapid signal transduction pathways, such as phosphoinositol-3-
kinase (PI3K) / protein kinase B (PKB, also known as Akt), extracellular signal-regulated 
kinases (ERK), and mitogen-activated protein kinase (MAPK)68,73. Both the canonical and 
rapid signaling pathways induced by E2-ER binding stimulate pro-tumorigenic 
phenotypes. In this way E2 is a potent mitogen and EMT stimulus, promoting invasion and 
metastasis in prostate, ovarian, breast, uterine, and LSCC cells67,74–79.  
E2-ER interactions encompass a complex network of canonical and rapid 
responses. In addition to stimulating a number of mitogenic and cell survival pathways in 
LSCC as described below, E2 also stimulates the transcription of its own receptors. 
Canonically, the ESR1 gene, which encodes ER, has both distal and proximal promoter 
regions. The E2-ER complex directly stimulates the transcription of ESR1 by binding to 
one or more of these promoters in certain cell types80,81 and indirectly stimulates them by 
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binding to other receptors that can enhance ER transcription downstream (such as 
EGFR)82,83. Treatment with dose-dependent E2 increased gene expression of ER36 and 
ER66 (Figure 2.2).  
 
 
 
Figure 2.2 E2 upregulates the expression of ERα36 and ERα66 in UM-SCC-12, a 
laryngeal cancer cell line. 
Effects of E2 on gene expression of [A] ERα36 and [B] ERα66 in estrogen receptor 
positive UM-SCC-12 laryngeal cancer cells84.  
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Rapid Estrogen Signaling 
Estrogen, like other steroid hormones, initiates some non-nuclear rapid signaling 
pathways that initiate a number of mitogenic, anti-apoptotic, invasive, and metastases-
promoting signaling mechanisms.30,85. Many of these pathways involve phospholipases, 
kinases and other secondary messengers such as phospholipase D (PLD) and protein 
kinase C (PKC)68.  These may result in altered mRNA transcripts downstream, but these 
non-genomic pathways are still distinct from classical signaling in that they do not directly 
involve the activation or suppression of DNA response elements by the E2-ER complex. 
One commonly studied membrane-associated estrogen receptor is ER36. 
ER36 lacks the transcriptional activation domains AF1 and AF2, which implies that 
ER36 is incapable of directly stimulating transcription by binding to gene promoter sites. 
This lack of transcriptional activity distinguishes the actions of ER36 from the 
transcriptionally active canonical receptor ER66. ER36 does, however, retain the DNA 
binding, ligand binding, and partial dimerization zones of the canonical protein42,86. Thus 
ER36 may act as a co-factor to dimerize with other, possibly transcriptionally active, 
ERs. ER36 also has a unique function mediated by 27 amino acids transcribed from the 
novel exon 9 of the ESR1 gene35. Although the specific function of these 27 amino acids 
has not been fully described, research suggests that they are involved in the membrane-
associated signaling actions of ER36. Breast cancer cells transfected with ER36 
lacking exon 9 are unable to trigger the rapid membrane-associated signaling described 
for wild-type ER36, suggesting a unique function for ER36 independent from its role 
as a truncated dimerizing ER66 variant55. 
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ER36 is highly expressed in many breast cancer tumors that were previously 
diagnosed as ER negative55,87. In these tumors, E2 signaling through ER36 stimulates 
some tumorigenic and cell cycle disrupting pathways1. Evidence of E2 signaling in  
ER66-,ER36+ cells has called into question traditional pathological classifications that 
describe ER66 negative breast cancers as ‘estrogen non-responsive.’ Furthermore, in 
addition to promoting E2 signaling, unlike the traditional ER66, high expression of ER36 
is associated with unfavorable clinical prognosis, suggesting that ER36 might have 
value as a prognostic biomarker88.  
Similar trends have been observed in LSCC, with ER36-expressing cancers 
expressing more markers of clinical aggression than their ER66 positive counterparts67.  
Some studies have shown that E2 increases proliferation in LSCC cells through both 
genomic89–91 and non-genomic mechanisms64. Our lab and others have shown that E2 
stimulation of ER36 triggers PKC activation66,67. This mechanism is also present in 
breast cancer cells1,67. In vitro activation of ER36 by E2 in HEp-2 and UM-SCC-12 cells 
inhibits apoptosis and enhances proliferation, and activates PLD and PKC (Figure 
2.3)66,67. Further investigation into the mechanism of membrane E2 signaling has revealed 
that the pro-proliferative and anti-apoptotic mechanisms of E2 are dependent upon PLD 
and PKC activation67. However, the specific receptors which control E2 signaling in 
laryngeal cancer have not been identified (Figure 2.3).  
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Figure 2.3 Mechanism of E2 signaling through ERα36. 
E2 activates ERα36 in the caveolae and leads to Gq-mediated phospholipase D and PLC 
pathways. PLD activates PI3K-mediated anti-apoptotic pathways, and PLC activates 
PKC-ERK pathways, leading to proliferation and metastasis68.   
Modulation of 24R,25(OH)2D3 Tumorigenicity by ER Isoforms in E2-Responsive Cancer • Spring 2019 
Anjali Verma • Ph.D. Dissertation • Biomedical Engineering • Virginia Commonwealth University 38 
 
24R,25(OH)2D3 signaling 
A similar parallel mechanism has been demonstrated in 24R,25(OH)2D3 signaling in 
chondrocytes 18,92,93, which has been shown to inhibit apoptosis through an as yet 
unidentified membrane receptor. Once ingested, vitamin D3 – the most bioavailable form 
of vitamin D – is hydroxylated in the liver into 25(OH)D3, the circulating form of vitamin D3 
commonly measured as ‘serum vitamin D’ 13. 25(OH)D3 is then further hydroxylated in the 
kidneys to become the steroid hormones 1,25(OH)2D3 or 24,25(OH)2D3 13. 1α,25(OH)2D3 
has been widely studied because of its role in regulated calcium homeostasis in concert 
with parathyroid hormone (PTH) 94. 1α,25(OH)2D3 is also an essential hormone for bone 
health because of its role in sequestering calcium within the bones to maintain bone 
mineralization and strength. 24R,25(OH)2D3 is not as well studied, partially because it is 
often regarded as a ‘waste product’ that cycles with 1α,25(OH)2D3 to regulate the 
production of the latter hormone. However, studies by our lab and others have 
demonstrated a role for 24R,25-(OH)2D3 in growth plate development and fracture callus 
healing, where 24R,25-(OH)2D3 has an anti-apoptotic effect and is an essential regulator 
of chondrocyte sensitivity to 1α,25(OH)2D3. 
24R,25(OH)2D3 plays a key role in fracture healing and chondrocyte differentiation via 
a membrane-mediated PLD dependent pathway 93,95. Unlike 1α,25(OH)2D3, which helps 
regulate calcium mineralization of the lower parts of the growth plate, 24R,25(OH)2D3 is 
essential for cell cycle regulation in earlier stages of the growth plate, particularly in the 
progression of pre-proliferative chondrocytes to proliferative chondrocytes 96. Recent 
studies have suggested that 24R,25(OH)2D3 or the 24-hydroxylase that produces it, 
CYP24A1, may modulate cell proliferation and apoptosis in cancer cells 97–99. This effect 
Modulation of 24R,25(OH)2D3 Tumorigenicity by ER Isoforms in E2-Responsive Cancer • Spring 2019 
Anjali Verma • Ph.D. Dissertation • Biomedical Engineering • Virginia Commonwealth University 39 
 
may be a direct result of the activities of either the hormone or enzyme; or may be the 
result of modulation of the effects of 1α,25(OH)2D3. 24,25(OH)2D3 has been shown to 
regulate the production of the 1-hydroxylase enzyme CYP27B1, which converts 
25(OH)D3 to 1,25(OH)2D3 100. In a similar manner, 24R,25(OH)2D3 promotes chondrocyte 
sensitivity to 1α,25(OH)2D3 93, encouraging a positive feedback loop where each hormone 
regulates the production of the other, resulting in 1α,25(OH)2D3 and 24R,25(OH)2D3 
cycling within the body 101,102. 
As described above, 24R,25(OH)2D3 has been shown to signal through an as-yet 
unidentified receptor to stimulate PLD and subsequent anti-apoptosis response in 
chondrocytes. The identity of this receptor has been a matter of debate for decades. 
Larsson et al., while studying the lysosomal membranes of chick intestinal cells, reported 
that catalase-1 specifically binds 24R,25(OH)2D3 21, suggesting a rapid peroxidase-
involved signal transduction pathway for 24,25(OH)2D3. A number of papers from the lab 
of Dr. Anthony Norman have reported evidence for a membrane-bound receptor for 
24R,25(OH)2D3 in chick fracture healing callus that may be involved in rapid or genomic 
signal transduction 19,20. Crystallographic studies of the classical vitamin D receptor (VDR) 
suggest that conformational changes in the receptor may accommodate the transient 
binding of 24R,25(OH)2D3 to the ligand-binding pocket of VDR54. Recently, another 
24R,25(OH)2D3 receptor, FAM57B2, was identified by Martineau et al., which may be 
essential to the 24R,25(OH)2D3 response in fracture callus repair22. Numerous studies in 
rat growth plate chondrocytes have characterized a specific membrane-associated signal 
transduction pathway that mediates both classical genomic and rapid responses of 
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24R,25(OH)2D3, strongly suggesting the presence of a membrane receptor or signaling 
complex that regulates the actions of 24R,25(OH)2D3 17,23,93,103. 
While a consensus receptor for 24R,25(OH)2D3 remains elusive, membrane signaling 
by 24R,25(OH)2D3 has been described. In costochondral resting zone chondrocytes, 
24R,25(OH)2D3 binds to an as yet unidentified membrane-bound receptor and inhibits 
phospholipase A2 activity (PLA2) 104. The resulting signaling pathway alters fatty acid 
turnover and subsequently inhibits the release of arachidonic acid and prostaglandin E2 
(PGE2) production 23,103,105. This inhibition of arachidonic acid turnover alters membrane 
fluidity and calcium flux within the cell, modulating signal transduction downstream and 
stimulating PKC activity 23,103,106,107. The effect of 24R,25(OH)2D3 is stereospecific; 
24S,25(OH)2D3 does not activate this pathway, providing further evidence that the 
response to the hormone is receptor mediated. 
24R,25(OH)2D3 binding to the membrane receptor also stimulates PLD, which 
increases diacylglycerol production (DAG), to in turn activate PKC 15,16,18. This increase 
in PKC has been observed in whole cell lysate and cell membrane fractions, while 
24R,25(OH)2D3 has been shown to increase PKC in resting zone matrix vesicles 23,108.  
Although 24,25(OH)2D3 stimulation of PLD2 activates DAG to stimulate PKC, this 
subsequent activation of PKC does not coincide with the translocation of PKC to the 
plasma membrane 16. This suggests that 24R,25(OH)2D3 stimulation of PKC activity via 
PLD may not be a direct result of 24R,25(OH)2D3 binding to a membrane receptor and is 
instead a result of downstream signaling by other secondary messengers. Furthermore, 
although resting zone cells have active phospholipase C (PLC) isoforms – namely PLC1 
and PLC3 – neither PLC is activated by 24R,25(OH)2D3, and inhibition of PLC does not 
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affect 24R,25(OH)2D3 stimulation of PKC 15,17. Together with the inhibition of PLA2 and 
stimulation of DAG act to enhance PKC activity to stimulate the phosphorylation of 
multiple proteins in multiple anti-apoptotic downstream pathways, including MAPK and 
ERK, which are also stimulated by 17-estradiol through both genomic and non-genomic 
pathways 36,47,83,109,110 (Figure 2.4).  
 
Figure 2.4 24R,25 signaling through PLD. 
24R,25(OH)2D3 binds to an unidentified membrane receptor to stimulate PLD2 in resting 
zone chondrocytes. Activation of PLD2 stimulates lysophosphatidic acid (LPA), which 
stimulates PLC and PI3K. Downstream of PI3K, 24R,25(OH)2D3 inhibits p53 
ubiquitination in chondrocytes, preventing apoptosis. 
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Vitamin D3 supplementation in cancer. 
 Preclinical studies and meta-analyses have suggested that 1,25(OH)2D3 and 
25(OH)D3 may have potential as a preventive therapy for breast cancer. Despite this, 
clinical studies investigating vitamin D supplementation on breast cancer prognosis have 
been largely inconclusive 8,111–113. Oral vitamin D3 has been shown to increase cell 
turnover, autophagy, and reduce tumor growth in the mammary glands of normal mice 
14,114, and intravenous 1α,25(OH)2D3 has been shown to reduce tumor growth in ER-
positive breast cancer xenografts 14. In vitro, 1α,25(OH)2D3 has been shown to reduce 
angiogenic, metastatic, and apoptotic markers in ER-positive breast cancer cells, but not 
in normal cultured human mammary epithelial cells 115–118. This could be a function 
specific to the interactions of 1α,25(OH)2D3 with the VDR, which regulates 
1α,25(OH)2D3’s genomic actions by dimerizing with the retinoic acid receptor to form a 
transcription complex 119. Dimerized VDR bound to 1α,25(OH)2D3 has been shown to 
suppress transcription of the ESR1 gene 120, which could inhibit the feed-forward loop of 
estrogen-ERα signaling 121. Alternatively, 1α,25(OH)2D3’s anti-tumorigenicity could be a 
function of its non-genomic actions, as its analogs 1,24,25-trihydroxyvitamin D3 and 
1,25,26-trihydroxyvitamin D3, which are incapable of binding to VDR, have also been 
shown to inhibit the growth of breast cancer cells in vitro 122. 
Studies examining the use of 1α,25(OH)2D3 as a safe, easy to deliver supplement 
against breast cancer tumorigenicity have been promising; however, there is a risk of 
hypercalcemia with excess 1α,25(OH)2D3. Hypercalcemia is a common co-morbidity of 
cancer, with up to 30% of all cancer patients suffering severe hypercalcemia 123. It is the 
leading cause of hospitalization in cancer patients, and who have breast cancer are 
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particularly susceptible 124. Excess 1α,25(OH)2D3 is a documented cause of 
hypercalcemia 125, and blood serum levels of free 1α,25(OH)2D3 as low as 200pmol/L 
(with ~85 pmol/L approximating normal 1α,25(OH)2D3 levels) can be toxic 126. Many in 
vitro studies only observe the anti-tumorigenic effects of 1α,25(OH)2D3 when treating with 
1-100 nmol/L, well above the toxicity threshold for this compound 127–129.  
The search for non-calcemic analogs of vitamin D3 that can approximate 
1α,25(OH)2D3’s anti-tumorigenic effects has led researchers to look at modifications of 
1α,25(OH)2D3 that do not bind to VDR and thus do not have the same hypercalcemic 
effects. Some of these studies have been successful, but the majority are not approved 
for the treatment of cancer 130. 
Although connections between improved breast cancer prognoses and high vitamin D 
serum levels have been well-established, there is no consensus on the efficacy of vitamin 
D supplementation in the treatment of breast cancer. Studies examining breast cancer 
prognosis and vitamin D serum levels could be improved by considering the breast cancer 
molecular subtypes, particularly the ER status, of the patients involved. 24R,25(OH)2D3, 
an understudied vitamin D3 metabolite, may have potential as a non-calcemic vitamin D3 
metabolite with tumor modulating properties. Further research is needed to understand 
the connections between ER status and the anti-tumorigenicity of vitamin D supplements, 
and the parallels between membrane mediated estrogen signaling through ERα36 and 
24R,25(OH)2D3 may provide insight into this connection.  
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Chapter 3.  
Estradiol Receptor Profile and Estrogen Responsiveness in Laryngeal Cancer and 
Clinical Outcomes  
[Chapter 3 is published as: Schwartz N, Verma A, Muktipaty C, Bivens C, Schwartz Z, 
Boyan BD. Estradiol receptor profile and estrogen responsiveness in laryngeal cancer 
and clinical outcomes. Steroids. 2019; 142(2):34-42] 
 
Introduction 
Laryngeal cancer, despite arising from a secondary sex organ and having a clear 
gender disposition, is not uniformly accepted as sex hormone-dependent. The 
determination of sex hormone responsiveness, specifically to 17β-estradiol (E2), impacts 
the prognosis of the patients and the treatment modalities that are implemented in these 
types of cancers. E2 plays a key role in the pathogenesis of hormone-responsive cancers, 
the most well studied being breast cancer and prostate cancer 46,131, by enhancing cell 
proliferation, survivability, and metastasis 76,132,133.  Due to its effects on cancer 
progression and behavior, the presence of E2 receptors (ER) has long been the most 
important molecular marker used in the diagnosis and as a predictor of prognosis in breast 
cancer dictating treatment. 
Classically, E2 mediates its effects through interaction with its nuclear receptors, ERα 
and ERβ. These receptors act as transcription factors by binding to specific response 
elements, or transcription initiation complexes, on the DNA to either activate or repress 
transcription in a process that occurs in a matter of hours to days 29,134. Steroid hormones 
also initiate non-nuclear, non-genomic rapid signaling within seconds to minutes that 
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occurs independently of transcription or translation 30,85. This results from steroid binding 
to specific extra-nuclear receptors associated with the cell membrane, leading to the 
activation of signaling cascades that involve kinases, phospholipases, calcium flux and 
other second messengers, and may result in altered mRNA levels 34,35. Recent studies 
indicate that motifs within ER exons encode sequences associated with palmitoylation, 
thereby linking the receptor to the membrane35.   
One of the key candidates for the membrane mediated action of E2 is a novel ERα 
splice variant with a molecular mass of approximately 36 kDa, which has been named 
ERα36. ERα36 differs from ERα66, the classic nuclear ER  receptor, by lacking both 
transcriptional activation domains (AF1 and AF2) (exons 7 and 8) but retaining the DNA-
binding domain and partial dimerization and ligand-binding domains of the nuclear 
receptor. This suggests that although it may still bind to DNA, ERα36 may not directly 
activate transcription. Rather, it may affect transcriptional function as a co-factor due to 
its ability to dimerize with other ERs and bind to DNA42,86. In addition, ERα36 contains a 
novel exon 9, which encodes 27 amino acids of unknown function35. Breast cancer cells 
transfected with ER 36 lacking exon 9, lack the ability to trigger rapid activation of 
membrane associated signaling55, suggesting that this may be an important key to its role 
in E2 responsiveness. 
ERα36 is gaining special interest particularly in regards to its role in mediating E2 
responsiveness in traditionally diagnosed ER negative tumors55,87, and its role in 
modulating anti-estrogen resistance in ER positive tumors1, which have otherwise been 
clinically regarded as hormone-unresponsive. Inclusion of this receptor in screens of ER 
negative breast cancers showed that high levels of ERα36 expression were correlated 
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with an unfavorable clinical prognosis independent of nuclear ER status88. Thus ERα36 
has been suggested as an important novel marker for breast cancer clinical 
characterization, suggesting it may serve a valuable function for laryngeal cancers as 
well.  
ERα36 has the ability to mediate the effects of E2 independently of nuclear ERα, as 
demonstrated in ERα66 null cells and in studies using antibodies against the nuclear and 
membrane isoforms of ERα 109. The receptor has been shown to initiate divergent 
pathways from the plasma membrane that re-converge downstream to affect cancer cell 
survivability. E2 binding to ERα36 affects proliferation through the activation of G-proteins, 
which in turn lead to the activation of phospholipase C (PLC). PLC activation leads to the 
production of diacylglycerol (DAG) and inositol trisphosphate (IP3), which subsequently 
trigger calcium signaling and protein kinase C (PKC) activation. Together, calcium 
signaling and PKC activation culminate in downstream activation of mitogen-activated 
protein kinase (MAPK) 1 to increase DNA synthesis and gene transcription. At the same 
time, E2 activation of ERα36 reduces apoptosis by blocking effects of common 
chemotherapeutics, such as Taxol 66, by activating phospholipase D (PLD) at the 
membrane, leading to activation of lysophosphatidic acid (LPA) signaling and 
phosphoinositol-3 kinase (PI3K). This in turn attenuates the caspase cascade that 
promotes apoptosis 27,55. This mechanism of E2’s action was also shown in laryngeal 
cancer cells 66. 
As laryngeal cancer is not perceived to be a sex hormone-responsive cancer, most 
studies do not examine tumor responses or tumorigenesis regulation by steroid hormones 
in laryngeal cancer. Little can be concluded from the sparse data available on the relation 
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of E2 with laryngeal cancer. Even the presence of classical cytosolic ERs in laryngeal 
cancer is controversial. Several studies have argued that laryngeal cancer does not 
possess any functional ER 135, or rather implied that the presence of the receptors 
originates from stromal or mesenchymal tissues in the larynx and not from the epithelial 
component, which constitutes the origin of laryngeal cancer 136. Other studies affirm the 
presence of classical nuclear ERs in laryngeal cancer 137,138 and even correlate the 
presence and number of the receptors with local metastasis status 139. Despite this lack 
of agreement, there is growing evidence that laryngeal cancer cells display E2 
responsiveness, as E2 was found to increase the proliferation of laryngeal cancer cells 89–
91 via a non-genomic mechanism 64. Furthermore, 4’hydroxytamoxifen has been 
demonstrated to inhibit the growth of laryngeal cancer, in part, due to its anti-estrogen 
effect 63,140; and this effect is eliminated with the addition of E263,64,137.  
Previously, we have shown that Hep2 laryngeal carcinoma epithelial cells express 
both ERα66 and ERα36. ERα36 was found to reside in the plasma membrane, and 
stimulation of ER36 by E2 stimulated PKC activation via a mechanism comparable to 
that shown in breast cancer cells 1. In vitro, E2 activation of ER36 was shown to cause 
a PLD-dependent increase in PKC activity, followed by an upregulation of angiogenic and 
metastatic factors. ERα36 signaling enhanced both proliferation and the anti-apoptotic 
effect of E2 against chemotherapeutics, indicating a role in tumorigenesis. Furthermore, 
it was demonstrated both in vitro and in vivo that E2 enhanced vascular endothelial growth 
factor (VEGF) and fibroblast growth factor (FGF) expression. An association has been 
suggested between high levels of ERα36 and VEGF and a more aggressive tumor 
phenotype, as evidenced by the correlation to lymph node metastasis66. 
Modulation of 24R,25(OH)2D3 Tumorigenicity by ER Isoforms in E2-Responsive Cancer • Spring 2019 
Anjali Verma • Ph.D. Dissertation • Biomedical Engineering • Virginia Commonwealth University 48 
 
These findings advocate a role for E2 in the tumorigenesis of laryngeal cancer and 
raise the option of heterogeneity of expression of ERs and responsiveness in the tumor 
cells that warrants further exploration. In the present study we studied two laryngeal 
cancer lines with different ERα expression to examine the signaling pathways activated 
by E2 in an attempt to clarify the importance of profiling laryngeal cancer E2 
responsiveness and the clinical implications ER profiling might have for the treatment of 
laryngeal cancer. 
 
Materials and Methods 
Cell Culture 
UM-SCC-11A and UM-SCC-12 cells were obtained from the Carey Laboratory at 
the University of Michigan (Ann Arbor, MI) and cultured in high-glucose Dulbecco’s 
minimum essential medium (HG DMEM) lacking phenol red (Invitrogen, Carlsbad, CA), 
supplemented with 10% fetal bovine serum (FBS) (ThermoFisher, Waltham, MA, USA), 
2mM L-glutamine, and 100U/100U penicillin-streptomycin (ThermoFisher). 
Presence of ER Isoforms 
ERα expression in laryngeal cancer cells was identified using sequence-specific primers, 
designed in our lab previously16, to identify traditional ERα66 and the spliced variant 
ERα36. A commercial primer was used to identify ESR2 (ERβ) (Qiagen, Hilden, 
Germany). UM-SCC-12 and UM-SCC-11A cells were plated in 24-well plates at 20,000 
cells/cm2 (n=6 per variable) and cultured to confluence. RNA was extracted with TRIzol 
and used to synthesize cDNA libraries (Thermo Fisher Scientific, High Capacity cDNA 
Reverse Transcription kit). Levels of RNA expression were quantified using gene-specific 
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primers (Table 3.1). RNA expression for ERα46/66 was done with primers that amplified 
exon 1 of the ESR1 gene, and primers for ERα36 amplified exon 9 of the ESR1 gene. 
Data were verified with a commercial primer from Qiagen, which amplified exon 3/4 of 
ESR1. Expression of ERβ was assessed with a commercial primer from Qiagen, which 
amplified exon 5/6 of ESR2. All gene expression was quantified using a whole-cell 
standard and normalized to GAPDH.   
 
 
Table 3.1 Human primers used in real-time PCR analysis. 
 
Western blots were used to identify and quantify ER protein in the laryngeal cell 
lines. Cells were plated at 10,000 cells/cm2 in T-75 flasks (Corning) and cultured to 
confluence. Monolayers were washed twice with 1X PBS and ERα66, ERα46, ERα36, 
and ERβ were assessed using a western blot assay with GAPDH protein as the loading 
control. UM-SCC-12, UM-SCC-11A, and MCF7 cells were lysed in 200μL 
radioimmunoprecipitation assay buffer (RIPA) and resolved on 4-20% Tris-glycine 
extended gels using gel electrophoresis. Proteins were transferred from the gel onto a 
PVDF membrane using the Bio-rad Mini Trans-Blot® Electrophoretic Transfer Cell. 
Membranes were blocked and probed with primary and secondary antibodies according 
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to the LI-COR Western Blot Protocol. Membranes were then imaged on the 
Odyssey®CLx Infrared Imaging System from LI-COR. 
Response to 17β-Estradiol 
17β-Estradiol (#BML-DM200-0050) was purchased from Sigma Aldrich 
(Farmingdale, NY) and reconstituted to 1mM stock solutions in absolute ethanol. Stock 
solutions were diluted in warm complete media to final treatment concentrations. For all 
experiments except DNA synthesis, cells were treated at confluence. Media were 
aspirated and cell layers were treated with media containing 0 (vehicle), 10-9M, 10-8M, or 
10-7M E2 for 9 minutes at 370C, 5%CO2, 100% humidity. Media were then removed by 
aspiration and cells were harvested (PKC, PLD assays) or incubated with fresh complete 
media for 24 hours (p53 and VEGF protein expression).   
Specific inhibition of membrane associated factors involved in ERα36 signaling 
was used to examine whether the effects of E2 were mediated via these mechanisms. 
PLD was inhibited by wortmannin (VWR, Radnor, PA, #80055-508) 15,141,142. Caveolae 
were disrupted using methyl β-cyclodextrin, which depletes the membranes of cholesterol 
(Millipore-Sigma, St. Louis, MO, #C4555-10G)  1.  Estrogen receptors were inhibited using 
a neutralizing antibody to ERα36 (Chi Scientific, Maynard, MA) 1. Confluent cultures were 
pre-treated with media containing different concentrations of the inhibitor as indicated 
below. After 30 minutes, the media were replaced with fresh media containing either 0, 
10-8, or 10-7 M E2 for 9 minutes. These media were removed by aspiration and cells were 
harvested immediately for analysis of PKC and PLD activity. Alternatively, fresh media 
were added to the cultures for 24 hours and protein expression for p53 and VEGF 
determined by duo-set ELISA as described below.   
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DNA Synthesis 
Cells were cultured to 70% confluence; then serum-starved in phenol-red free HG 
DMEM supplemented with 1% charcoal-dextran filtered FBS and 100U/100U penicillin-
streptomycin. After 48 hours in starvation media, cells were treated with 17β-estradiol or 
inhibitors (see above) and incubated with fresh complete media for 20 hours. At that time, 
cells were pulsed with 10µL of a 1:100 dilution of 5-ethynyl-2’-deoxyuridine (EdU) and 
incubated for an additional 4 hours. Cells were then harvested and assayed for EdU 
incorporation according to manufacturer’s instructions (ThermoFisher Scientific). 
DNA Fragmentation 
Apoptosis was examined by assessing cells for DNA fragmentation by colorimetric 
terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (Trevigen, 
TiterTAC™ in situ microplate TUNEL assay). After E2 treatment, cells were incubated 
with fresh media for 24 hours and fixed with formaldehyde containing 3.7% sucrose 
before being processed for TUNEL staining following manufacturer’s instructions. Final 
absorbance was detected at 450 nm using a microplate spectrophotometer. 
PKC Specific Activity 
Cells were cultured to confluence in 24-well plates and treated with E2 as above; 
media were removed by aspiration and cells were washed twice with 2mL/well of 1X PBS. 
Cells were lysed in 200µL of PKC lysis buffer as per manufacturer’s instructions and 
assayed for PKC activity using the PKC Activity Kit from (AbCam, Cambridge, UK). Cell 
lysates were assessed for total protein content using the Pierce BCA 660 reagent kit 
(VWR) and PKC activity was normalized to total protein. 
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PLD Specific Activity 
Cells were cultured to confluence in 24-well plates and treated with E2 as above; 
media were removed by aspiration and cells were washed twice with 2mL/well of 1X PBS. 
Cells were lysed in PLD lysis buffer as per manufacturer’s instructions and assayed for 
PLD activity using the PLD Activity Kit from Thermo Fisher Scientific. Cell lysates were 
assessed for total protein content using the Pierce BCA 660 reagent kit and PLD activity 
was normalized to total protein. 
Total p53 Levels 
P53 is a tumor suppressor gene that induces apoptosis 143. Total p53 levels were 
measured 24 hours post-treatment using a sandwich ELISA (Human Total p53 DuoSet® 
IC, R&D Systems, Minneapolis, MN). Cells were plated in 24-well plates, treated with E2 
for 9 minutes as described above, and incubated for 24 hours. After 24 hours, cells were 
lysed in 200μL of 1X PBS, 1mM EDTA, 0.5% Triton™ X-100 144.  Lysates were centrifuged 
at 10,000g for 15 minutes and the supernatant was collected and assayed for total protein 
content (ThermoFisher, Pierce 660 nm Protein Assay) and total p53 content following 
manufacturer’s instructions. Data are presented as a ratio of picograms of total p53 to 
total protein content. 
Statistical Analysis 
Data are presented as mean ± standard error of six independent cultures per 
treatment group. Outliers were removed with Grubbs’ test using a P-value of 0.05. Data 
with one independent variable were analyzed by analysis of variance (ANOVA) with 
Tukey’s post-test to determine significance between groups. Groups that do not share a 
letter are considered significant with p-values < 0.05. Experiments with two independent 
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variables (DNA synthesis, total p53 content, PKC, and PLD assays) were analyzed with 
one-way ANOVA as described above and two-way ANOVA with Bonferroni’s modification 
of Student’s t-test post-tests between all group means using Graphpad Prism 7. P-values 
<0.05 were considered significant and were marked with ∗ denoting significance between 
0 vs. E2 treatments for a given x-axis group. 
 
Results 
Western blots of UM-SCC-12 and UM-SCC011A cells showed that different 
laryngeal carcinoma cell lines express different sex hormone receptors (Figure 3.1A). As 
expected, the breast cancer MCF7 cell line possessed ER66, ER46, ER36, and ER, 
confirming the gel system was working. UM-SCC-12 cells expressed mRNA for ERα66 
whereas none was found in the UM-SCC-11A cells (Figure 3.1B). Both laryngeal cancer 
cell lines expressed mRNA for ER36 (Figure 3.1C), but only UM-SCC-11A cells 
expressed mRNA for ER (Figure 3.1C).  
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Figure 3.1 Estrogen receptor expression in whole cell lysates of UM-SCC-12 and 
UM-SCC-11A cells. 
 [A] ERα66, ERα36, and ERβ protein were identified via western blot using MCF7 breast 
cancer cells as controls. mRNA expression of [B] exon 1 of ESR1 (ERα66), [C] exon 9 of 
ESR1 (ERα36), and [D] ESR2 (ERβ) was measured by real-time qPCR. 
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E2 regulated proliferation in the two cell lines in a differential manner. E2 caused a 
slight decrease in DNA synthesis in UM-SCC-11A cells, which was significant at 10-7M 
(Figure 3.2A). In contrast, E2 increased DNA synthesis in UM-SCC-12 cells, which was 
significant at 10-8M and 10-7M (Figure 3.2B). Antibodies to ER36 had no effect on cell 
proliferation in untreated UM-SCC-11A cells, but slightly increased proliferation in UM-
SCC-11A cells treated with E2 (Figure 3.2C). In contrast, antibodies to ERα36 did not 
affect the stimulatory effect of E2 on cell proliferation in the UM-SCC-12 cells (Figure 
3.2D). In UM-SCC-11A cells, inhibition of PLD  with wortmannin alone did not affect 
proliferation. However, treatment with 0.1 and 1 M wortmannin in combination with 10-7M 
E2 reduced DNA synthesis as compared to matched-dose wortmannin treatment alone 
(Figure 3.2E). Similarly, wortmannin alone did not affect DNA synthesis, but it prevented 
an E2-dependent increase in DNA synthesis in UM-SCC-12 cells (Figure 3.2F).  
Apoptosis was regulated by E2 in a cell line-specific manner. E2 did not have a 
significant effect on DNA fragmentation measured via TUNEL assay in the UM-SCC-11A 
cells (Figure 3.3A). In contrast, E2 caused a dose-dependent inhibition in TUNEL in the 
UM-SCC-12 cells (Figure 3.3B). E2 did not affect total p53 in the UM-SCC-11A cells 
(Figure 3.3C) but reduced significantly p53 content of UM-SCC-12 cells (Figure 3.3D). 
Depletion of membrane cholesterol with methyl -cyclodextrin reduced p53 levels to the 
same extent as 10-7M E2 in UM-SCC-12 cells but did not further reduce the inhibitory 
effect of the hormone (Figure 3.4). 
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Figure 3.2 UM-SCC-12 and UM-SCC-11A cells were serum-starved and treated with 
E2 for 9 minutes. 
Media were changed, and 24 hours later: [A, B] DNA synthesis was measured using a 
ClickiT EdU Microplate assay. [C, D] A second set of cultures was pre-treated with media 
or an antibody to ERα36 and then treated with vehicle or 10-7M E2 for 9 minutes. Media 
were changed and 24 hours later, DNA synthesis was measured. [E, F] A third set of 
cultures was pre-treated with wortmannin and then treated with vehicle or 10-7M E2 for 9 
minutes before media were changed and DNA synthesis was measured 24 hours later. 
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Figure 3.3 UM-SCC-12 and UM-SCC-11A cells were treated with E2 for 9 minutes. 
 [A, B] Media were changed, and 24 hours later, DNA fragments were measured in 
cultures using TUNEL staining. [C, D] A second set of cultures was treated identically and 
total intracellular p53 content was quantified with a sandwich ELISA assay. 
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Figure 3.4 UM-SCC-12 cells were treated with methyl-β-cyclodextrin for 30 minutes, 
then treated with 10-8M E2 for 9 minutes. Media were changed, and 24 hours later 
total intracellular p53 content was quantified with a sandwich ELISA assay. 
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PKC activity in the UM-SCC-12 cells was regulated by a membrane-associated 
mechanism. E2 caused a dose-dependent increase in PKC specific activity (Figure 3.5A). 
This stimulatory effect of E2 required intact caveolae. Depletion of plasma membrane 
cholesterol prevented the E2-dependent increase in enzyme activity (Figure 3.5B) in a 
biphasic manner, with the maximum effect at 0.1mM methyl-β-cyclodextrin (MBC). 1mM 
MBC slightly reduced basal PKC activity, but 1mM MBC and 10-7M E2 together slightly 
increased PKC activity (Figure 3.5B). A neutralizing antibody specific to ERα36 increased 
PKC activity, but the addition of 10-7M E2 to cultures treated with the ERα36 antibody did 
not further increase PKC activity, suggesting that the effects of E2 in UM-SCC-12 cells 
are at least partially elicited through the activation of membrane ERα36 (Figure 3.5C). 
E2 caused a biphasic increase in PLD specific activity in the UM-SCC-12 cells that 
was significant at 10-8M (In the present study, we observed that the expression of ERs in 
laryngeal cancer cell lines is not uniform, which might explain the controversies in the 
literature regarding the presence and nature of the ER in laryngeal cancer. UM-SCC-11A 
expressed ERα36 and ERβ with no apparent ERα66, while UM-SCC-12 expressed both 
ERα66 and ERα36 with minimal ERβ. This diversity in ER expression translates to a 
disparate response to E2. E2 had a detrimental effect in UM-SCC-12 cells, enhancing 
proliferation and reducing apoptosis. UM-SCC-11 cells were much less responsive to E2, 
inhibiting DNA synthesis at high concentrations, although not affecting the apoptotic rate.  
UM-SCC-11A cells expressed high levels of ERβ, which might offer an explanation 
for the protective effect conferred by E2. ERβ has been postulated to be a 
dominant-negative regulator of ERα modulating transcriptional responses to 
estrogens. The ratio of ERα vs. ERβ within a cell may determine the cell sensitivity 
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to E2 and its biological responses26. This protective effect of ERβ has been 
observed in breast cancer cells in which the expression of ERβ was found to inhibit 
proliferation and cell invasion146, and in colorectal cancer in which the decrease 
of expression of ERβ was hypothesized to have a role in tumorigenesis147 and 
might demonstrate the same effect in laryngeal cancer cells.  
 
Figure 3.5 E2 stimulates PKC activity in UM-SCC-12 cell layer lysates. 
[A] UM-SCC-12 cells were treated with E2 for 9 minutes. [B] A second set of cultures was 
treated with methyl-β-cyclodextrin for 30 minutes, then treated with 10-8M E2 for 9 
minutes. [C] A third set of cultures was treated with a neutralizing antibody to ERα36 for 
30 minutes, then treated with 10-8M E2 for 9 minutes. For all cultures, media were 
aspirated and monolayers were washed twice with 1X PBS. PKC activity in cell layer 
lysates was measured using a commercial kit and normalized to total protein content and 
reaction incubation time. 
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Figure 3.6 E2 stimulates PLD 
activity in UM-SCC-12 cell 
layer lysates. 
[A] UM-SCC-12 cells were 
treated with E2 for 9 minutes. 
[B] A second set of cultures 
was treated with methyl-β-
cyclodextrin for 30 minutes, 
then treated with 10-8M E2 for 9 
minutes. [C] A third set of 
cultures was treated with an 
antibody to ERα36 for 30 
minutes, then treated with 10-
8M E2 for 9 minutes. For all 
cultures, media were aspirated 
and monolayers were washed 
twice with 1X PBS. PLD 
activity in cell layer lysates was 
measured using a commercial 
kit and normalized to total 
protein content and reaction 
incubation time. 
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Discussion 
 E2 initiates multiple rapid signaling pathways from the cell membrane in different 
types of cells and via different membrane receptors, many of which remain the subject of 
active investigation. While there is evidence indicating that these receptors are in fact the 
traditional receptors residing in the cell membrane36,40,  novel orphan receptors have been 
identified and are being implicated in rapid membrane signaling by E242,145. Previously we 
showed that Hep2 laryngeal carcinoma epithelial cells express both traditional ERα66 
and the recently identified splice variant, ERα36. ERα36, which was found to be a key 
cellular and transcriptional regulator of proliferation and enhanced aggressiveness in 
breast cancer 1,86, was shown to reside in the plasma membrane of Hep2 cells and to 
mediate the activation of PKC in response to E2 via a mechanism comparable to that seen 
in the breast cancer cells66. ERα36 signaling had roles in tumorigenesis of laryngeal 
cancer enhancing proliferation and in the anti-apoptotic effect of E2 against 
chemotherapeutics such as Taxol66. 
In the present study, we observed that the expression of ERs in laryngeal cancer 
cell lines is not uniform, which might explain the controversies in the literature regarding 
the presence and nature of the ER in laryngeal cancer. UM-SCC-11A expressed ERα36 
and ERβ with no apparent ERα66, while UM-SCC-12 expressed both ERα66 and ERα36 
with minimal ERβ. This diversity in ER expression translates to a disparate response to 
E2. E2 had a detrimental effect in UM-SCC-12 cells, enhancing proliferation and reducing 
apoptosis. UM-SCC-11 cells were much less responsive to E2, inhibiting DNA synthesis 
at high concentrations, although not affecting the apoptotic rate.  
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UM-SCC-11A cells expressed high levels of ERβ, which might offer an explanation 
for the protective effect conferred by E2. ERβ has been postulated to be a dominant-
negative regulator of ERα modulating transcriptional responses to estrogens. The ratio of 
ERα vs. ERβ within a cell may determine the cell sensitivity to E2 and its biological 
responses26. This protective effect of ERβ has been observed in breast cancer cells in 
which the expression of ERβ was found to inhibit proliferation and cell invasion146, and in 
colorectal cancer in which the decrease of expression of ERβ was hypothesized to have 
a role in tumorigenesis147 and might demonstrate the same effect in laryngeal cancer 
cells.  
 
UM-SCC-12 cells demonstrated responses to E2 similar to those seen in ERα-
positive MCF7 and ERα-negative HCC38 breast cancer cells 1 as well as the Hep2 
laryngeal cancer cell line66. E2 caused dose dependent enhancement of proliferation and 
inhibition of apoptosis. These effects were mediated by the stimulation of the known PLD 
and PKC signaling cascades, as evidenced by the activation of both enzyme activities in 
UM-SCC-12 cells in response to E2 and by the inhibition of proliferation when cultures 
were pre-treated with wortmannin, a specific PLD inhibitor at the concentrations used in 
this study. Pretreatment with methyl β-cyclodextrin, which depletes the membranes of 
cholesterol and thereby disrupts the caveolae, inhibited the activation of PKC and PLD 
and abolished the anti-apoptotic effect, indicating the importance of the specialized 
membrane compartment for E2-dependent signaling pathway in UM-SCC-12 laryngeal 
cancer cells.  
Despite the clear similarity to the mechanism and effects of E2 seen in our previous 
work, in UM-SCC-12 cells it seems that ERα36 plays only a part in the membrane 
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signaling pathways of E2. While antibodies against ERα36 prevented the stimulatory 
effect of E2 on the activation of PKC, they did not inhibit the effects of E2 on proliferation 
rate or PLD activity. This suggests that E2 causes an increase in PKC activity and 
proliferation by activating another estrogen receptor, rather than ERα36 as previously 
described in HCC38 breast cancer cells66. It should also be noted that while the antibody 
to ERα36 did not affect cell proliferation in UM-SCC-12 cells, it stimulated both PKC and 
PLD activity in these cells, suggesting that neutralizing ERα36 stimulates an unidentified 
mechanism which stimulates PKC and PLD in a compensatory pro-survival pathway. 
Furthermore, it is possible that the antibody to ERα36 simply stimulated PKC activity to a 
saturated point, preventing further increases in PKC activity by any stimulant rather than 
specifically blocking the effects of E2.  
The mechanism of E2’s action in the UM-SCC-12 laryngeal cancer cell line is 
intricate and not yet clarified completely. One hypothesis for the incongruity with previous 
results is that in UM-SCC-12 cells, the effects of E2 are the result of the convergence and 
crosstalk of the different membrane receptor pathways, ERα66 and ERα36. An alternate 
hypothesis could be that the tumorigenic effects of E2 are the result of E2 binding to ERα46 
or ERα66, has been shown previously in osteoblasts 148, or to an as-yet-uncharacterized 
novel membrane-bound estrogen receptor (Figure 3.7). 
Classical sex hormone nuclear receptors have been found in the plasma 
membranes of hormone-responsive cancers where they elicit rapid signaling pathways, 
which enhance cancer cell survival and proliferation 46.  From the plasma membrane it is 
thought that the classical receptors exert their effect through transactivation of the EGF 
or IGF-1 tyrosine kinase receptors in order to stimulate kinase cascades47.  It has been 
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suggested that the mechanism for trafficking of the classical sex hormones to the plasma 
membrane involves palmitoylation 35; the attachment of palmitic acid to an internal 
cysteine residue, which promotes the association of the receptor with caveolin-1, a 
transporter protein, to caveolae rafts in the plasma membrane49. Once the receptor is 
incorporated in the caveolae it may interact with many signaling proteins incorporated in 
the caveolae rafts and activate various Gα and Gβ/γ proteins within seconds52,149.  
ERs have been the primary receptors studied in order to ascertain this theory of 
the nature of membrane steroid hormone receptors. Immunological studies found that the 
membrane-localized estrogen binding protein shared epitope homology to the nuclear 
receptors150. Endothelial cells from combined ERα/ERβ deleted mice and breast cancer 
MCF-7 cells that lack nuclear ERα as well as small interfering RNA directed against the 
classical ER, eliminated estrogen binding at the cell surface and the rapid hormone 
signaling elicited by E236. Transfection of ER cDNA of classical ERα or ERβ in ER-null 
cells resulted in induction of both nuclear and membrane signaling pathways 34. Taken 
together there is evidence to support the role of classical nuclear receptors in membrane 
mediated rapid responses, which might clarify the effects seen in UM-SCC-12 cells of a 
synergistic effect of both ERα66 and ERα36 through membrane mediated signaling. 
Another plausible explanation for the results found in UM-SCC-12 cells may originate 
from crosstalk between membrane ER signaling with growth factor receptors, which 
results in the activation of the common membrane delineated pathways such as ERK-
MAPK, PI3k-Akt and Src68. Thus once ERα36 has been activated with resulting activation 
of PKC, the subsequent activation of growth factor receptor pathways may be responsible 
for the ensuing enhancement of proliferation. Such signaling cascades have been 
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implicated to have a major role in the carcinogenesis and progression of breast cancer 
independently and in collaboration with classical genomic E2 signaling. The interaction 
between membrane ER and transmembrane growth factor signaling pathways such as 
insulin-like growth factor I receptor (IGF-IR), epidermal growth factor (EGFR), Src and 
HER2 and the upregulation of these signaling pathways has been accepted as being one 
of the mechanisms underlying resistance to endocrine therapy in breast cancer151. The 
activation of these signaling pathways has a variety of documented effects including 
inhibition of apoptosis, stimulation of cell proliferation, enhanced invasion and cell motility, 
and induction of angiogenesis110,152.  
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Figure 3.7 17β-estradiol activates PKC in UM-SCC-11A cells; and PKC and PLD in 
UM-SCC-12 cells by binding to ERα36 in the caveolae. 
In UM-SCC-12, 17β-estradiol activation of PLD results in increased DNA synthesis. 17β-
estradiol also activates PLD through an unknown caveolae-bound estrogen receptor to 
decrease total p53 levels and apoptosis.   
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The findings of this study present compelling evidence that laryngeal cancer is sex 
hormone responsive, specifically to E2. Rapid non-genomic membrane signaling has 
been found to have an important role in mediating the effect of E2 in laryngeal cancer 
cells. These effects are hypothesized to be mediated by the activation of different 
membrane receptors and subsequent activation of growth factor receptors and tyrosine 
kinase receptors. The full impact of steroid hormones is the result of the convergence and 
crosstalk of the membrane and classical nuclear receptor pathways. Their integrative, at 
times synergistic or alternatively antagonistic, effects confer a variability and complexity 
to steroid hormone function.  
This is emphasized in the two laryngeal cell lines studied, in which one exhibited 
a protective effect of E2 while in the other, E2 had a deleterious effect augmenting 
proliferation and conferring anti-apoptotic potential to the cancer cells. These findings 
stress the importance of establishing the molecular and clinical characterization of the 
specific tumor in order to tailor treatment accordingly, thus optimizing treatment while 
reducing adverse effects for each individual patient. Further investigation is warranted in 
order to elucidate the versatile role of E2 in laryngeal cancer pathogenesis and 
progression, the array of membrane-mediated mechanisms by which these effects come 
in to play, and to shed light on their impact on the treatment and management of laryngeal 
cancer. 
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Chapter 4.    
Loss of estrogen receptors is associated with increased tumor aggression in 
laryngeal squamous cell carcinoma 
[Chapter 4 is in preparation as: Verma A, Schwartz N, Cohen DJ, Patel V, Boyan BD, 
Schwartz Z. Loss of estrogen receptors is associated with increased tumor aggression in 
laryngeal squamous cell carcinoma. Scientific Reports. In Preparation] 
 
Introduction 
The larynx is an overlooked secondary sex hormone organ. Similar to other sex 
hormone organs, it undergoes trophic changes in response to hormonal changes during 
puberty, and morphological changes during adulthood. Steroid hormones have been 
reported to play a significant role in voice changes during maturation, as their effects 
mediate the lengthening and thickening of the male vocal folds.153 In the female larynx, 
fluctuations in estrogen levels during the menstrual cycle are accompanied by variations 
in the pitch of the voice.154 Atrophy and dystrophy have been found to be pronounced in 
the larynges of postmenopausal women as well as in the vocal fold tissue of 
ovariectomized rats.155 These subjects are known to suffer from edema of the laryngeal 
lamina propria, inflammation in squamous and respiratory epithelia, pseudostratification, 
and cilia loss,  but these symptoms were rectified with estrogen replacement therapy.156  
Despite the obvious responsiveness of the larynx to estrogen, the presence and 
differential expression of estrogen receptors (ER) is a matter of debate, particularly in 
laryngeal cancer. ER, mainly ER66, the traditional ER translated from the ESR1 gene, 
has been reported in laryngeal epithelia in both females157 and males,158 and changes in 
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ER are associated with inflammation and benign lesions.159 ER expression has also been 
verified in laryngeal cancer138,160 and at higher levels than in adjacent normal mucosa.139 
Moreover, the non-traditional transmembrane ERs G-protein coupled estrogen receptor 
(GPER1, sometimes called GPR30) and ER36, a splice variant of the traditional ER66, 
have been found in human vocal folds71 and laryngeal cancer cells,66 respectively.  
Another ER, ERβ, which is encoded by the ESR2 gene, has been inversely correlated 
with increased cancer aggression in laryngeal squamous cell carcinoma (LSCC).70  
However, opposing studies have not identified ER161 or any other steroid hormone 
receptors162,163 in the larynx or laryngeal cancer cells.135 The clinical implication of ER 
expression in laryngeal cancer is equally confounding. In a previous study, we found a 
correlation between the number of ERs and regional lymph node metastasis.66 This differs 
from other studies that reported a reduced prognosis164 and lower rates of lymph node 
metastasis with increased ER expression.139  
17β-estradiol (E2) is produced from testosterone by the enzyme aromatase during 
normal physiological function. At the cellular level, E2 elicits a wide array of nuclear and 
membrane signaling responses in different cells via different ERs. An assessment of 
estrogen’s full impact on laryngeal cancer must consider the vast number of nuclear, 
cytosolic, and membrane-associated ERs, the differential expression of ER in different 
cell types, and the convergence and crosstalk of the membrane and classical ER 
pathways in each cell. It is their integrative, at times synergistic or alternatively 
antagonistic, effects that confer the variability and complexity of E2 function in both normal 
and cancer cells.68  
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Estrogen exerts regionally specific effects on cell proliferation and mRNA 
expression of extracellular matrix (ECM)-associated genes in normal fibroblasts. 
Cervicothoracic fibroblasts from the vocal fold, trachea, and esophagus have been shown 
to respond differently to estrogen based on their specific estrogen profiles.165  Studies 
examining the presence of ERα in vocal cord fibroblasts show that it is localized 
predominantly in the nucleus and cytoplasm.159 Previous work by our group66 and 
others165 has shown that treatment with E2 suppresses extracellular matrix gene 
expression in laryngeal and vocal fold tissue, but through a membrane-associated 
estrogen receptor rather than a nuclear ER. The complexity of E2 function and its 
dependency on local ER expression are further emphasized in our previous study with 
laryngeal cancer cell lines, in which we found E2 exhibited either a protective effect 
inhibiting DNA synthesis, or a deleterious effect augmenting proliferation and conferring 
anti-apoptotic potential to the cancer cells in a manner specific to the ER profile in each 
cell line.67   
These findings stress the importance of further establishing the molecular and 
clinical characterization of laryngeal cancer in order to improve our understanding of the 
disease and its therapeutic options. The aim of our study was to further evaluate the 
different ER profiles that laryngeal cancer cells express and to correlate ER status with 
clinical prognoses. Furthermore, we implement our findings in vivo to evaluate how these 
cancers progress and behave with and without E2 in an animal model. 
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Materials and Methods 
Cell Culture 
 UM-SCC-12 cells and UM-SCC-11A were purchased from the Cancer Research 
Laboratory, Department of Otolaryngology/Head and Neck Surgery at the University of 
Michigan. Cells were maintained as previously described.67 Estrogen receptor profiles 
were reported in a previous publication67 and were compared against previously 
established estrogen receptor profiles137.  The two cell lines were further characterized 
as described below. 
Estradiol Production 
Aromatase Activity.  
Confluent cultures of UM-SCC-11A and UM-SCC-12 cells were harvested and assessed 
for aromatase activity (Aromatase (CYP19A) Activity Assay Kit (Fluorometric), Biovision, 
Milpitas, CA) according to manufacturer’s instructions. Monolayers were also assessed 
for total protein content (Pierce 660nm Protein Assay, ThermoFisher, Waltham, MA), and 
aromatase activity was normalized to total protein.  
17β-estradiol parameter assay.  
UM-SCC-11A and UM-SCC-12 cell monolayers were cultured to confluence in 
hormone-free phenol-red media supplemented with 10% charcoal-dextran stripped fetal 
bovine serum (CD-FBS). At confluence, cell supernatants were collected and assessed 
for total 17β-estradiol content (Estradiol parameter assay kit, RnD Systems, Minneapolis, 
MN). Monolayers were washed twice in 1X PBS, lysed in 0.05% Triton X 100, and 
assessed for total double-stranded DNA content as described below. Total supernatant 
17β-estradiol was normalized to total double-stranded DNA content. 
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Total p53 Content 
 p53 is a tumor suppressor gene that can induce apoptosis. Total p53 levels were 
measured 24 hours post-treatment with a sandwich ELISA (Human Total p53 DuoSet® 
IC, R&D Systems, Minneapolis, MN). Cell monolayers were cultured to confluence in 24W 
plates, then treated with fresh full media containing either 0 or 10-7M E2 for 9 minutes. 
These media were removed by aspiration and fresh media were added to the cultures for 
24 hours. Cultures were then washed twice in 1X PBS and harvested in 200μL of p53 
lysis buffer according to manufacturer’s instructions, then assayed for total protein content 
(ThermoFisher, Pierce 660 nm Protein Assay), and normalized as previously described67. 
DNA Quantification 
 Cultures were treated with 0 or 10-7M E2 for 9 minutes as above and harvested 
with p53 lysis buffer. Cultures were then assessed for total double-stranded DNA content 
using the QuantiFluor® dsDNA System according to manufacturer’s instructions 
(Promega, Madison, WI). 
Production of UM-SCC-12 Cells Silenced for ESR1 
 Cells lines containing scramble control mRNA (TurboGFP Cat.# SHCOO4V, 
Millipore Sigma, Burlington, MA) and cells silenced for ESR1 (shESR1-UM-SCC-12) 
(Cat.# SHCLNV-NM_000125, Millipore Sigma) were created by transducing WT UM-
SCC-12 cells with commercially available lentiviral shRNA plasmids and selecting the 
cells with 5μg/mL puromycin. Cells were maintained in full media containing 5μg/mL 
puromycin. Knockdown was assessed with western blots as described below. 
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Tumor Model 
Subcutaneous xenograft laryngeal cancer mouse model.  
UM-SCC-11A (n=16) and UM-SCC-12 (n=16) cell lines were mixed with 1X DPBS 
(Thermo Fisher Scientific, Waltham, MA) and phenol-red free Cultrex basement 
membrane extract (BME, Trevigen, Gaithersburg, MD) to a concentration of 7.5 mg/mL 
BME and 10 million cells/mL. The resulting cell suspension was kept on ice and 100μL (1 
million cells) was injected subcutaneously into the left flank of a 6-week old male NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse, Cancer Mouse Models Core, Massey Cancer 
Center, Virginia Commonwealth University, Richmond, VA) to create a subcutaneous 
xenograft model of laryngeal cancer.166 At the time of cell injection, each animal was also 
subcutaneously implanted with a 0.96mg/60-day release E2 pellet or a corresponding 
placebo pellet to create four experimental groups: UM-SCC-11A + Placebo, UM-SCC-
11A + E2, UM-SCC-12 + Placebo, UM-SCC-12 + E2 (n=8 for each condition).167 Tumors 
were allowed to grow for 8 weeks, and tumor measurements were taken with digital 
calipers starting at week 2 until the end of the study. After 8 weeks, mice were euthanized 
by CO2 inhalation and cervical dislocation and tumors were extracted and preserved on 
wet ice (<6 hours) until μCT analysis. After μCT analysis, tumors were fixed in formalin 
and histologically analyzed as described below. All animal experiments were conducted 
in full compliance with the recommendations for the Care and Use of Laboratory Animals 
of the National Institutes of Health under a protocol approved by the Virginia 
Commonwealth University Institutional Animal Care and Use Committee (protocol 
number AD10000675). 
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 In a second experiment, WT UM-SCC-12, and shESR1-UM-SCC-12 
subcutaneous xenografts were created as described above (n=16 for each cell line). 
Animals were subcutaneously implanted with a 0.96mg/60-day release E2 pellet or a 
corresponding placebo pellet as described above to create four experimental conditions: 
WT UM-SCC-12 + Placebo, WT UM-SCC-12 + E2, shESR1-UM-SCC-12 + Placebo, 
shESR1-UM-SCC-12 + E2 (n=8 for each condition). To preserve animal life, xenografts 
with scrambled control UM-SCC-12 cells were not created for this experiment. Tumors 
were monitored for 8 weeks until harvest. Animals were euthanized as described above 
and tumors were fixed in formalin. 
μCT analysis.  
After harvest, tumors were preserved for less than 6 hours on wet ice and scanned 
with a Bruker Skyscan 1173 μCT at 55kV and 70μA at a resolution of 560x560 pixels with 
an image pixel size of 40.26μm, an exposure time of 125ms and a rotation step of 0.8 
degrees.166  NRecon software version 1.6.10.4 (Kontich, Belgium) with a smoothing 
kernel of 0 and a beam hardening correction of 20% was used to reconstruct and analyze 
the tumors with a standard reconstruction protocol.  Total tissue volume approximated 
total tumor volume. 
Histology.  
After harvest, xenograft tumors were fixed in 10% neutral formalin for 7 days, 
processed, and embedded in paraffin.  Samples were then sectioned into 4μm thickness 
and stained with haemotoxylin and eosin as previously described.168  Slides were imaged 
at 10X and 40X (Zeiss AxioVision Microscope, Carl Zeiss, Oberkuchen, Germany). 
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Clinical Sample Acquisition 
 Frozen tissue samples and prepared haematoxilin and eosin (H&E) slides were 
acquired from Meir Hospital, Kfar Saba, Israel under Institutional Review Board (IRB) 
protocol #0497-13-RMC or from Massey Cancer Center, Virginia Commonwealth 
University (VCU), Richmond, Virginia under an anonymization agreement in compliance 
with the Office for Human Research Protections’ “Guidance on Research Involving Coded 
Private Information or Biological Specimens”.  Information on patient gender, age, 
tobacco and alcohol use, and tumor location (glottic/supraglottic), was provided by 
respective institutions. A value of ‘0’ indicates no or infrequent use of tobacco or alcohol 
products as reported by the patient; a value of ‘1’ indicates self-reported regular, heavy 
use of tobacco or alcohol products. 
 
 
ID number Origin Gender Age Location Tobacco Alcohol 
1 Meir Hospital, Israel M 78 glottic 1 0 
2 Meir Hospital, Israel M 76 glottic 1 1 
3 Meir Hospital, Israel M 68 glottic 1 0 
4 Massey Cancer Center, USA M 73 glottic 1 0 
5 Massey Cancer Center, USA M 57 glottic 1 1 
6 Massey Cancer Center, USA M 59 supraglottic 1 0 
7 Massey Cancer Center, USA F 67 supraglottic 0 0 
8 Massey Cancer Center, USA M 69 supraglottic 1 1 
9 Massey Cancer Center, USA M 64 glottic 1 1 
10 Massey Cancer Center, USA M 51 supraglottic 1 1 
11 Massey Cancer Center, USA M 64 supraglottic 1 0 
12 Meir Hospital, Israel M 58 supraglottic 1 0 
13 Meir Hospital, Israel M 70 glottic 1 0 
14 Meir Hospital, Israel M 65 glottic 1 0 
Table 4.1 Laryngeal squamous cell carcinoma samples and patient demographics 
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Number of Patients 14 
Mean Age 65.6 ± 7.59 
Female 1 
Male 13 
Supraglottic 6 
Glottic 8 
Heavy Tobacco User 13 
Heavy Alcohol Consumer 5 
Table 4.2 Summary of clinical laryngeal squamous cell carcinoma samples. 
Preparation of Lysates 
 
For samples obtained from Meir Hospital, Israel, tissue pieces were weighed, and 
>10mg of tissue was minced into pieces <1mm3 with a No.11 scalpel blade. Tissue pieces 
were homogenized with a Dounce tissue grinder in Nonidet p-40 (NP-40) containing 5mM 
NaF and 20μL of protease inhibitor cocktail (Sigma-Aldrich #P3480) per mL of NP-40. 
After homogenization, samples were sonicated on ice at 40 amperes for 5 seconds to 
obtain tissue lysates as previously described.169,170   
For samples from the VCU Tissue and Data Acquisition and Analysis Core 
Laboratory (TDAAC), frozen tissue shavings were obtained and washed twice with 2 mL 
of 1X PBS containing 40μL of protease cocktail inhibitor.  Samples were vortexed and 
centrifuged at 1000 rpm for 5 minutes between each wash.  Tissue pellets were then 
resuspended in 200μL of radioimmunoprecipitation assay (RIPA) buffer and sonicated on 
ice at 40 amperes for 5 seconds to obtain tissue lysates.   
To assess ERα66 and ERα36 knockdown in shESR1-UM-SCC-12, WT UM-SCC-
12, and Scramble Control UM-SCC-12, monolayer cultures were grown in T-75 flasks 
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(n=1 flask per cell line) until confluent, washed twice with 1X phosphate buffered saline 
(PBS), and harvested with 300μL RIPA as previously described to create cell lysates.171  
Tissue and cell lysates were incubated on ice for 30 minutes and centrifuged at 
13000g for 20 minutes at 4C.  Supernatants were saved and assayed for total protein 
content and used in western blots as described below. 
Western Blots 
50μL of tissue or cell lysate containing 8-35μg protein were loaded onto 4-20% 
Mini-PROTEAN®TGX™ precast polyacrylamide gels (Bio-Rad, Hercules, CA). Proteins 
were transferred to low-fluorescence PVDF membranes using a Trans-Blot® 
Turbo™Transfer System (Bio-Rad).  Membranes were blocked for 1 hour at room 
temperature in odyssey blocking buffer (LI-COR) and then incubated with antibodies 
against GAPDH (mouse monoclonal, Millipore, Burlington, MA) and ERα (rabbit 
polyclonal, Chi Scientific, Maynard, MA) or ERβ (rabbit polyclonal, Abcam, Cambridge, 
United Kingdom) for 24 hours at 4oC. Membranes were then incubated with IRDye 
700CW (goat anti mouse) and IRDye 800CW (goat anti-rabbit) conjugated secondary 
antibodies (LI-COR) for 45 minutes at room temperature and imaged using the LI-COR 
Odyssey® CLx Infrared Imaging System. Western blots were carried out at a central 
institution (VCU) to minimize variation and repeated once (a total of two experiments per 
assay) with 1 replicate per sample in each experiment. Signal intensity for proteins of 
interest (ERα66, ERα36, and ERβ) was normalized to GAPDH. Where no signal was 
detected, samples were considered to have ‘0’ signal intensity and marked with ‘N.D.’, or 
no signal detected, on graphs (Figure 4.1, Figure 4.2).  
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Normalized signal intensity for ERα66, ERα36, and ERβ in each tumor sample was 
grouped by stage (stage 1, stage 2 & 3, stage 4) and graphed (Figure 4.3A-4C); or 
normalized to corresponding signal intensities in adjacent epithelial tissue (Figure 4.3D). 
A normalized ratio of greater than 1 was recorded with a blue upward-pointing arrow ↑, 
and a ratio less than 1 was recorded with a red downward-pointing arrow ↓ (Table 4.3). 
To generate heat maps, log10 of normalized signal intensities of tumor (Figure 4.3E) or 
normal epithelial tissue (Figure 4.3F) was calculated and graphed using the Graphpad 
Prism 7 Heatmap generator.  Samples were grouped by stage and arranged in order of 
increasing cancer aggression (top-bottom) (Figure 4.3E-F). 
 
 
Figure 4.1 Expression of ER in individual LSCC samples. 
Quantification of western blots for [A] ERα66, [B] ERα36, and [C] ERβ for individual 
clinical tumor samples. Y-axes are given as log scales. Samples are color-coded 
according to clinical stage. Stage 1 samples are green, stage 2 yellow, stage 3 orange, 
and stage 4 red. 
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Figure 4.2 Expression of ER in individual normal laryngeal tissue samples (LSCC 
surround). 
Quantification of western blots for [A] ERα66, [B] ERα36, and [C] ERβ for normal epithelia 
adjacent to clinical tumor samples. Y-axes are given as log scales. Samples are color-
coded according to clinical stage. Stage 1 samples are green, stage 2 yellow, stage 3 
orange, and stage 4 red. 
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Figure 4.3 Expression of ER isoforms in stage 1-4 clinical laryngeal cancer. 
Quantification of western blots of [A] ERα66, [B] ERα36, and [C] ERβ. Samples were 
grouped by cancer stage (stage 1, stages 2 and 3, stage 4) and analyzed by one-way 
ANOVA with Tukey’s correction. Bars not sharing a letter are significantly different from 
each other with P < 0.05. Bars are shown as total protein expression, with solid bars 
representing protein expression in normal epithelia and patterned bars representing 
protein expression in tumor tissue. Y-axes are given as log scales. [D]  Protein expression 
in LSCC samples was normalized to expression in surrounding epithelia, grouped by 
stage, and graphed. * indicates significance against stage 1 within protein groups. Panels 
E and F:  Heat maps showing [E] tumor and [F] surrounding epithelia expression of 
ERα66, ERα36, and ERβ for each sample. Individual protein expression was measured 
by western blot and graphed as log10 of normalized signal intensity. 
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Ratio Symbol 
>1 ↑ 
<1 ↓ 
 
 
Table 4.3 Estrogen receptor protein expression in clinical laryngeal squamous cell 
carcinoma samples. 
  
ID 
number 
Pathology  cT cN cM Stage Tumor/Normal 
ERα66 ERα36 ERβ 
1 invasive keratinizing SCC, NOS 1 0 0 1 ↑ ↑ ↓ 
2 invasive keratinizing SCC, NOS 1 0 0 1 ↑ N/A ↓ 
3 invasive keratinizing SCC, NOS 1 0 0 1 ↑ N/A ↑ 
4 invasive keratinizing SCC moderate diff 2 x x 2 ↑ ↓ N/A 
5 invasive keratinizing SCC moderate diff 2 0 x 2 ↓ ↓ N/A 
6 invasive keratinizing SCC moderate diff 3 0 x 3 ↑ ↑ N/A 
7 invasive keratinizing SCC moderate diff 3 0 x 3 ↑ ↑ N/A 
8 invasive keratinizing SCC moderate diff 3 0 x 3 ↑ N/A N/A 
9 invasive keratinizing SCC moderate diff 4 x x 4 ↑ ↑ N/A 
10 invasive keratinizing SCC moderate to poorly diff 4 2b x 4 ↓ ↑ N/A 
11 invasive keratinizing SCC moderate diff 4 2c x 4 ↓ ↑ N/A 
12 invasive keratinizing SCC moderate diff 4 1 0 4 ↓ ↓ ↓ 
13 invasive keratinizing SCC moderate to poorly diff 4 2 0 4 ↓ ↓ ↓ 
14 invasive keratinizing SCC, NOS 4 0 0 4 ↓ ↓ ↓ 
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Accessing ESR1 and ESR2 Gene Transcript Expression Data 
 ESR1 and ESR2 expression data were publically available and were obtained from 
Total Cancer Genome Atlas (TCGA) cohort (Project Id: TCGA-HNSC) (n=525 patients) 
(https://portal.gdc.cancer.gov/projects/TCGA-HNSC) using University of California Santa 
Cruz (UCSC) Xena (http://xena.ucsc.edu/).172,173  In brief, ESR1 and ESR2 expression 
data were downloaded from Xena and only samples taken from primary solid head and 
neck squamous cell carcinomas were included in overall head and neck cancer analyses.  
Samples were further separated by neoplasm tissue type, and only primary LSCC 
samples were included in the second analysis.  Overall survival (OS) was defined as time 
of death by any cause and capped at fifteen years.  Kaplan-Meir curves of OS were 
generated by GraphPad Prism v5.0 (GraphPad Software Inc.).  Patients were grouped 
according to median gene expression as described previously.174   
Statistical Analysis 
 μCT tumor volumes were compared with one-way ANOVA analysis with Tukey’s 
correction.  Tumor volume measurements over time were analyzed with a repeated-
measures ANOVA.  Ex vivo western blots were grouped by stage and analyzed with one-
way ANOVA analysis with Tukey’s correction to compare between stages and two-way 
ANOVA analysis with Bonferroni post-tests between stages to determine significance 
between precancerous and tumor tissue.  Tumor protein expression for ERα66, ERα36, 
and ERβ was normalized to matched precancerous tissue and graphed as 
treatment/control.  Two-way ANOVA analysis with Bonferroni post-tests between stages 
was done to determine significance between stages.  Statistical analysis was performed 
by using GraphPad Prism v5.0.  Comparison of high and low ESR survival curves was 
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done with a Log-rank Mantel-Cox χ2 test.  For all studies, p-values < 0.05 were considered 
significant. 
 
Results 
UM-SCC-12 and UM-SCC-11A locally produce 17β-estradiol. 
 Both ER positive (ER+) UM-SCC-12 cells, which express ERα66 and ERα36, and 
ER negative (ER-) UM-SCC-11A cells, which do not express ERα66 and only express 
ERα36, produce similar concentrations (~250 pg/mL supernatant) of 17β-estradiol 
(Figure 4.4A).67 However, ER- UM-SCC-11A produced ~1.5 times more 17β-estradiol per 
cell than their ER+ UM-SCC-12 counterparts (Figure 4.4B). Similarly, UM-SCC-11A cells 
had higher basal aromatase activity than UM-SCC-12 cells (Figure 4.4C), with 
approximately 4nU of enzyme per mg of protein compared to UM-SCC-12’s 1nU/mg 
protein.  
 
17β-estradiol increased tumor aggression in estrogen receptor positive laryngeal cancer, 
but not estrogen receptor negative cancer in vivo.   
ER positive UM-SCC-12 xenografts grown in placebo-treated mice initially increased in 
volume (slope ≠ 0, Table 4.4), but did not increase in size after 4 weeks of growth (slope 
≈ 0, Table 4.5) and ultimately reached a volume of 250-500 mm3 (Figure 4.5A,C). In 
contrast, UM-SCC-12 xenografts grown in E2-treated mice increased in size over time 
(slope ≠ 0, Table 4.4, Table 4.5) and attained a final volume of 500-1000 mm3, 2-fold 
larger than tumors grown in control-treated mice (Figure 4.5A,C). Most of this increase 
was observed after week 4. This effect was not observed in ER negative UM-SCC-11A 
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tumors, where both control and E2 treated tumors increased in size at a similar rate and 
to a similar final volume (Figure 4.5B,C). Histology of UM-SCC-12 tumors revealed even 
cell shape, chromatin distribution, and uniform morphology in control tumors (Figure 
4.5D), similar to stage 1 LSCC (Figure 4.6A,E). E2 treated tumors stained with eosin and 
haematoxylin (H&E) had similar eosin staining but darker haematoxylin staining, more 
irregular nuclei, and uneven chromatin distribution as compared to control treated tumors 
(Figure 4.5E), similar to stage 2 LSCC (Figure 4.6B,F). 
 
 
 
Table 4.4 Xenograft models of LSCC tumor growth curve: linear fit, weeks 2-8. 
11A Control 11A 17b-Estradiol 12 Control 12 17b-Estradiol
Best-fit values
Slope 346.1 ± 46.88 428.2 ± 47.74 63.91 ± 12.24 164.9 ± 19.50
Y-intercept when X=0.0 -1091 ± 280.8 -1254 ± 263.7 47.39 ± 65.68 -352.4 ± 106.0
X-intercept when Y=0.0 3.152 2.929 -0.7415 2.138
1/slope 0.002890 0.002335 0.01565 0.006065
95% Confidence Intervals
Slope 249.3 to 442.8 331.5 to 525.0 39.31 to 88.51 125.9 to 203.9
Y-intercept when X=0.0 -1671 to -511.3 -1789 to -719.8 -84.66 to 179.4 -564.6 to -140.3
X-intercept when Y=0.0 2.001 to 3.866 2.103 to 3.519 -4.449 to 0.9814 1.085 to 2.844
Goodness of Fit
R square 0.6943 0.6850 0.3530 0.5478
Sy.x 417.0 612.1 180.6 306.4
Is slope significantly non-zero?
F 54.50 80.46 27.28 71.48
DFn, DFd 1.000, 24.00 1.000, 37.00 1.000, 50.00 1.000, 59.00
P value < 0.0001 < 0.0001 < 0.0001 < 0.0001
Deviation from zero? Significant Significant Significant Significant
Data
Number of X values 7 7 7 7
Maximum number of Y replicates 5 7 8 9
Total number of values 26 39 52 61
Number of missing values 44 31 18 9
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Table 4.5 Xenograft models of LSCC tumor growth curve: linear fit, weeks 4-8. 
 
 
 
Figure 4.4 E2 is locally produced in vitro by UM-SCC-12 and UM-SCC-11A cultures. 
Production of 17β-estradiol by ER+ UM-SCC-12 and ER- UM-SCC-11A [A] overall and 
[B] per cell. [C] Basal aromatase activity in laryngeal cancer cell lines. P-values less than 
0.05 were considered significant. *indicates significance against UM-SCC-12.  
11A Control 11A 17b-Estradiol 12 Control 12 17b-Estradiol
Best-fit values
Slope 441.2 ± 69.19 684.9 ± 79.54 19.09 ± 22.63 209.0 ± 37.80
Y-intercept when X=0.0 -1728 ± 443.0 -2958 ± 503.3 343.3 ± 140.8 -638.4 ± 234.5
X-intercept when Y=0.0 3.917 4.318 -17.99 3.055
1/slope 0.002267 0.001460 0.05239 0.004785
95% Confidence Intervals
Slope 296.9 to 585.5 521.4 to 848.4 -26.93 to 65.11 132.7 to 285.3
Y-intercept when X=0.0 -2653 to -804.3 -3992 to -1923 56.95 to 629.7 -1112 to -164.9
X-intercept when Y=0.0 2.664 to 4.606 3.627 to 4.784 -infinity to -0.8896 1.221 to 3.969
Goodness of Fit
R square 0.6703 0.7404 0.02050 0.4213
Sy.x 417.2 574.1 194.5 350.3
Is slope significantly non-zero?
F 40.66 74.15 0.7115 30.57
DFn, DFd 1.000, 20.00 1.000, 26.00 1.000, 34.00 1.000, 42.00
P value < 0.0001 < 0.0001 0.4048 < 0.0001
Deviation from zero? Significant Significant Not Significant Significant
Data
Number of X values 5 5 5 5
Maximum number of Y replicates 5 7 8 9
Total number of values 22 28 36 44
Number of missing values 28 22 14 6
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Figure 4.5 E2 increases tumor burden in UM-SCC-12, but not UM-SCC-11A 
xenografts. 
[A,B] Effect of 17β-estradiol on tumor growth of ER+ and ER- xenografts in vivo. Tumor 
growth of [A] UM-SCC-12 (ER+) and [B] UM-SCC-11A over time with and without 
estradiol supplementation. * indicates significance against week-matched control tumor 
volume. [C] Final tumor volume was measured with μCT Bars not sharing a letter have 
significantly different volumes with P < 0.05. [D-F] Representative histology of [D,E] ER+ 
and [F,G] ER- tumors [E,G] with and [D,F] without 17β-estradiol stained with hematoxylin 
and eosin and imaged at 40X. Scale bars = 20μm. 
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Estrogen receptor negative laryngeal cancer is more aggressive than estrogen receptor 
positive cancer.   
UM-SCC-11A subcutaneous xenografts implanted into mice grew ~250 times their 
original size to a final volume of 1000-2000 mm3 (Figure 4.5B). UM-SCC-11A tumors 
attained a final volume 2-4 times greater than that observed in UM-SCC-12 xenografts 
(Figure 4.5C). UM-SCC-11A also grew at a continuous exponential rate throughout the 
study (R2=0.77-0.88, Table 4.6) with a faster doubling time than comparable UM-SCC-12 
tumors (Table 4.6). Histology on UM-SCC-12 xenografts revealed moderately 
differentiated tumors with defined edges and uniform cell shapes (Figure 4.5D-E). 
Conversely, histology of UM-SCC-11A xenografts revealed anaplastic tumors with high 
variability in nucleus and cell size within the tumor. These tumors also showed a 
significant amount of invasion into the surrounding tissue (Figure 4.5F-G). The limited 
invasion and defined tumor edges observed in UM-SCC-12 cells are reminiscent of the 
defined tumor edges and even cell morphology observed in Stage 1 and 2 LSCC (Figure 
4.6A,B,E,F). The increase in invasion in UM-SCC-11A tumors as compared to UM-SCC-
12 tumors is similar to the increase in tumor invasion observed in samples of stages 3 
and 4 (Figure 4.6C,D). The similar eosin staining, darker haematoxylin staining, irregular 
cell shape, and irregular nuclei structure observed in UM-SCC-11A tumors are similar to 
the cell morphology observed in stage 3 and 4 clinical LSCC samples (Figure 4.6G,H).  
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Figure 4.6 Representative Histology of Clinical Samples of Laryngeal Cancer. 
Representative histology of [A,E] stage 1, [B,F] 2, [C,G] 3, and [D,H] 4 LSCC. Images 
were taken at [A-D] 10X and [E-H] 40X. [A-D] Scale bars = 100μm. [E-H] Scale bars = 
20μm. 
 
 
Table 4.6 Xenograft models of LSCC tumor growth curve: exponential fit, weeks 2-
8. 
Exponential growth equation 11A Control 11A 17b-Estradiol 12 Control 12 17b-Estradiol
Best-fit values
Y0 44.95 15.50 163.4 54.62
k 0.4723 0.6563 0.1533 0.3782
Tau 2.117 1.524 6.524 2.644
Doubling Time 1.468 1.056 4.522 1.833
Std. Error
Y0 24.49 7.819 38.50 21.42
k 0.07290 0.06586 0.03665 0.05400
95% Confidence Intervals
Y0 -5.601 to 95.49 -0.3556 to 31.35 86.01 to 240.8 11.77 to 97.48
k 0.3218 to 0.6227 0.5228 to 0.7898 0.07960 to 0.2270 0.2701 to 0.4862
Tau 1.606 to 3.108 1.266 to 1.913 4.406 to 12.56 2.057 to 3.702
Doubling Time 1.113 to 2.154 0.8776 to 1.326 3.054 to 8.708 1.426 to 2.566
Goodness of Fit
Degrees of Freedom 24 37 50 59
R square 0.7679 0.8778 0.3106 0.5898
Absolute Sum of Squares 3.168e+006 5.376e+006 1.738e+006 5.025e+006
Sy.x 363.3 381.2 186.5 291.8
Number of points
Analyzed 26 39 52 61
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Estrogen receptor expression in clinical cases of laryngeal squamous cell carcinoma is 
highly variable and regionally localized.   
Quantification of western blots showed that ERα66 (Figure 4.1A, Figure 4.2A), 
ERα36 (Figure 4.1B, Figure 4.2B), and ERβ (Figure 4.1C, Figure 4.2C) signal intensity 
varied exponentially from samples to sample. While all samples taken from stage 4 
patients had similar total levels of ERα66 (Figure 4.1A, Figure 4.2A) regardless of locality, 
ERα36 and ERβ expression was highly variable and appeared to be regionally localized. 
Stage 4 samples collected at Meir Hospital, Israel had greater ERα36 staining (Figure 
4.1B, Figure 4.2B) and ERβ staining (Figure 4.1C, Figure 4.2C) than samples collected 
at Massey Cancer Center, U.S.A. All samples collected in Israel expressed high levels of 
ERβ, but none of the samples collected in the U.S.A. expressed ERβ (Figure 4.1C, Figure 
4.2C). This regional variability was also apparent when considering the ratio of ER 
expression in tumor vs. precancerous tissue. All stage 3 and 4 samples collected in the 
U.S.A. had higher ratios of ERα36 in tumor tissue vs precancerous tissue (Table 4.3). 
However, stage 4 samples collected in Israel expressed less ERα36 in tumor tissue as 
compared to precancerous tissue (Table 4.3). If neither tumor nor matched normal tissue 
expressed protein for ERα66, ERα36, or ERβ as measured by western blot, a value of 
‘N/A’ was recorded for that sample (Table 4.3). 
 
Decreased absolute and normalized ERα66 expression is associated with advanced 
cancer stage in clinical samples of laryngeal squamous cell carcinoma.   
A general trend of towards lower ERα66 expression was observed in more 
aggressive tumors (Stage 2-4) as compared to indolent tumors (Stage 1) (Figure 4.3A,E). 
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The total amount of ERα66 in these samples was greatest in stage 1 cancer (Figure 4.3A), 
and the proportion of ERα66 expressed by the tumor tissue as compared to matched 
precancerous tissue was also greater in stage 1 samples as compared to stage 4 samples 
(Figure 4.3D-F, Table 4.3). Samples from patients with stage 2-3 cancer had less ERα66 
overall as compared to stage 1 samples (Figure 4.3A) but, like stage 1 samples, tumor 
tissues expressed more ERα66 than matched precancerous tissue (Figure 4.3D, Table 
4.3). This trend did not hold true for Stage 4 cancer samples, where the ratio of ERα66 
expression to precancerous tissue was flipped and precancerous tissue expressed more 
ERα66 than matched tumor tissue samples (Figure 4.3A,D-F; Table 4.3).  
Patterns of relative ER expression among cancer stages described for ERα66 
above also held true for ERα36 and ERβ (Figure 4.3B,C). Tumor tissue taken from 
patients with stage 4 cancer generally expressed less ERα36, and ERβ than matched 
precancerous samples (Figure 4.3B-F, Table 4.3). The ratio of ER expression in tumor 
vs. precancerous tissue was significantly lower in stage 4 samples as compared to stage 
1 samples for all ERs: ERα66, ERα36, and ERβ (Figure 4.3D, Table 4.3).   
Unlike ERα66, absolute expression of ERα36 and ERβ was similar in stage 1 and 
stage 4 cancers (Figure 4.3B,C). The most aggressive cancers (stage 4) generally had 
low ERα66 expression and high ERα36 expression (Figure 4.1A-B). Absolute ERα36 
expression in stage 2 and 3 cancer samples was lower than stage 1, but ERα36 
expression generally increased with stage in tumor samples taken from stage 2-4 patients 
(Figure 4.1B). Normal tissue surrounding stage 4 samples expressed higher ERα36 than 
matched normal tissue from lower stage cancers. Neither tumor nor precancerous 
samples taken from stage 2 and 3 samples patients expressed ERβ. However, it is 
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important to note that all stage 2 and 3 samples were collected in the U.S.A., while stage 
4 samples were collected in both the U.S.A. and Israel. 
 
Higher expression of ESR1 but not ESR2 is associated with increased survival in patients 
with primary laryngeal squamous cell carcinoma.   
Analysis of RNAseq data taken from the TCGA study of 525 patients with primary 
head and neck cancer showed that patients with higher than median tumor ESR1 
expression (ESR1 > 5.56) had significantly better survival rates than patients with lower 
tumor ESR1 expression (Figure 4.7A). This trend was also observed when patients were 
stratified by tumor ESR2 expression, with patients with higher than median ESR2 
expression (ESR2 > 3.69) (Figure 4.7B) having significantly higher survival rates than 
patients with lower ESR2 expression after 15 years.   
RNAseq data taken from a TCGA study of 128 patients with primary LSCC showed 
that patients with higher than median tumor ESR1 expression (ESR1 > 5.56) had 
significantly higher survival rates as compared to patients with lower tumor ESR1 
expression (Figure 4.7C) with p-value < 0.0001 and a hazard ratio of 0.02845. However, 
no correlation between ESR2 expression and survival was observed when patients were 
stratified into groups of higher and lower than median ESR2 expression (Figure 4.7D) (p-
value = 0.83).   
Silencing ESR1 in estrogen receptor positive laryngeal squamous cell carcinoma 
eliminates the 17β-estradiol response and increases aggression. 
Silencing the ESR1 gene, which encodes all known ERα isoforms, in UM-SCC-12 
cells reduces ERα66 expression by 76% as compared to a 33.5% knockdown in scramble 
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control cells (Figure 4.8A,B). Similarly ESR1 silencing knocked down ERα36 expression 
by 75.2% as compared to 44.4% knockdown in scramble control cells (Figure 4.8A,C).  
Silencing ESR1 in UM-SCC-12 did not change cell number in vitro as measured 
by total double-stranded DNA content (Figure 4.9A). However, silencing ESR1 altered 
total p53 content in these cells (Figure 4.9B). p53 protein production is associated with 
apoptosis. Total p53 content was significantly lower for shESR1-UM-SCC-12 cells as 
compared to WT and scramble control UM-SCC-12 cultures. Furthermore, silencing 
ESR1 in UM-SCC-12 eliminated the response of these cells to E2. Both vehicle and E2-
treated shESR1-UM-SCC-12 cultures had approximately 1/3 the p53 content of WT 
vehicle-treated UM-SCC-12, whereas both vehicle and E2-treated shESR1-UM-SCC-12 
cultures levels of p53 similar to those observed in WT UM-SCC-12 cells treated with E2 
(Figure 4.9B). 
UM-SCC-12 subcutaneous xenografts silenced for the ESR1 gene grew 
approximately 4 times larger than WT UM-SCC-12 xenograft tumors and twice as large 
as WT UM-SCC-12 xenografts treated with E2. shESR1-UM-SCC-12 xenografts grew to 
similar sizes regardless of E2 supplementation. Both silenced and WT xenografts grew in 
an approximately linear fashion, suggesting a faster doubling time in vivo for shESR1-
UM-SCC-12 cells as compared to WT UM-SCC-12. 
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Figure 4.7 Intra-tumoral ESR1 expression correlates with survival. 
Kaplan-Meier survival curves for patients with any [A,B] primary head and neck 
squamous cell carcinoma or [C,D] primary LSCC stratified by higher or lower than median 
[A,C] ESR1 or [B,D] ESR2 expression. Survival curves were analyzed with Log-rank 
Mantel-Cox χ2 tests. P-values less than 0.05 were considered significant.  
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Figure 4.8 Knockdown of ER in UM-SCC-12 cells. 
A representative [A] western blot showing ERα expression in WT, scramble-control, and 
ESR1-silenced UM-SCC-12 cell lines. GAPDH was used as a protein loading control. [B] 
ERα66 and [C] ERα36 protein expression were normalized to GAPDH and quantified by 
normalized signal intensity. N=1. 
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Figure 4.9 Silencing ESR1 in ER+ LSCC increases tumor aggression. 
Effect of silencing ESR1 in ERα66+ UM-SCC-12 cells in vitro on [A] cell number and the 
response to estrogen as measured by [B] total p53. Bars that do not share a letter are 
considered significant with p-values less than 0.05. In vivo, WT and ESR1-silenced UM-
SCC-12 cell-line xenografts were implanted in a subcutaneous xenograft mouse model 
and [C] tumor burden was measured over time. Black * indicates significance against 
week-matched WT-vehicle tumor volume. Red squares ■ indicate significance against 
week-matched WT-E2 tumor volumes. P-values less than 0.05 were considered 
significant.   
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Discussion 
Accumulated evidence has substantiated that laryngeal cancer, a common head 
and neck cancer in the United States, is a hormone responsive cancer, comparable to 
other more renowned secondary sex hormone cancers. Despite the reports of E2 
detrimental effects in laryngeal cancer89,90 and that anti-estrogen treatment has a 
beneficial effect64 originating almost three decades ago,62 there has been little advance 
in translating this recognition of the importance of E2 to practical clinical implications. This 
might be explained by the cofounding and heterogeneous ER profile detected in these 
cancer cells. The cumulative effects of this heterogeneity translate to disparate responses 
to E2 and must be clarified before implementation to clinical practice.  
Local production of E2 has been described in many steroid hormone responsive 
cancers, including breast,175 endometrium,176 cervical,177 and testicular cancer.178 Here, 
we observed a saturation in local E2 production that occurred around 250 pg/mL, roughly 
20 times previously reported levels of estradiol in serum from healthy adult males,179 but 
not dissimilar from E2 levels reported in plasma from pre-menopausal breast cancer 
patients.180 Similar levels of E2 production have also been observed in breast cancer-
associated fibroblasts.82 The tumorigenic properties of estrogen have been well-
described in breast cancer,55,76 and our previous work has shown that E2 is also 
tumorigenic in ER+, but not in ER-, laryngeal cancer.66,67 The increase in aromatase 
activity and corresponding increase in E2 production per cell in ER- LSCC vs. ER+ LSCC 
was surprising; however similar disparities in E2 production have been observed in ER+ 
and ER- breast cancer.181 Increased serum E2 is associated with compensatory 
mechanisms that arise in conjunction with defective estrogen signaling in normal breast 
Modulation of 24R,25(OH)2D3 Tumorigenicity by ER Isoforms in E2-Responsive Cancer • Spring 2019 
Anjali Verma • Ph.D. Dissertation • Biomedical Engineering • Virginia Commonwealth University 98 
 
tissue,182,183 and elevated serum E2 has also been reported in estrogen insensitive triple-
negative breast cancer (TNBC) patients as compared to those with ER+ tumors.181 It is 
possible that the increase in aromatase activity and subsequent increase in E2 production 
per cell was due to a saturation in E2 concentration reminiscent of a classic negative 
signaling feedback loop184. However, it is also possible that the elevated E2 production 
and aromatase activity observed in ER- LSCC is a result of similar compensatory 
signaling associated with these cells’ insensitivity to estradiol.67  
Consistent with previous reports,138,139,157–160 evaluation of the laryngeal epithelia 
adjacent to laryngeal cancer reveals expression of both classical nuclear ERs and 
membrane ERs, specifically the ERα isoform ERα36. ERα36 is a well-established ERα 
splice variant which can mediate the effects of E2 independent of nuclear ERα. This effect 
has been demonstrated in ERα66 null cells and in studies using antibodies against the 
nuclear and membrane isoforms of ERα.109 The receptor initiates divergent pathways 
from the plasma membrane that re-converge downstream to affect cancer cell 
survivability.27 In our study a striking difference is evident between the epithelia adjacent 
to advanced aggressive tumors and to more indolent tumors. While ER expression is 
highly variable, both ER variants, the classical nuclear ERα66 and ERα36, are 
expressed in high levels in the epithelia adjacent to tumors displaying aggressive 
behavior, while absent in the indolent samples. In this, the ERα expression patterns in 
the epithelia adjacent to aggressively malignant samples (stage 4) is reminiscent of the 
ERα66 and ERα36 expression profiles generally seen in more indolent tumor samples. 
It is well known that laryngeal squamous cell carcinoma arises from precancerous 
lesions, mainly dysplastic lesions. However, the exact molecular mechanisms of 
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malignant transformation of laryngeal mucosa are not clear. Moreover, the ability to 
identify patients who are most likely to progress into invasive laryngeal cancer or possess 
warning aggressive markers early in the course of their disease is paramount to early 
diagnosis and treatment to confer better prognoses. The presence of markers that 
correlate with pre-malignancy or early-stage cancer could have cardinal bearing on 
clinical decisions to observe or aggressively treat lesions.  
Various classification systems have been crafted in an attempt to describe the 
histologic features of these laryngeal epithelial precursor lesions. Unfortunately, a 
universally accepted histopathological classification system and consensus on diagnostic 
criteria for LSCC are lacking. Different diagnostic techniques, specifically imaging 
modalities of laryngeal epithelial lesions, have been developed, but they do not offer a 
single system to make a differential diagnosis.185 Consequently, new markers are 
required to reliably identify those high-risk precancerous lesions. Effort has been 
directed to identify molecular biomarkers that will enable the stratification of risk for 
malignant transformation and aggressive tumor behavior in patients with precancerous 
lesions. Some proposed biomarkers include the presence of chromosome instability 
markers,186 cell cycle proteins,187 -catenin,188 and microRNA-21.189  
To our knowledge, ER characterization and profiling has not been studied in the 
context of precancerous lesions. Our findings imply that laryngeal epithelia expressing 
high levels of ERα66 and ERα36 are at risk for aggressive malignant transformation. Thus 
patients expressing this phenotype should be considered for more aggressive treatment 
and followed closely. Our sample number is too small to draw conclusions; however, in 
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this evolving field, ER should be considered as another biomarker that can shed light on 
the malignant potential of the tumor and direct treatment. 
Evaluation of advanced and aggressive tumors, with clinical stage 4, revealed 
recovered high rates of ERα36, while remarkably losing or reducing their expression of 
ERα66. Indolent tumors, clinical stage 1, unexpectedly were found to upregulate the 
expression of both ERα66 and ERα36 compared to the adjacent epithelia. The majority 
of stage 2 and 3 tumors have reduced ERα66 expression as compared to more indolent 
samples, but retain their overexpression of ERα66 as compared to adjacent tissue. 
Conversely, there is a general trend of increasing ERα36 expression in more aggressive 
samples, suggesting that it is only in the final most aggressive stage 4 that tumors begin 
to loose ERα66 and regain ERα36 expression. In an attempt to interpret the differentiate 
ER expression between more indolent and aggressive tumors we turn to the prototype by 
which intricate ER cellular functions have been extensively studied, breast cancer. 
The presence of the classical nuclear ERα66 has long been the most important 
molecular marker used in the diagnosis and as a predictor of prognosis in breast cancer. 
The presence of the receptor has a substantial role in dictating treatment, making anti-
estrogen treatment a viable option for those patients with ERα overexpressing tumors. 
However, eventually most breast tumors become resistant to anti-estrogen treatment 
either through de-novo or acquired resistance.190 One prevailing theory for the resistance 
to anti-estrogen treatment is the loss of the expression of ERα66, either as the presenting 
phenotype in ER negative tumors or in ER positive tumors during treatment, imparting 
loss of constraints and deleterious effects on tumor behavior. ER negative breast cancer, 
specifically the subclass of triple negative cancers, are renowned for their aggressive 
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nature and grave malignant potential.191–193 Thus, in the case of the most renowned 
hormone responsive cancer, it is the loss of that responsiveness that causes the most 
aggressive behavior.   
Interestingly, ER positive breast cancer acquired loss of the expression of ER 
precipitates the same aggressive phenotype. That same loss of ER expression has been 
described to incur trans-differentiation from epithelial to mesenchymal phenotype, which 
is responsible for increased aggressiveness and metastatic propensity.194 More than a 
third of patients with recurrence and metastases from primary ER positive breast cancer 
were found to have lost their expression of ER upon recurrence,195,196 which incurred a 
worse prognosis.197 Coupled with the fact that almost half of patients with aggressive 
breast cancer characterized with high rates of recurrence and distant metastasis are 
classified as bearing primary triple negative cancers,198 it seems evident that the lack of 
ER expression confers poor prognosis.  
That loss of ER confers a poorer prognosis was further evidenced in our animal 
model. While the subcutaneous xenograft model we used does not traditionally 
metastasize,199–201 the increased aggression associated with low ER and E2 sensitivity in 
breast cancer was observed, with ER- LSCC reaching final tumor volumes more than 
twice as large as their ER+ LSCC counterparts regardless of estrogen supplementation. 
This was further borne out in a second LSCC xenograft model, which showed that natively 
ER+ LSCC silenced for the ESR1 gene behaves like ER- LSCC in vivo. shESR1-UM-
SCC-12 xenografts grew to larger tumor sizes than either WT or E2-treated ER+ LSCC 
xenografts regardless of estrogen supplementation.  
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In vitro studies confirm this, with silencing ESR1 in ER+ LSCC reducing total p53 
levels to those on par with E2-treated ER+ LSCC. This suggests that ERα loss mimics the 
effects of E2 treatment on ER+ LSCC, implying that the presence of ERα, independent of 
its role as an estrogen receptor, affects some anti-tumorigenic signaling, which is 
superseded in the presence of supra-physiological doses of E2. E2-ERα signaling has 
been well established as pro-tumorigenic190 in breast cancer, but the role of ERα 
independent of its actions as an E2 conduit has not been widely studied. However, other 
studies in breast and other hormonally response cancers have shown that loss of ER 
contributes to tumor aggression 195,196,202. 
Although ER expression profiles were not confirmed in the harvested xenograft, 
expression of ERα and ERβ isoforms pre-implantation suggests that both UM-SCC-12 
and UM-SCC-11A have similar levels of ERα36 expression, but only UM-SCC-12 express 
ERα66. This is in line with observations from clinical and TCGA data, which suggest that 
increased ERα is associated with lower aggression in LSCC. It should also be noted that 
silencing ESR1 in UM-SCC-12 reduces both ERα66 and ERα36 expression in these cells, 
making it difficult to determine if the increase in aggression in shESR1-UM-SCC-12 is due 
to a reduction in ERα66, ERα36, or some combination of the two. The similar levels of 
ERα36 in UM-SCC-11A and UM-SCC-12 suggest that the increased aggression 
observed in shESR1-UM-SCC-12 is due to a reduction in ERα66 expression, but further 
studies are needed to determine which isoform(s) of ERα are involved in ERα-silencing 
induced increases in tumor aggression. 
Survival data from head and neck cancer and LSCC patients further suggest that 
lack of ERα is associated with poorer prognoses, again in a manner similar to breast 
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cancer. It is well known that loss of ER correlates with reduced survival in breast cancer 
patients69, and similar trends were observed in our meta-analysis of recent head and neck 
cancer cohorts. Although all head and neck cancer patients show a slight correlation 
between increased ERα or ERβ expression and improved survival odds; this trend is not 
mirrored in laryngeal cancer, where ERα is the predominant determinate of ER-
associated survival. It should be noted that the majority of the samples in this data set 
came from patients with stage 4 cancer (n = 81 of 140), suggesting that the prognostic 
value of ESR1 expression as a marker of LSCC aggression may exist independent of any 
association with late-stage cancer. It is also interesting to note the discrepancy between 
the whole head and neck cancer dataset and laryngeal cancer survival specifically. 
RNAseq data necessarily lacks information about post-transcriptional modification of 
transcribed proteins and can offer limited insights about splice variants and alternative 
isoforms of the traditional ERα and ERβ, many of which have been identified.36,68,203,204  
A lack of correlation between ESR1 and ESR2 expression may indicate a mechanistic 
difference in the ERα and ERβ membrane and cytosolic signaling pathways that could be 
dependent on alternative isoforms of both ERs.   
The mechanism underlying the loss of ER expression in primary ER positive 
tumors has not yet been clarified. Genomic and posttranscriptional silencing mechanisms 
offer an explanation for the loss of ER expression. One proposed mechanism is the 
inactivation of ER gene transcription due to methylation of cytosine-rich areas termed 
CpG islands.205 This mechanism has also been described in another hormone responsive 
tumor, endometrial cancer.206 Similar silencing of ER gene transcription is the basis of the 
mechanism underlying the action of micro-RNA. The micro-RNA are a class of regulatory 
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molecules that have been shown to control gene expression such as ERα in breast 
cancer,207,208 and have been implicated in ovarian,209 endometrial210 and laryngeal 
cancer.211 An alternative genomic mechanism has been proposed, that entails the loss of 
heterogeneity in ER genes such as allelic loss in microsatellites located in regulatory 
regions of ER genes,212 which was verified as an independent prognostic factor for 
relapse free survival.213  
These mechanisms of loss of ER expression resemble the findings we have 
observed in laryngeal cancer. The indolent laryngeal cancer cells express both ERα66 
and ERα36, and their ER profile resembles that of the epithelia adjacent the aggressive 
tumors, being part of a spectrum from precancerous lesions to low grade tumors. Stage 
2 and 3 samples begin to loose ERα66 and gain ERα36 expression, and, the aggressive 
tumors are distinctly characterized by the loss of ERα66 and high expressing ERα36. 
There is growing interest in the clinical implication of the membrane ERα36, 
particularly in regard to its role in mediating E2 responsiveness in ER negative tumors and 
anti-estrogen resistance in ER positive tumors. About 40% of ER positive and ER 
negative breast cancer cells express ERα36 in the plasma membrane.214 High levels of 
ERα36 expression correlate with an unfavorable prognosis, independent of ER status and 
have been suggested as an important novel marker for breast cancer clinical 
characterization.88 In our previous studies and in this recent study we have consistently 
identified high rates of ERα36 expression in laryngeal cancer cells.66,67 Furthermore, in a 
previous study, we demonstrated that activation of ERα36 resulted in an upregulation of 
angiogenic and metastatic factors and observed an association between the amount of 
ERα36, VEGF, and lymph node metastasis in laryngeal cancer patients, indicating that 
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ERα36 has a role in metastasis.66 In laryngeal cancer it seems that ERα36 has a pivotal 
role in tumorigenesis and tumor progression, with both indolent laryngeal cancer samples 
and epithelia adjacent to aggressive samples expressing high levels of ERα36.  
The epithelia adjacent to all the tumors collected from Meir Hospital, Israel in our 
study expressed high levels of ERβ, and the level of expression of ERβ was maintained 
in the indolent tumor. In contrast the aggressive tumors from this sample set 
demonstrated a marked decline or full suppression of the expression of ERβ. These 
results indicate that ERβ confers protective effect in laryngeal cancer cells, an effect that 
has also been reported in previous studies of head and neck carcinoma.70 ERβ has been 
postulated to be a dominant-negative regulator of ERα modulating transcriptional 
responses to estrogens. The ratio of ERα vs. ERβ within a cell may determine the cell 
sensitivity to E2 and its biological responses.26 This protective effect of ERβ has been 
observed in breast cancer cells in which the expression of ERβ was found to inhibit 
proliferation and cell invasion.146,215 Further, ERβ expression has been clinically 
correlated with low grade tumors, low S phase fraction, negative axillary node status and 
most importantly higher likelihood to respond to hormonal therapy.216 These findings 
coincide with our observation that advanced laryngeal tumors with metastasis to regional 
lymph nodes, fully suppress the expression of ERβ. The relative conservation of ERβ was 
correlated with a more indolent tumor behavior. Up to 90% of triple negative breast cancer 
have been found to express ERβ,217 the activation of which resulted in suppression of cell 
proliferation, presumably due to suppression of cyclin kinase 1 and 7 and blockage of cell 
cycle progression.218 ERβ target genes have been postulated to regulate apoptosis and 
cell survival, cell development and movement, growth and proliferation as well as genes 
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involved in -catenin and cell cycle checkpoint pathways.217 Knockdown of the ERβ 
expression in triple negative breast cancer cells increased the invasiveness of the cells 
about three fold,219 while ERβ agonists had the opposite effect,220 raising the possibility 
of their role in the treatment of these cancers.  
A number of studies have identified geographic and racial disparities in ERα and 
ERβ expression in other hormonally responsive cancers, particularly breast cancer and 
prostate cancer. Geographic incidences of ER negative breast cancer are highly variable 
both within the U.S. and internationally,221–225 and this disparity has been associated with 
higher incidences of ERα negative, ERβ positive, and triple-negative breast cancer in 
women of African descent.226–231 The opposite trend has been observed in prostate 
cancer, with one study of 300 prostate cancer samples from African American (AA) and 
Caucasian American (CA) men identifying increased ERβ expression in tumor and 
precancerous samples from AA patients as compared to CA men.232  However, both sets 
of patients had increased intra-tumor ERβ staining as compared to matched 
precancerous samples.  
The proportion of ERα positive breast cancer incidence relative to the total 
diagnoses is similar for patients in the United States and Northern Israel;224,225 however, 
our data suggest that ERβ positive cancer incidence may be more regionally localized.  
Other studies have reported high variability of ERβ expression in laryngeal cancer 
samples, similar to the trends we observed in our samples.233 It is important to note that, 
although western blots were conducted in a centralized lab, our samples were originally 
fixed and processed at two different institutions, which could have caused ‘batch 
processing effects’ that could also account for the regional variation we observed in our 
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samples. Additional demographic data on race and ethnicity were not available for our 
samples; however, the wide variability of ERα and ERβ expression in our data could be 
indicative of variability in race and ethnicity among our sample set. While our sample size 
is too small to draw conclusions, further investigation into geographic variability of ERα 
and ERβ expression in laryngeal cancer is needed to further understand the potential of 
ERs as diagnostic and prognostic markers of laryngeal cancer. 
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Chapter 5.  
24R,25-Dihydroxyvitamin D3 regulates breast cancer cells in vitro and in vivo  
[Chapter 5 is published as: Verma A, Cohen DJ, Muktipaty C, Schwartz N, Boyan BD, 
Schwartz Z. Loss of estrogen receptors is associated with increased tumor aggression in 
laryngeal squamous cell carcinoma. BBA-Gen. 2019] 
 
Introduction 
Interest in anti-tumorigenic effects of vitamin D3 began with reports of an inverse 
association between sunlight exposure and age-adjusted breast cancer mortality 234. 
Subsequent studies have demonstrated a connection between serum 25-hydroxyvitamin 
D3 (25(OH)D3) and breast cancer risk and prognosis, with low serum levels correlating 
with increased incidence of breast cancer and high serum levels correlating with reduced 
recurrence and increased survival in breast cancer patients 112,235,236. Despite this, studies 
evaluating the effectiveness of vitamin D supplementation on cancer progression and 
survival have been inconclusive 236–240. Interestingly, one study examining post-remission 
vitamin D supplementation showed that supplement use was associated with reduced 
recurrence rates among patients with estrogen receptor (ER) positive breast cancer, but 
not patients with ER negative breast cancer 8. Similarly, high serum 25(OH)D3 levels 
correlate with improved survival as measured by reduced hazard ratios in post-
menopausal patients (statistically associated with higher rates of ER positive cancer 241), 
but no correlation was identified in pre-menopausal patients (statistically associated with 
ER negative or triple-negative breast cancer 242) 243.  
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Many physicians prescribe vitamin D3 to breast cancer patients, and even more 
breast cancer patients are believed to supplement their dietary vitamin D intake with over-
the-counter supplements 244,245. Vitamin D3 is hydroxylated in the liver to form 25(OH)D3 
246, which binds to albumin and vitamin D-binding protein in the blood and is subsequently 
transported to the kidney where it is metabolized to 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3) and 24,25-dihydroxyvitamin D3 (24,25(OH)2D3) 13. Although the kidney 
produces the bulk of circulating 1,25(OH)2D3 and 24,25(OH)2D3, 25(OH)D3 metabolism 
also occurs locally in some cell types 247–249.  
Preclinical studies indicate that 1,25(OH)2D3 and its precursor 25(OH)D3 may have 
potential as a preventive therapy for breast cancer. Oral vitamin D3 increased autophagy 
and cell turnover in normal murine mammary gland 114 and both oral vitamin D3 and 
intravenous 1α,25(OH)2D3 reduced tumor growth in estrogen receptor (ER) positive 
breast cancer xenograft models 14. In vitro, 1α,25(OH)2D3 reduced cancer cell growth, 
angiogenesis, and metastasis, and induced apoptosis in ER positive breast cancer cells 
115–117 but not in normal breast epithelial cells 118. This may be a function of 
1α,25(OH)2D3’s genomic 120 or non-genomic 118,250 actions. 1α,25(OH)2D3-liganded 
vitamin D receptor (VDR) suppresses transcription of the ESR1 gene 120; and both 
1α,25(OH)2D3 118 and its non-VDR binding analogs 1,24,25(OH)3D3 and 1,25,26(OH)3D3 
inhibit growth of breast cancer cells in vitro 122.  
While these studies are promising, there is some concern about the risk of 
hypercalcemia that accompanies treatment with high doses of 1,25(OH)2D3. Both 
25(OH)D3 and 1α,25(OH)2D3 have narrow therapeutic windows when given 
intravenously, with serum levels of ~1x10-6M 25(OH)D3 and ~9x10-10M 1,25(OH)2D3 being 
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associated with clinical hypercalcemia 126. The potentially toxic effect of 1α,25(OH)2D3 
with regard to calcium handling and its narrow therapeutic window prompted the search 
for synthetic vitamin D analogs that share its anti-cancer properties while bearing a less 
calcemic profile 251,252.  
We propose an alternative endogenous metabolite of vitamin D, 24R,25(OH)2D3. 
This naturally occurring steric epimer of 24,25(OH)2D3 plays an active role in developing 
skeletal tissue 23,253. Furthermore, 24,25(OH)2D3 is less calcemic than 1,25(OH)2D3, with 
doses up to 500 times greater than 1,25(OH)2D3 toxicity thresholds having no effect on 
serum calcium in rats 125.  
The identity of the 24R,25(OH)2D3 receptor remains elusive. Larsson et al. 
reported specific receptors for this vitamin D metabolite in lysosomal membranes in 
intestinal cells 21 and Seo et al. 19 and Kato et al. 20 have shown evidence for a membrane-
bound receptor for 24,25(OH)2D3 in chick fracture healing callus. Martineau et al. recently 
identified a novel 24R,25(OH)2D3 receptor, FAM57B2, which may regulate the 
24R,25(OH)2D3 response in chondrocytes 22. Analysis of the crystal structure of the 
classical VDR suggests that conformational changes in the receptor may accommodate 
binding of a variety of 1,25(OH)2D3 analogues, raising the possibility that 24,25(OH)2D3 
might also occupy the ligand binding pocket on the receptor, at least transiently 54. Studies 
using rat growth plate resting zone chondrocytes have characterized specific membrane-
associated signal transduction pathways that mediate both rapid non-genomic, and 
genomic responses 17,23,93, supporting the presence of receptor(s) for 24R,25(OH)2D3 but 
whether one or more of the receptors identified above are involved is not known.  
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Steroid hormones act through both traditional and non-traditional receptors, which 
operate in parallel pathways and collaborate to exert the hormone’s full effect 68. Such a 
model exists in the case of 1,25(OH)2D3; VDR and membrane-associated Pdia3 co-
localize with the caveolae scaffolding protein, caveolin-1, in osteoblasts. Ligand binding 
changes the interactions of the two receptors and rapidly activates phospholipase A2 
(PLA2) and Src 254,255. 24R,25(OH)2D3 acts via membrane-associated phospholipid 
metabolism, resulting in activation of phospholipase D (PLD)-mediated signaling and 
protein kinase C, amplifying the complexity of the actions of this secosteroid 15,105.  
 24R,25(OH)2D3 is produced via hydroxylation of 25(OH)D3 on C-24 by CYP24A1 
256. Overexpression of CYP24A1 increases 24,25(OH)2D3, which may have growth 
modulating effects independently and in combination with 1,25(OH)2D3 on various 
cancers, including ovarian cancer 257, colon cancer 98, lung cancer 258 and breast cancer 
128,259. One such study showed that 24R,25(OH)2D3 treatment prolonged survival of mice 
with Lewis lung carcinoma in vivo 260,261. In rats, 24R,25(OH)2D3 reduced the development 
of cancerous and precancerous lesions in the glandular stomach in a dose-dependent 
manner by altering calcium pharmacodynamics during the post-initiation phase of 
glandular stomach carcinogenesis 262. In the colon, a similar chemopreventive effect was 
observed via anti-proliferative actions. Pretreatment and, more markedly, continuous 
administration of 24R,25(OH)2D3 reduced the total numbers of aberrant crypt foci and 
putative pre-neoplastic lesions to inhibit development of colon cancer foci 263. Alterations 
in c-fos, c-myc, and c-jun oncogene expression were proposed as potential mechanisms 
for incurring these anti-proliferative actions, suggesting that rapid actions of the vitamin 
D metabolite were involved.  
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In the search for compounds that mimic the growth regulating effects of vitamin D3 
independent from its calcium mobilizing actions, 24R,25(OH)2D3 has emerged as an 
exceptional candidate as it incorporates the anti-proliferative and anti-tumorigenic effects 
of 1,25(OH)2D3 without disrupting calcium homeostasis by elevating calcium blood 
levels 262. To further improve the understanding of the role of 24R,25(OH)2D3 in the 
tumorigenesis and progression of breast cancer we established an in vivo model of tumor 
growth and metastasis in mice using MCF7 breast cancer xenografts. In addition, we 
examined the underlying mechanism of 24R,25(OH)2D3’s effect in vitro using MCF7. We 
hypothesized that the effect exerted by 24R,25(OH)2D3 on breast cancer cells involves 
protecting against proliferation, promoting apoptosis and suppressing migration and 
metastatic gene expression, resulting in reduced invasion and metastasis. To validate the 
hypothesis that the secosteroid can modulate breast cancer cell survival, we also 
assessed the response of two breast cancer cell lines. 
 
Materials & Methods 
Cell Lines 
MCF7, T-47D, and HCC38 breast cancer cells were authenticated by ATCC 
(Manassas, VA) using STR profiling and were used within 6 months of purchase as 
described previously 1.  Cells were maintained in media and passaged in accordance with 
ATCC guidelines. Red fluorescent protein (RFP) expressing-MCF7 cells (RFP-MCF7) 
were created by transfecting cells with an RFP-encoding plasmid (pMirTarget, 
#PS100062, Origene, Rockville, MD) using TurboFectin 8.0 (Origene #TF81001) 
according to manufacturers’ protocol. 
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In Vivo Studies 
Female NSG mice skeletally mature (6-8 weeks old) were obtained from the 
Virginia Commonwealth University (VCU) Cancer Mouse Models Core Laboratory at 
Massey Cancer Center, (Richmond, VA). All animal experiments were approved by 
VCU’s Institutional Animal Care and Use Committee. 
MCF7 Xenograft Model.  
To create MCF7 tumors, female 6-8 weeks old mice (N = 8) were injected 
intraperitoneally with 2.5mg/kg of 17β-estradiol (#E8875; Sigma-Aldrich, St. Louis, MO) 
or 2% ethanol:1X distilled phosphate buffered saline (DPBS) vehicle one week prior to 
tumor initiation. These injections continued twice a week for the remainder of the study 
(11 weeks in total). One week after the first 17β-estradiol or vehicle injection, tumors were 
initiated by injecting 1 million MCF7 cells in 50μL of 1:1 DPBS:BME (Cultrex Pathclear 
basement membrane extract Type 3, 14.5mg/mL; #3632; R&D Systems, Minneapolis, 
MN) solution into the lactiferous duct of the right fourth mammary gland of the mouse264–
266. Beginning at 2 weeks post-cell injection, tumors were measured along two 
perpendicular axes (length and width) with digital calipers, and tumor volume was 
calculated using the following formula: 𝑉𝑜𝑙𝑢𝑚𝑒 =  
𝐿𝑒𝑛𝑔𝑡ℎ∗𝑊𝑖𝑑𝑡ℎ2
2
 264,265,267,268. Tumor 
volume was plotted against time and comparisons between vehicle and control mice were 
made using a repeated-measured analysis of variance (ANOVA). P-values <0.05 were 
considered significant. Tumor measurements were taken once a week for 10 weeks until 
harvest. 
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Mice were euthanized at 10 weeks via CO2 inhalation. Tumors were harvested and 
preserved in 10% neutral buffered formalin. Fixed tissues were processed, embedded in 
paraffin, and cut into 3-5μm sections. Sections were stained with H&E to examine cell 
morphology109.  
In a second study, 5-week old female NSG mice were ovariectomized167. Two 
weeks post-operatively, mice were injected with 17β-estradiol (N=6) or vehicle (N=6) 
twice a week for 11 weeks as described above. One week after the first 17β-estradiol or 
vehicle injection, mice were implanted with MCF7 cells in the right fourth mammary gland 
as described above. Tumor size was measured once a week with digital calipers and 
tumor volume was calculated using the established system described above. Tumors 
grown in ovariectomized mice were harvested after 10 weeks, analyzed with μCT, and 
preserved in formalin. Histologic sections were stained with H&E and analyzed. Tumor 
volume and percent growth of tumor were graphed vs. time. Animals in both studies were 
monitored for signs of estrogen toxicity, such as urinary bladder distension and skin rash. 
μCT Tumor Volume Measurements.  
Tumors were harvested and immediately scanned with a Bruker Skyscan 1173 
μCT at 55kV and 70μA, with a resolution of 560x560 pixels with an image pixel size of 
40.26μm, an exposure time of 125ms and a rotation step of 0.8o 166. A standard 
reconstruction was conducted on the tumors using the NRecon software version 1.6.10.4 
(Kontich, Belgium) with a smoothing kernel of 0 and a beam hardening correction of 20%. 
μCT reconstructions of the tumors were analyzed using the CTAn software version 
1.16.1.0 (Kontich, Belgium). Total tumor volume was measured as the total tissue volume. 
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Calculated tumor volumes as measured by digital calipers and total tumor volumes from 
μCT scans were compared using a 2-way ANOVA with Bonferroni post-tests with α=0.05. 
Effect of 24R,25(OH)2D3.  
Two weeks after subcutaneous implantation of zero-order release 17β-estradiol 
pellets (0.96mg/45 days) (Innovative Research of America, Sarasota, FL) 167   at ‘week 
0’, female NSG mice (N=24) were injected with 1 million RFP-MCF7 cells in the right 
lactiferous duct of the fourth mammary fat pad. MCF7 tumors were allowed to grow for 5 
weeks. At that time, mice were divided into 3 groups (n=8) and each group was injected 
intraperitoneally 3 times a week with 0, 25ng, or 100ng of 24R,25(OH)2D3 (#BML-DM300-
0050; Enzo Life Sciences, Farmington, NY) in a 2% ethanol: DPBS vehicle. Mammary fat 
pad tumors were measured with calipers throughout the study. Tumor volume and tumor 
accretion rate (tumor volume over time normalized to original tumor volume) were 
graphed vs. time. Tumor growth rate from weeks 6-10 was analyzed with a linear 
regression model for each group (0, 25, and 100ng of 24R,25(OH)2D3). Animal survival 
was tracked throughout the study and percent surviving mice vs. length of survival was 
recorded. Animal survival was plotted on a hazard curve and analyzed with the chi-
squared logrank test for trend at α=0.05. Throughout the study, animals were monitored 
for signs of hypercalcemia, such as changes in appetite or lethargy. 
On the day of harvest, animals were euthanized with CO2 and metastases was 
identified by the presence of RFP (443/581nm) using a Zeiss SteroDiscovery.V12 
fluorescence dissecting microscope with an AxioCam MRm digital camera. Tumors were 
harvested and analyzed with μCT. Axial and inguinal lymph nodes, lungs, and livers were 
grossly examined for RFP expression. Fluorescing organs were harvested and fresh 
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flash-frozen on block dry ice in optimal cutting temperature compound (OCT) (#25608; 
VWR, Radnor, PA) for histological analysis. After μCT analysis, tumors were fresh flash-
frozen in OCT as above. OCT-embedded samples were cut into 3-5μm sections on a 
cryostat, post-fixed with fresh 4% paraformaldehyde for 10 minutes, and stained with H&E 
to confirm metastasis. Total metastatic incidence and metastatic incidence by organ were 
recorded. 
 
In vitro Studies 
Response to Vitamin D3 Metabolites.  
To assess specificity of the response of MCF7 cells to 24R,25(OH)2D3 confluent 
cultures were treated with media containing 1α,25(OH)2D3 (10-10-10-8M, Enzo #BML-
DM200-0050); 24R,25(OH)2D3 (10-9-10-7M); 24S,25(OH)2D3 (10-9-10-7M, Sigma Aldrich 
#29447); 25(OH)D3 (10-9-10-7M, Sigma Aldrich #17938); or vehicle. All vitamin D 
metabolites were reconstituted to 1mM stock solutions in absolute ethanol. Stock 
solutions were diluted in warm complete media to final treatment concentrations. Media 
were removed by aspiration at 15 min or 24 hours and cells were incubated with fresh 
complete media until harvest as indicated below.  
Signaling Pathway Inhibition.  
In these experiments, cells were pre-treated for 30 minutes with inhibitors or 
vehicle in warm complete media. At that time, fresh media containing 24R,25(OH)2D3 or 
vehicle were added on top of inhibitor treatments, and cells were incubated for a further 
15 minutes before the conditioned media were aspirated. Cultures were then incubated 
in fresh complete media until harvest. To determine if the effect of 24R,25(OH)2D3 was 
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mediated by palmitoylation, cultures were pretreated with 1-10μM 2-bromopalmitate 
(Sigma-Aldrich #21604)269. PLD was inhibited by pretreatment with 0.1 to 1 μM 
wortmannin (VWR #80055508, Radnor, PA) 15. To assess whether intact caveolae were 
required, cultures were pretreated with 1 or 10mM methyl β-cyclodextrin (Sigma-Aldrich 
#C4555) in serum-free media to deplete cell membranes of cholesterol 169,270,271. In order 
to assess the role of ERα66, cultures were pretreated with 10-7M ICI-182780, an inhibitor 
to cytosolic and nuclear ERs (Sigma-Aldrich #I4409) 272,273. The contribution of ERα36 
was determined by pretreating MCF7 cells with 1μg of a neutralizing antibody to the 
membrane-associated estrogen receptor (Chi Scientific #8-80113, purchased from VWR) 
55. 
Outcome Measures 
DNA synthesis. Cells were cultured to 70% confluence, then serum-starved for 48 
hours in phenol-red free MEM supplemented with 1% charcoal-dextran filtered FBS and 
50U/50U penicillin-streptomycin. At that time, cells were treated with 24R,25(OH)2D3, 
24S,25(OH)2D3, 25(OH)D3, or 1α25(OH)2D3 for 15 minutes and incubated with fresh 
complete media for 24 hours. In a separate experiment, cells were treated with these 
vitamin D3 metabolites for 24 hours. At the 20 hour mark, cells in both experiments were 
pulsed with 10μL of a 1:100 dilution of 5-ethynyl-2’-deoxyuridine (EdU) and incubated for 
4 hours. Cells were harvested and assayed for EdU incorporation according to 
manufacturer’s instructions (ThermoFisher Scientific #C10214).  
Gene expression. Cells were cultured to confluence, then treated with 
24R,25(OH)2D3 or 24S,25(OH)2D3 or vehicle in complete media for 15 minutes as 
described above. Cultures were then aspirated and incubated with complete media for 12 
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hours. RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA) and quantified (Take3 
Micro-Volume Plate, Biotek, Winooski, VT) before being used to synthesize cDNA 
libraries (High Capacity cDNA Reverse Transcription kit, Promega, Madison, WI). 
Apoptosis markers were B cell lymphoma protein 2-associated X protein (BAX) to B cell 
lymphoma protein 2 (BCL2) mRNA expression. Epithelial to mesenchymal transition 
markers were C-X-C- motif chemokine 12 (CXCL12), chemokine receptor type 4 
(CXCR4), snail family transcriptional repressor 1 (SNAI1), erythroblastic oncogene B 
(ERBB2), and matrix metalloproteinase 1 (MMP1). Markers of metastasis were 
osteoprotegerin (OPG), and nuclear factor kappa-B ligand (RANKL)274–277.  
mRNAs were quantified with real-time quantitative PCR using Power SybrGreen® 
Master Mix (Applied Biosystems) and gene-specific primers described in Table 5.1. 
Commercially available primers (Qiagen, Hilden, Germany) were used to quantify BCL2 
(Hs_BCL2-1-SG QuantiTect Primer #249900), ESR1 (Hs_ESR1-1-SG QuantiTect Primer 
#044492), RANKL (Hs_TNFSF11-1-SG QuantiTect Primer #PPH01048F), and SNAI1 
(Hs_SNAI1-1-SG QuantiTect Primer #010010) mRNA. All other primers were self-
designed using the National Center for Biotechnology Information PrimerBLAST 278 and 
ordered from ThermoFisher Scientific (Waltham, MA). Exact sequences for all 
ThermoFisher primers are given in Table 5.1. RNA quantities were determined by the 
standard curve method. mRNA levels were normalized to levels of glyceralde-3-
phosphate dehydrogenase (GAPDH) mRNA. mRNA for BAX, BCL2, CXCR4, and 
CXCL12 are presented as ratios of BAX to BCL2 and CXCR4 to CXCL12.  
  
Modulation of 24R,25(OH)2D3 Tumorigenicity by ER Isoforms in E2-Responsive Cancer • Spring 2019 
Anjali Verma • Ph.D. Dissertation • Biomedical Engineering • Virginia Commonwealth University 119 
 
 
Gene Primer Sequence 
BAX 
F GACGAACTGGACAGTAACATGG 
R AAAGTAGAAAAGGGCGACAACC 
CXCL12 
F GCCTCTGAAGCCTATGTATG 
R GACGAACTGGACAGTAACATGG 
CXCR4 
F TAGCAAAGTGACGCCGAGGG 
R TGGTTCTCCAGATGCGGTGG 
ERBB2 
F CCGCTGAAGTCCACACAGTT 
R AAAGGTTCTACCCCGCATGG 
GAPDH 
F CTATAAATTGAGCCCGCAGCC 
R TGGCGACGCAAAAGAAGATG 
MMP1 
F AGAAAGAAGACAAAGGCAAGTTGA 
R TCCCCAGTCACTTTCAGCCC 
OPG 
F GTGTGCGAATGCAAGGAAGG 
R CACTCCAAATCCAGGAGGGC 
 
Table 5.1 Human primers used in real-time PCR analysis. 
 
Total p53 content. Total p53 was measured 24 hours post-cell treatment with 
vitamin D metabolites as described above using a sandwich enzyme-linked 
immunosorbent assay (ELISA) (R&D Systems, Human Total p53 DuoSet® IC). Cells 
were plated in 24 well plates, treated with vitamin D3 metabolite for 15 minutes, and 
incubated for 24 hours in complete media. Conditioned media were collected and cell 
layers were lysed by sonication (40A for 5 seconds) in 200μL lysis buffer according to 
manufacturer’s protocol. Lysates were centrifuged at 10,000g for 15 minutes; the 
supernatant was collected and assayed for total protein content (ThermoFisher, Pierce 
660 nm Protein Assay) and total p53 content following the manufacturer’s instructions. 
Data are presented as a ratio of nanograms of total p53 to total protein content. 
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DNA fragmentation. DNA fragmentation was assessed by colorimetric terminal 
deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (Trevigen, 
TiterTAC™ in situ microplate TUNEL assay). Cells were incubated with vehicle, 
24R,25(OH)2D3, or 24S,25(OH)2D3 for 15 minutes followed by incubation in fresh media 
for 24 hours. After fixing the cultures with 3.7% sucrose-buffered formaldehyde, samples 
were processed for TUNEL staining following manufacturer’s instructions. Final 
absorbance was detected at 450 nm using a microplate spectrophotometer. 
Enzyme-linked immunosorbent assays for secreted proteins. Confluent cultures of 
MCF7 cells were plated in 6 well plates, treated with vehicle or 24R,25(OH)2D3 for 15 
minutes as described above, aspirated, and then incubated in complete media. After 24 
hours, conditioned media were collected in 5mL polypropylene tubes, frozen at -80oC and 
lyophilized (Labconco, Kansas City, Missouri, Freezone Freeze Dryer #7740020). 
Lyophilized samples were reconstituted in 200 μL of filtered 1XPBS containing 1% BSA 
and assayed for OPG and RANKL using sandwich ELISAs (R&D Systems, Human 
TRANCE/RANK L/TNFSF11 DuoSet ELISA #DY626, Human 
Osteoprotegerin/TNFRSF11B DuoSet ELISA #DY805). Cell monolayers were lysed in 
1mL 0.5% Triton™ X-100. Cell lysates were assayed for total DNA content (Promega, 
QuantiFluor dsDNA, #E6150). OPG and RANKL content are expressed as a ratio of 
OPG/RANKL.  
Matrix metalloproteinase 1. Collagenase (MMP1) content in the cultures was 
measured using an MMP1 assay kit (SensoLyte® Plus 520 MMP-1 Assay Kit 
*Fluorimetric and Enhanced Selectivity*, Anaspec #AS-72012). Cells were plated in 24 
well plates and treated with vehicle or 24R,25(OH)2D3 as described above. At harvest 
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conditioned media were collected; cell monolayers were lysed in 500μL 0.05% Triton-X-
100 and total DNA content measured. Total MMP1 was measured in the media and 
normalized to total DNA content. Data are presented as a ratio of ng MMP1/μg DNA. 
Wound closure assay. A wound closure assay was used to demonstrate 
metastasis. Confluent cultures of MCF7 cells were treated for 15 min with media 
containing vehicle or 24R,25(OH)2D3. Another set of cultures was treated with 10-7M 17β-
estradiol as a positive control. Following treatment, a scratch was drawn from one end of 
the well to the other using a sterile 1 mL pipette tip. The loosened cells were aspirated 
along with the treatment media, and fresh media added to the cultures. A phase-contrast 
microscope was used to take pictures of each well at 0, 3, 6, 9, 12, and 24 hours after the 
scratch was made. Wound area was calculated using Adobe Photoshop™ 2 software, 
normalized to the original wound closure area, and presented as percent wound closure. 
Data presented are from one of two repeated experiments. 
Statistical Analysis 
Data shown are from single representative experiments of two or more repeats 
and are presented as mean ± standard error of six independent cultures per treatment 
group. Data were analyzed by ANOVA with Tukey’s post-test to determine significance 
between groups. Experiments with two independent variables (DNA synthesis, total DNA 
content, and total p53 time courses) were analyzed with two-way ANOVA with 
Bonferroni’s modification of Student’s t-test post-tests to determine the variance between 
row and column factors. The wound closure assay was analyzed with a repeated 
measures ANOVA test with comparisons between time points. P-values <0.05 were 
considered significant.   
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Results 
17β-Estradiol supplementation stimulated MCF7 breast cancer tumor growth in mice.  
MCF7 (estrogen receptor positive, ER+, progesterone receptor positive, PR+) 
breast cancer cells were injected into the duct of the fourth mammary gland. Mice 
receiving 17β-estradiol injections grew tumors 3-5 times their original size. In contrast, 
tumors grown in animals given a vehicle control injection showed minimal growth over 10 
weeks (Figure 5.1). Tumors in mice given 17β-estradiol increased from approximately 
40mm3 to an average of 200mm3, approximately 500% of their original volume, with a 
linear growth increase over the course of 8 weeks (week 2 to week 10). However, tumors 
grown in mice given a vehicle injection reached an average size of 55mm3, an increase 
of approximately 10% of their original volume (Figure 5.1A). In ovariectomized animals, 
the difference between vehicle versus 17-estradiol injected mice was even more 
pronounced, with tumors grown in 17β-estradiol injected mice reaching an average size 
of 100mm3 versus only 25mm3 in vehicle-injected ovariectomized mice (Figure 5.1B,C). 
Tumor morphology was similar in both 17β-estradiol and vehicle-injected mice, and there 
was no observed difference in tumor morphology in samples taken from normal vs. 
ovariectomized mice [representative image, (Figure 5.1D)]. At harvest, final tumor volume 
in 17β-estradiol animals was approximately 4 times greater than tumor volume in vehicle-
treated animals in both the normal and ovariectomized mouse models (Figure 5.1E). 
None of the animals in either experiment showed signs of estrogen toxicity. 
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Figure 5.1 17β-estradiol stimulates MCF7 tumor growth in a mammary fat pad 
xenograft model in NSG mice. 
 [A]  Non-ovariectomized mice injected with 17β-estradiol showed a significant increase 
in tumor growth as compared to the vehicle after 3 weeks of injection until the end of the 
study at week 10. [B] Similar trends were observed in a separate study with 
ovariectomized animals, with animals treated with 17β-estradiol showing a significant 
increase in tumor growth as compared to vehicle at weeks 4 and 5 and weeks 7-10 of the 
study. [C] At harvest, tumors grown in ovariectomized mice supplemented with 17β-
estradiol reached an average volume of 120mm3, nearly 6 times greater than tumors 
grown in vehicle-treated mice. [D] Histology of the fourth mammary fat pad revealed 
neoplastic tissue characteristic of MCF7 tumors. 
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(continued from page 124) [E] Final tumor volume was largest in control mice 
supplemented with 17β-estradiol. Ovariectomized mice supplemented with 17β-estradiol 
had tumor volumes that were smaller than those from normal mice, but still larger than 
tumors grown in ovariectomized mice given a vehicle control. Groups that share a letter 
are not statistically significant at α=0.05 with two-way ANOVA. 
 
 
Treatment with 24R,25(OH)2D3 reduced tumor aggression and increased animal 
survival.  
Red fluorescent protein (RFP)-overexpressing MCF7 mammary fat pad tumors 
were grown in female NSG mice for 10 weeks. Estrogen supplementation was given for 
2 weeks prior to tumor initiation, then continued for the first 4 weeks of tumor growth. 
Dose-dependent 24R,25(OH)2D3 was initiated at the beginning of week 5, and continued 
for the rest of the 10 week study. Mice receiving either 25ng or 100ng per injection of 
24R,25(OH)2D3 survived longer than mice injected with vehicle alone. 6/8 and 7/8 animals 
in the 25ng and 100ng groups, respectively, survived until harvest, while only 3/8 animals 
survived in the control group (Figure 5.2A). Animals in the control group also started dying 
earlier (at day 38) than animals given 24R,25(OH)2D3 (day 56) (Figure 5.2B). Both 25ng 
and 100ng treated tumors exhibited a lower percent increase in size compared to vehicle-
treated mice. Tumors in both 24R,25(OH)2D3 treated groups achieved approximately 
500% of their original volume, while vehicle-treated tumors grew to approximately 1000% 
of their original volume (Figure 5.2C). Tumors in mice given 25ng 24R,25(OH)2D3 reached 
volumes of approximately 400mm3 at harvest, roughly 80% the size of the tumors in 
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vehicle-treated mice, which reached a volume of 500mm3 on average. Tumors in mice 
given 100ng showed an even steeper growth depression, reaching final volumes of 
200mm3 on average, roughly 40% of vehicle-treated tumors (Figure 5.2D,E).  
The difference in tumor volume was due to growth that occurred in the last 4 weeks 
of the study, after 24R,25(OH)2D3 injections were begun. All tumors were approximately 
the same size at week 6, at the onset of treatment. From week 6-10, vehicle-treated 
tumors had a growth rate of 79.54 ± 9.40 mm3/week (R2 =0.96); 25 ng-treated tumors had 
a growth rate of 57.90 ± 8.70 mm3/week (R2 =0.94); and 100ng-treated tumors had a 
growth rate of 40.61 ± 6.60 mm3/week (R2 =0.93). The slopes were significantly different 
(P=0.0213). Calculated tumor volumes from caliper measurements were not significantly 
different from tumor volumes generated by μCT analysis (Figure 5.2E). Haematoxylin and 
eosin (H&E) staining revealed similar tumor morphology in tumors from each group 
[representative image, (Figure 5.2F)]. 
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Figure 5.2 24R,25(OH)2D3 reduces MCF7 tumor burden and increases animal 
survival. 
 [A] After 8 weeks, 3 animals from the vehicle group, 6 animals from the low-dose 
24R,25(OH)2D3 group, and 7 animals from the 24R,25(OH)2D3 group survived out of an 
original n of 8. [B] Animals in the vehicle group had a statistically significant reduced 
survival rate as compared to animals in the low or high dose groups by the chi-squared 
logrank test for trend (P=0.0433). [C] Tumor accretion rate was calculated by normalizing 
tumor volumes at each week to the original tumor volume calculated at week 2.  
(continued from page 122) [D] Animals given 24R,25(OH)2D3 showed a decreased rate 
of growth after vitamin D3 injections were begun at week 6 of the study. Statistics were 
done using a repeated-measures ANOVA test to compare between the vehicle, low, and 
high-dose groups within weeks. 
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(continued from page 127) Purple squares □ indicate significance against the high-dose 
group, and blue open circles ○ indicate significance against the low-dose group. [E] After 
harvest, tumor volume was quantified using µCT analysis. Calculated caliper volumes 
and µCT-derived volumes were graphed together, and statistics were done using ANOVA 
with Tukey’s correction. Bars that share a letter are not significant at α=0.05. Both caliper 
measurements and μCT analyses showed statistically significant decreases in final tumor 
volume between the high-dose 24R,25(OH)2D3 group and the vehicle control; and μCT 
analysis showed a statistically significant difference between both the vehicle and the low-
dose 24R,25(OH)2D3 group as compared to the high-dose 24R,25(OH)2D3 group. [F] 
Histology of the fourth mammary fat pad showed cells with a dense epithelial-like 
phenotype consistent with MCF7 morphology and previous MCF7 xenograft studies, bar 
50 m.  
 
 Metastatic burden was detected in animals by assessing individual organs for RFP 
expression using a fluorescent dissection microscope at harvest. Animals treated with 
24R,25(OH)2D3 had a lower metastatic burden than vehicle-injected controls, with fewer 
organs that were positive for RFP-tagged MCF7 cells. Animals treated with 25ng 
24R,25(OH)2D3 had, on average, 1-2 incidences of metastasis/animal, while 100ng 
treated animals averaged 0-1 metastatic incidence per animal. Control group animals 
averaged 3-4 incidences of metastasis per animal (Figure 5.3A). Animals treated with 
24R,25(OH)2D3 also had fewer incidences of local and distant metastasis than control 
group animals, with animals injected with 25ng 24R,25(OH)2D3 having fewer incidences 
of multiple lymph node, lung, and liver metastases. This effect was even greater in 
Modulation of 24R,25(OH)2D3 Tumorigenicity by ER Isoforms in E2-Responsive Cancer • Spring 2019 
Anjali Verma • Ph.D. Dissertation • Biomedical Engineering • Virginia Commonwealth University 128 
 
animals treated with higher doses of 24R,25(OH)2D3 (100ng). These animals had fewer 
lymph node and lung metastases and no incidences of multiple lymph node or liver 
metastases (Figure 5.3B). Metastatic sites were characterized by round clusters of RFP-
positive cells with defined edges, characteristic of MCF7 metastases 279 (Figure 5.3C-E). 
Morphology of metastatic sites was similar to the morphology of the primary tumor (Figure 
5.3F-H). None of the animals showed signs of hypercalcemia throughout the study or 
upon dissection at harvest. 
 
24R,25(OH)2D3 induced both proliferation and apoptosis in ER+ cells in vitro.  
When MCF7 cells were treated for 15 minutes with 24R,25(OH)2D3, its enantiomer 
24S,25(OH)2D3, or its precursor 25(OH)D3, proliferation was increased after 24 hours. 
The effect of 24R,25(OH)2D3 and 24S,25(OH)2D3 was dose-dependent with the greatest 
increase at 10-8M 24R,25(OH)2D3 (Figure 5.4A) and 10-7M 24S,25(OH)2D3 (Figure 5.4B); 
all doses (10-9-10-7M) of 25(OH)D3 increased proliferation (Figure 5.4C). In contrast, 
1α,25(OH)2D3, did not increase proliferation at 24 hours (Figure 5.4D). None of these 
metabolites increased proliferation in MCF7 monolayers that were treated with vitamin D 
metabolites for 24 hours (Figure 5.5), and only 24R,25(OH)2D3 increased apoptosis in 
these cells after 24 hours (Figure 5.6). 
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Figure 5.3 24R,25(OH)2D3 reduces metastatic burden in MCF7 xenograft mouse 
models. 
[A] High-dose 24R,25(OH)2D3 reduced the total metastatic burden of red fluorescent 
protein-expressing MCF7 tumors and [B] reduced the number of metastatic incidences to 
the lymph nodes, lungs, and liver. Statistics were not done on metastatic incidence per 
organ data due to the ordinal nature of the data collected and the small sample size of 
the surviving animals in the vehicle group (n=3). 
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(continued from page 125)  In fig [A], groups that share a letter are not significant at 
α=0.05. Metastatic organs – [C,E] lymph node, [D,G] lungs, and [E,H] liver – were 
identified at harvest with a fluorescent microdissection scope set [C,E] an RFP/ tdTomato 
filter at 10X magnification and [D] 40X magnification. Metastases were confirmed with [F-
H] H&E staining, and images are displayed at [F] 10X or [G,H] 40X magnification.   
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Figure 5.4 24,25(OH)2D3 induces both proliferation and apoptosis in MCF7 cells 
with varying specificities. 
[A] 24R,25(OH)2D3 induced proliferation in MCF7 cells 24 hours after a 15-minute 
treatment. [B] Its enantiomer 24S,25(OH)2D3 also increased proliferation in this system 
[C] and so did their precursor 25(OH)D3. [D] The vitamin D isoform 1α,25(OH)2D3 did not 
increase proliferation in these cells. [E-G] In contrast, 24R,25(OH)2D3 induced apoptosis 
in MCF7 cells  24 hours after a 15-minute treatment, [H-J] but its enantiomer 
24S,25(OH)2D3 did not. [E,H] Apoptosis was measured by BAX/BCL2 expression, [F,I] 
total p53 levels, [G,J] and TUNEL staining. Groups that do not share a letter are 
statistically significant at α=0.05.  
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Figure 5.5 Treatment with vitamin D3 metabolites for 24 hours does not alter MCF7 
cell proliferation. 
[A] 24R,25(OH)2D3, [B] 24S,25(OH)2D3, [C] 1α,25(OH)2D3, and [D] 25(OH)D3 did not 
induce DNA synthesis in MCF7 cells after 24 hours of treatment.  
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Figure 5.6 24R,25(OH)2D3 specifically induces apoptosis in MCF7 cells after 24 
hours of treatment. 
[A] 24R,25(OH)2D3 increased total p53 production after 24 hours of treatment in MCF7 
cells but [B] 24S,25(OH)2D3 did not. 
 
24R,25(OH)2D3 caused a dose-dependent increase in BAX to BCL2 expression 
ratios (BAX/BCL2), which was significant at 10-7M (~4-fold) (Figure 5.4E). 24R,25(OH)2D3 
had a bi-phasic effect on total p53 levels and TUNEL staining, with the 10-8M dose 
producing the maximum increase in p53 levels (~1.5 fold) (Figure 5.4F)and TUNEL (~2 
fold) (Figure 5.4G). The enantiomer 24S,25(OH)2D3 did not affect apoptosis in these cells, 
as measured by BAX/BCL2 expression (Figure 5.4H), total p53 levels (Figure 5.4I), and 
TUNEL staining (Figure 5.4J). In another ER+ cell line, T-47D cells, 10-7M 24R,25(OH)2D3 
increased total p53 content (Figure 5.7A), TUNEL staining (Figure 5.8A) , and proliferation 
(Figure 5.8B) after 15 minutes of treatment. In contrast, in a third breast cancer cell line, 
HCC38, which are ER-, all doses of 24R,25(OH)2D3 decreased total p53 content (Figure 
5.7). 
Modulation of 24R,25(OH)2D3 Tumorigenicity by ER Isoforms in E2-Responsive Cancer • Spring 2019 
Anjali Verma • Ph.D. Dissertation • Biomedical Engineering • Virginia Commonwealth University 134 
 
 
 
 
Figure 5.7 24R,25(OH)2D3 differentially changes apoptosis in other breast cancer 
cell lines. 
Treatment of cultures for 15 minutes with 24R,25(OH)2D3 increased total p53 production 
in [A] T-47D cells and [B] HCC38 cells.  
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Figure 5.8 24R,25(OH)2D3 increases apoptosis and proliferation in T47D, an ER+ 
breast cancer cell line. 
Treatment of cultures for 15 minutes with 24R,25(OH)2D3 increased [A] total TUNEL 
staining and [B] proliferation in T-47D cell monolayers. 
 
 
24R,25(OH)2D3 decreased epithelial-to-mesenchymal transition, metastasis, and 
migration in MCF7 cells in vitro.  
MCF7 monolayers were treated with dose-dependent 24R,25(OH)2D3 for 15 
minutes, then harvested after 12 hours to assess gene expression. Treatment with 10-8M 
and 10-7M 24R,25(OH)2D3 significantly reduced expression of the mesenchymal-
associated transcription factor SNAI1 compared to cells treated with vehicle (Figure 
5.9A). ERBB2 and MMP1, which are associated with tumor aggression and matrix 
turnover respectively, were also reduced. 24R,25(OH)2D3 (10-7M) caused a 50% 
reduction in ERBB2 expression (Figure 5.9B), and both 10-8M and 10-7M 24R,25(OH)2D3 
reduced expression of MMP1 expression by more than 75% (Figure 5.9C). 
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24R,25(OH)2D3 had a biphasic effect on collagenase with the most significant reduction 
observed in cultures treated with 10-8M (Figure 5.9D). 24R,25(OH)2D3 decreased cell 
migration in the scratch test assay; 10-7M 24R,25(OH)2D3 increased wound size to 300% 
of its original area while both the vehicle control and the positive control (10-7M 17β-
estradiol) reduced wound size to 50% of original area (Figure 5.9E). 24R,25(OH)2D3 also 
decreased metastatic markers. 24R,25(OH)2D3 decreased CXCR4 to CXCL12 ratios 
(CXCR4/CXCL12) in a dose-dependent manner, with 10-7M 24R,25(OH)2D3 decreasing 
CXCR4/CXCL12 expression in MCF7 cells 8-fold as compared to cells treated with 
vehicle (Figure 5.9F). 24R,25(OH)2D3 also increased OPG to receptor activator of RANKL 
ratios (OPG/RANKL) - which is contraindicative of osteoclast activity - in both gene 
expression and protein. 24R,25(OH)2D3 increased OPG/RANKL gene expression 5-fold 
at 10-7M (Figure 5.9G), and both 10-8M and 10-7M 24R,25(OH)2D3 increased OPG/RANKL 
protein by 100% (Figure 5.9H).  
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Figure 5.9 24R,25(OH)2D3 reduces epithelial-to-mesenchymal transition and 
migration in MCF7 cultures. 
[A] 24R,25(OH)2D3 decreases the gene expression of snail [B], her2 [C], collagenase and 
[D] total collagenase protein. [E] 24R,25(OH)2D3 also inhibited migration in MCF7 
monolayers and significantly increased wound size in a scratch test assay as compared 
to vehicle and E2-treated cultures, and [F] decreased the gene expression ratio of 
migratory markers CXCR4/CXCL12. [G] 24R,25(OH)2D3 also inhibited bone resorption 
and distant metastasis marker OPG/RANKL as measured by gene expression and [H] 
protein. Groups that do not share a letter are statistically significant at α=0.05. 
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24R,25(OH)2D3 increased proliferation and apoptosis through a membrane-mediated, 
PLD-dependent pathway.  
MCF7 cell monolayers were treated for 30 minutes with increasing concentrations 
of inhibitors of membrane-associated steroid hormone signaling mechanisms, then 
treated with high-dose 24R,25(OH)2D3 for 15 minutes. After 24 hours, proliferation and 
apoptosis markers were assessed. Inhibition of palmitoylation with 2-bromopalmitate 
blocked the stimulatory effect of 24R,25(OH)2D3 on DNA synthesis (Figure 5.10A), 
TUNEL staining (Figure 5.10I), and p53 production (Figure 5.10E), indicating that the 
24R,25(OH)2D3 effect on both proliferation and apoptosis required docking of protein 
receptors to the membrane. Treatment of the cultures with wortmannin blocked the 
24R,25(OH)2D3 dependent increase in DNA synthesis (Figure 5.10B) and p53 production 
(Figure 5.10F). The PLD inhibitor increased TUNEL staining in control cultures to levels 
comparable to 24R,25(OH)2D3 treated cultures (Figure 5.10J). Depletion of membrane 
cholesterol by methyl β-cyclodextrin blocked 24R,25(OH)2D3 stimulated increases in DNA 
synthesis (Figure 5.10C). At the higher concentration, it increased p53 levels in control 
cultures to levels seen in 24R,25(OH)2D3-treated cultures (Figure 5.10G); all methyl-β 
cyclodextrin treated cultures had TUNEL staining comparable to the 24R,25(OH)2D3-
treated cells (Figure 5.10K). Antibodies blocking ERα36 prevented 24R,25(OH)2D3-
stimulated proliferation but the treatment of the culture with 10-7M ICI-182780, a cytosolic 
and nuclear ER inhibitor, had no effect (Figure 5.10D). Both anti-ERα36 and ICI-182780 
blocked the stimulatory effect of 24R,25(OH)2D3 on p53 (Figure 5.10H) and TUNEL 
(Figure 5.10L). 
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Figure 5.10 24R,25(OH)2D3 induces proliferation and apoptosis in MCF7 cells 
through a membrane-mediated mechanism. 
Inhibitors against palmitoylation ([A], [E], [I], 2-bromopalmitate), phospholipase D ([B], [F], 
[J], wortmannin), caveolae ([C], [G], [K], methyl β-cyclodextrin), membrane estrogen 
receptor ⍺ 36 ([D], [H], [L], anti-ER⍺36 antibody) and cytosolic and nuclear estrogen 
receptor α ([D], [H], [L]) (ICI-182780) were used to gain insight into the mechanism by 
which 24R,25(OH)2D3 acts on apoptosis and proliferation in MCF7 cells. Proliferation was 
measured by [A-D] DNA synthesis assay and apoptosis was measured by [E-H] total p53 
ELISA and [I-L] TUNEL staining. All doses of 2-bromopalmitate, which inhibits 
palmitoylation, inhibited a 24R,25(OH)2D3 induced increase in [A] proliferation, [E] p53 
content, and [I] TUNEL staining. Wortmannin, a non-specific phospholipase-D inhibitor,  
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(continued from page 135) [B] inhibited a 24R,25(OH)2D3 induced increase in 
proliferation, [F] p53 content, and [J] TUNEL staining in a similar manner. Methyl β-
cyclodextrin, which depletes the cell membrane of cholesterol to inhibit caveolae function, 
[C] inhibited a 24R,25(OH)2D3 induced increase in proliferation at 1 and 10mM, [G] p53 
content at 10mM, and [K] TUNEL staining at 0.1-10mM. The anti-ERα36 antibody to block 
membrane-ERα isoforms also [D] inhibited a 24R,25(OH)2D3 increase in proliferation, [H] 
p53 content, and [L] TUNEL staining. [D, H, and L] To confirm membrane ER 
involvement, ICI-182780 was included as a control in anti-ER⍺36 experiments. However, 
[D] while ICI-182780 did not inhibit 24R,25(OH)2D3-induced proliferation, it did inhibit 
apoptosis as measured by both [H] TUNEL staining and [L] total p53 content. All graphs 
were analyzed by two-way ANOVA at α=0.05 with Bonferroni’s correction. 
 
Discussion 
Vitamin D has been shown to have a significant anti-tumorigenic effect against 
breast cancer in epidemiological, pre-clinical, cellular and molecular studies 111,280–282. 
The expanding body of evidence using new synthetic analogs of vitamin D has 
demonstrated the possibility of developing compounds that can regulate cellular 
processes independently from their calcemic effects, enabling the expansion of the 
therapeutic window of vitamin D-related compounds 280.  
We have identified an alternative active endogenous metabolite of vitamin D, 
24R,25(OH)2D3. 24R,25(OH)2D3 has a marked inhibitory action on bone resorption 283,284, 
reducing calcium release and thus not causing hypercalcemia 285. In the present study, 
we have established its anti-tumor and pro-apoptotic effects in MCF7 breast cancer cells. 
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Our results clearly demonstrate an anti-cancer effect indicated by reduced tumor 
growth, improved prognosis, and longer survival rates. Treatment with 24R,25(OH)2D3 
significantly reduced tumor volumes in mice implanted with MCF7 breast cancer 
xenografts. 17-estradiol supplementation was required to initiate MCF7 tumor growth in 
these mice, but after 4 weeks of 17-estradiol supplementation, tumors continued 
growing without additional supplementation. Supplementation with 24R,25(OH)2D3 
caused a dose-dependent decrease in the rate of tumor growth, with improvement in 
survival and final tumor volume. Furthermore, increasing concentrations of 
24R,25(OH)2D3 correlated with a significant reduction in total metastatic burden, loco-
regional and distant metastatic incidence. These effects resemble the correlation 
described in the literature between increasing serum vitamin D3 and improved survival in 
breast cancer 251,286, and support the hypothesis that 24R,25(OH)2D3 does, in fact, 
possess anti-tumorigenic properties. 
These findings are further supported by the observation that 24R,25(OH)2D3 
inhibited expression of metastatic markers, including expression of Snail, Her2, and 
collagenase, as well as the ratio of CXCR4 to CXCL12.  Migration was inhibited in a dose-
dependent manner when testing wound closure using the scratch test, and the ratio of 
OPG to RANKL, both in terms of expression and protein production, was stimulated by 
high-dose 24R,25(OH)2D3. Total collagenase was not affected to the same extent as 
MMP1 expression, probably due to the experimental design, where mRNA was assessed 
at 12 hours and enzyme content was assessed at 24 hours. 
In contrast with our in vivo observations, and the evidence shown above that 
24R,25(OH)2D3 had an anti-tumor effect, 24R,25(OH)2D3 enhanced proliferation of MCF7 
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cells in vitro. The effect of 24R,25(OH)2D3 on proliferation of MCF7 cells was not 
stereospecific as a similar response was seen with 24S,25(OH)2D3. Although the 
precursor 25(OH)D3 had the same stimulatory effect on proliferation as 24R,25(OH)2D3, 
1α,25(OH)2D3 had no effect, indicating that the site of the second hydroxyl on either C-24 
or C-1 was the important differentiator, but whether the hydroxyl on C-24 was in a R or S 
configuration did not matter. It is possible that the addition of the C-1 hydroxyl caused a 
stereospecific inhibition in the binding of the molecular to an as-yet-unidentified receptor. 
The study did not take into account, however, that vitamin D3 metabolism occurs in a 
cyclic manner in vivo, both locally in cells that possess appropriate hydroxylases, and in 
the kidney 13,287.  MCF7 cells normally express 1-hydroxylase, but do not typically express 
24-hydroxylase unless stimulated by 1,25(OH)2D3 288.  It is possible that either local levels 
or systemic levels of 1,25(OH)2D3 may have been sufficient to reduce or prevent the 
proliferative effect of 24R,25(OH)2D3, particularly in response to indirect upregulation of 
Cyp27B1 and production of 1,25(OH)2D3 due to the 24R,25(OH)2D3 treatment. None of 
these vitamin D3 metabolites had any effect on cell proliferation after 24 hours of treatment 
in vitro, which could also indicate another undiscovered pathway that counteracts the 
initial pro-proliferative pathway stimulated by the 15 minute treatment.  
Our in vitro studies were performed using MCF7 cells in order to have a direct 
correlation with our in vivo observations. In order to determine whether our results using 
this well-studied ER+ breast cancer cell line were also found using other breast cancer 
cell lines, we examined the responses of ER+ T-47D cells and ER- HCC38 cells to 
24R,25(OH)2D3. At least with respect to p53 abundance, the effect of 24R,25(OH)2D3 was 
not consistent between MCF7, T-47D, and HCC38 cells, suggesting that the response to 
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this secosteroid may be cell-type dependent. 24R,25(OH)2D3 increased p53 content in 
both MCF7 and T-47D cell lines, which express similar levels of ERα66 and its isoforms 
43.  HCC38, on the other hand, expresses high levels of ERα36 and no ERα66 27. It is 
possible that each cell line’s ERα profile has a modulating effect on the tumorigenicity of 
24R,25(OH)2D3. This could provide an explanation for conflicting reports on the 
tumorigenicity of 24R,25(OH)2D3 and 24-hydroxylase. In ERα+ Lewis lung carcinoma 
cells 72, 24R,25(OH)2D3 was reported to have an anti-tumorigenic effect 260, but in ERα- 
ERβ-expressing HT29 colorectal cancer cells 11, CYP24A1 overexpression enhanced 
tumor volume, an effect that was further compounded by a diet high in soy-based 
phytoestrogens 98. Further studies are ongoing to investigate the universality of 
24R,25(OH)2D3’s therapeutic effect against breast cancer in other cell types. However, it 
is clear from our data that 24R,25(OH)2D3 has a cell survival modulating effect on breast 
cancer. 
Our results using MCF7 cells indicate that the stimulatory effects of 24R,25(OH)2D3 
and 24S,25(OH)2D3 involved membrane-associated signaling pathways. Pretreatment 
with 2-bromopalmitate, which blocks palmitoylation of membrane receptors, and inhibition 
of PLD activity as well as destruction of caveolae structural integrity with -cyclodextrin 
abolished their effects. The stimulatory effect of both 24,25(OH)2D3 enantiomers on DNA 
synthesis was only evident in cultures treated for 15 minutes, suggesting a rapid signaling 
mechanism was involved, although a specific membrane receptor for either the R or S 
form of the secosteroid might not be required. The effect on DNA synthesis was not 
evident in cultures treated for 24 hours, raising the possibility that the augmentation of 
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proliferation was not specific to either enantiomer and might reflect a crosstalk with other 
membrane or nuclear signaling pathways, as seen extensively in steroid hormones 34,68.  
Treatment with 24R,25(OH)2D3 induced apoptosis in MCF7 cell monolayers as 
evidenced by elevated levels of Bax/Bcl2 gene expression, total p53 production, and DNA 
fragmentation (as measured by TUNEL staining). This effect was stereo-specific, as the 
enantiomer 24S,25(OH)2D3 did not alter Bax/Bcl2 expression, p53 content, or TUNEL 
staining after treatment for either 15 minutes or 24 hours. The mechanism by which 
24R,25(OH)2D3 induced apoptosis is not yet known, although our findings indicate that a 
membrane-mediated pathway was involved. The 24R,25(OH)2D3-dependent increase in 
p53 production and TUNEL staining required palmitoylation, PLD activation, and intact 
caveolae. It should be noted that although the effect of 24R,25(OH)2D3 on apoptosis was 
stereo-specific and the effect on proliferation was not specific to the ‘R’ isoform, inhibitor 
studies suggest that both effects use similar pathways. 
Treatment with 24R,25(OH)2D3 not only retarded breast cancer tumor growth, but 
also lead to the suppression of the primary tumor from metastasizing to other secondary 
sites. This may be due to an inhibitory effect on the epithelial-to-mesenchymal transition 
associated with metastasis as previously observed in MCF7 cells 194.  24R,25(OH)2D3 
reduced the expression of several epithelial-mesenchymal transition and tumor 
aggression-associated factors such as Snail1, which leads to a down-regulation of cell-
cell interaction proteins such as cadherins to assist the cell’s transition from a static 
epithelial cell to a migratory mesenchymal cell 289,290. 24R,25(OH)2D3 also suppressed 
migration-associated markers, such as the ratio of gene expression of metastatic factor 
CXC chemokine receptor type 4 (CXCR4) to its ligand CXC ligand 12 291–294, and the 
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migration of cells in vitro. Matrix metalloproteinases (MMPs), a family of zinc-dependent 
endopeptidases, which are involved in the degradation of extracellular matrix 295, have 
also been associated with cancer invasion, metastasis and angiogenesis 296. 
24R,25(OH)2D3 caused a reduction in MMP1 expression. Together with its effect in 
reducing chemotaxis, as evidenced by reducing the rate of wound closure in a two-
dimensional culture, our results indicate that 24R,25(OH)2D3 mediates a reduction in 
breast cancer cell invasion.  
Overexpression of Her2, which is regarded as a growth factor receptor oncogene 
297, plays an essential role in the development and progression of certain aggressive 
types of breast cancer. Expression of Her2 has become an important biomarker and 
target of therapy for approximately 30% of breast cancer patients 298, as its 
downregulation is correlated with growth inhibition of breast cancer cells 299. Studies with 
antibodies against Her2 demonstrated improved survival and response rates to 
chemotherapy 300. 24R,25(OH)2D3 downregulated expression of Her2, supporting its 
potential as a negative regulator of tumor growth, by inhibiting the ability of breast cancer 
cells to detach from the primary tumor and migrate to distant sites of the body. This anti-
metastatic effect was further observed in vivo, in the reduction of loco-regional and distant 
metastasis observed in animals treated with 24R,25(OH)2D3. Thus, the reduction of 
migratory factors observed with 24R,25(OH)2D3 treatment suggests that it confers a 
protective effect opposing the growth of breast cancer cells.  
The pro-apoptotic effect of 24R,25(OH)2D3 was stereo-specific; 24S,25(OH)2D3 
failed to elicit a response from the cells. This effect was rapid, with 15 minutes of 
24R,25(OH)2D3 treatment inducing the pro-apoptotic response in cultures harvested 12 
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to 24 hours later. The effect of 24R,25(OH)2D3 on proliferation was similarly rapid, 
although it was not stereo-specific. This prompted us to determine the role of the 
membrane in the 24R,25(OH)2D3 pro-apoptotic response, as membrane-associated 
actions of 24R,25(OH)2D3 have been shown to affect apoptosis and DNA synthesis in 
other cell types 17,18,93,105,301.  Pretreatment with methyl -cyclodextrin, which depletes the 
membranes of cholesterol and thereby disrupts the caveolae 169, abolished the pro-
apoptotic effect, indicating the importance of the specialized membrane compartment for 
the 24R,25(OH)2D3-dependent signaling pathway in MCF7 breast cancer cells.  
24R,25(OH)2D3 is a steroid hormone, and like 1 ,25(OH)2D3 and ERα, acts by a 
set of membrane-associated mechanisms to exert its effect. Steroid hormone receptors 
are trafficked to the plasma membrane to serve as transmembrane receptors via a 
uniform mechanism involving palmitoylation 35, the attachment of palmitic acid to an 
internal cysteine residue, which promotes the association of the receptor with caveolin-1, 
a transporter protein, to caveolae rafts in the plasma membrane 49. Palmitoylation plays 
a role in signaling through the membrane-associated ERα 78,302. The canonical vitamin D 
receptor (VDR), which binds 1α,25(OH)2D3, can act through rapid membrane associated 
signaling pathways 39,254. Our results show that the apoptotic effects of 24R,25(OH)2D3 
require palmitoylation, as they were blocked by 2-bromopalmitate, which is an inhibitor of 
palmitoylacetyl-transferase and prevents palmitoylation of steroid hormone receptors 269.  
Previous studies in our lab using chondrocytes show that 24R,25(OH)2D3 
increases proliferation (DNA synthesis) and differentiation while inhibiting apoptosis 303. 
These actions involved PLD-mediated increases in PKC, as well as through inhibition of 
the phospholipase A2 (PLA2) pathway 15,16,255. It has been suggested that the point of 
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regulation in the mechanism of 24R,25(OH)2D3 stimulated PKC is PLA2, which controls 
the availability of substrate for Cox-1 17. Further, the activation of PLD resulted in 
increased production of lysophosphatidic acid (LPA) and consequently LPA-mediated 
proliferation, maturation, inhibition of phosphate-induced apoptosis, and reduction of p53 
18,92,93. Both genomic and non-genomic signaling pathways have been implicated in the 
actions of 24R,25(OH)2D3 and it has been suggested that it exerts its effects via more 
than one signaling pathway. These pathways may be interrelated via the modulation of 
PLA2 17. In our study, both the pro-apoptotic and proliferative effects incurred by 
24R,25(OH)2D3 in MCF7 breast cancer cells were abolished by pretreatment with 
wortmannin, a non-specific inhibitor of PLD 15,142. Thus, a PLD mediated signaling 
pathway is implicated in both 24R,25(OH)2D3’s pro-apoptotic and proliferative effects in 
breast cancer cells.  
The full impact of 24R,25(OH)2D3 is the result of the convergence and crosstalk of 
the different signaling pathways, which at times are antagonistic, and its interaction with 
other steroid hormones such as other vitamin D metabolites 18 or sex hormones. 
However, it is important to note that wortmannin is also a weak inhibitor of PKC and PI3K, 
which have both been shown to be involved in rapid signaling by steroid hormones and 
resultant regulation of proliferation and apoptosis 31,68.  Further investigation is necessary 
to determine whether this effect is cell type specific or if the PLD, PLA2 mechanism shown 
in chondrocytes universally governs 24R,25(OH)2D3’s apoptotic effects. 24R,25(OH)2D3 
function is variable and complex and necessitates further research to clarify the signaling 
pathways involved and to clarify the effects of 24R,25(OH)2D3 on breast cancer cells.  
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Finally, we assessed the relationship between the effect of 24R,25(OH)2D3 and 
ER, the classical nuclear receptor for the sex steroid 17-estradiol (E2). A known 
correlation between 1,25(OH)2D3 and E2 exists. 1,25(OH)2D3 downregulates E2 
receptor abundance by binding to VDR and activating negative response elements in the 
ESR1 promoter 120; suppresses E2 actions in MCF7 breast cancer cells 120,304; and 
restores antiestrogen responsiveness 129. Our findings stress a striking resemblance in 
the signaling pathways of the two steroid hormones despite having antagonist actions in 
breast cancer cells. E2 signaling is pivotal in the initiation and progression of breast 
cancer; it functions as a potent mitogen inducing the activation of c-Myc and an array of 
cyclin genes promoting cell cycle progression from G1 to S phase 305. The novel 
membrane receptor ERα36 is gaining interest as a key player in breast cancer, especially 
in conferring aggressive features and resistance to hormonal treatment.  
ER36 mediates the anti-apoptotic effect of E2 by activating PLD at the membrane 
leading to activation of LPA signaling and PI3K, which in turn leads to attenuation of the 
caspase cascade that promotes apoptosis 1. E2-ER36 signaling has also been 
implicated in the activation of other rapid pathways such as ERK-MAPK, PI3K-Akt, and 
PKC-ERK, and may have downstream effects on the employment of IGF-IR, EGFR, 
HER2 306, resulting in a decrease in apoptosis and an increase in proliferation and 
metastatic potential in a variety of cancer cells, including breast cancer cells 68,109. These 
pathways have been reported to stimulate tumorigenicity in both ER positive and negative 
breast cancer tumors 27,55. These rapid signaling mechanisms mediated by ERα36 are 
insensitive to anti-estrogens and have even been shown to employ agonist activities in 
response to anti-estrogens, such as tamoxifen and ICI-182,780, which are both known 
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inhibitors of the classical ERα66 129. Both antibodies that block the ER 36 mediated 
effect of E2 and ICI 182,780 (which blocks cytosolic and nuclear ERs) abolished the pro-
apoptotic effect of 24R,25(OH)2D3. However, only the antibody to ERα36 blocked the 
proliferative effect. This implies that 24R,25(OH)2D3 and both the canonical and 
membrane-associated signaling pathways of E2 share a common downstream pathway, 
the exact mechanism of which remains to be revealed (Figure 5.11).  
Upon activating a signaling cascade at the membrane, 24R,25(OH)2D3 stimulates 
the secondary messenger PLD. PLD stimulates the LPAR1/3 receptor and downstream 
signaling stimulates PI3K, upregulates Bax, and downregulates Bcl2 expression to 
increase p53 production and induce apoptosis in MCF7 cells. A similar mechanism is 
responsible for the proliferative actions of 24R,25(OH)2D3, which is regulated by a 
membrane-mediated receptor in the caveolae niche via a PLD-dependent mechanism. 
24R,25(OH)2D3 also decreases invasion and metastatic markers through an as yet 
unidentified mechanism. 
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Figure 5.11 24R,25(OH)2D3 induces apoptosis and proliferation through a 
membrane-mediated caveolae-dependent mechanism involving one or more as yet 
undescribed palmitoylated nuclear receptors. 
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Chapter 6.  
24R,25-dihydroxyvitamin D3 regulates breast cancer progression in an estrogen 
receptor α 66-dependent manner.  
[Chapter 6 is in preparation as: Verma A, Cohen DJ, Jacobs TW, Boyan BD, Schwartz Z. 
Loss of estrogen receptors is associated with increased tumor aggression in laryngeal 
squamous cell carcinoma. Mol. Can. Res. In preparation] 
 
Introduction 
Vitamin D3 has been of interest as an anti-tumorigenic agent for decades. Interest 
in vitamin D3 first peaked when epidemiologists noticed that the incidence of certain 
cancers, including breast cancer, inversely correlated with daily sun exposure 307,308. 
Vitamin D3 is an essential pro-hormone that is synthesized in response to UVB radiation 
from sunlight. Retrospective clinical studies have shown that reduced exposure to UVB 
correlates with low levels of serum vitamin D3, and low serum vitamin D3 correlates with 
an increased risk for breast cancer 113. Similarly, epidemiological studies have shown 
vitamin D3 supplementation is associated with a reduced risk of breast cancer recurrence 
8. However, recent large-scale double-blind clinical trials have concluded that there is no 
connection between vitamin D3 supplementation and breast cancer incidence in the 
general population 6,7. 
There are two possible reasons for this discrepancy. One reason may be that most 
clinical studies that examine the efficacy of vitamin D3 treat breast cancer as a 
homogenous disease with uniform presentation. In actuality, breast cancer is a 
heterogeneous disease that can present with several distinct molecular subtypes. 
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Detailed clinical and retrospective analyses have shown that low serum vitamin D3 is 
associated with an increased risk of developing estrogen receptor positive (ER+) cancer, 
but not estrogen receptor negative (ER-) cancer 309. Furthermore, vitamin D 
supplementation is associated with a reduced risk of developing new or recurrent tumors 
in patients with estrogen receptor positive (ER+) cancer, but not patients with estrogen 
receptor negative (ER-) cancer) 8,310. 
Another reason may be that most studies that examine the anti-cancer properties 
of vitamin D3 limit their investigations by correlating cancer incidence with oral vitamin D3 
intake or serum 25-hydroxyvitamin D3 (25(OH)D3) 112,240,311. Serum 25(OH)2D3 is an 
incomplete picture of the active vitamin D metabolome. Once ingested, vitamin D3 is 
metabolized in the liver into 25(OH)D3 246. From there it circulates in the blood as serum 
25(OH)D3 until it reaches the kidney, where it is hydroxylated into a number of active 
vitamin D3 metabolites, including the well-described metabolite 1,25-dihydroxyvitamin 
D3 (1,25(OH)2D3) and the understudied 24R,25-dihydroxyvitamin D3 (24R,25(OH)2D3) 
13. 1,25(OH)2D3 is partially responsible for maintaining calcium homeostasis and bone 
mineralization and has been shown to have some anti-cancer properties. However, it has 
a narrow therapeutic window and can induce hypercalcemia. 24R,25(OH)2D3 is a less 
studied, less calcemic vitamin D3 metabolite. Previous studies in our lab and others have 
shown that 24R,25(OH)2D3 is responsible for maintaining cartilage differentiation and may 
regulate the cell cycle in chondrocytes 23,93,312.  
24,25(OH)2D3 has been shown to have anti-tumorigenic properties in certain 
cancers 260, including lung and stomach carcinomas 260,262. However, an increase in 24-
hydroxylase, the enzyme that increases 24R,25(OH)2D3 in vivo, has been associated with 
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increased tumorigenicity in models of colorectal carcinoma 98. Recently, our lab has 
shown that 24R,25(OH)2D3 is active in breast cancer cell lines and that 100 ng of 
24R,25(OH)2D3 given three times a week is non-calcemic and anti-tumorigenic in a model 
of ER+ breast cancer 313. However, while 24R,25(OH)2D3 was anti-tumorigenic in ER+ 
breast cancer cell lines, it was pro-tumorigenic in HCC38, an ER- breast cancer cell line 
313. In vitro studies revealed that the actions of 24R,25(OH)2D3 are modulated by a rapid, 
membrane-associated, mechanism in breast cancer 313.  
Breast cancer cells that are ‘ER+’ express the classical estrogen receptor α (ERα) 
isoform ERα66, while ‘ER-’ cells do not express ERα66. Both cell types may express 
other ERα isoforms, including the membrane isoform ERα36 27,55. HCC38 does not 
express ERα66, however, it expresses ER36 1. ER36 mediates rapid signaling by 17-
estradiol (E2) in cancer cells 55. We hypothesized that the pro-apoptotic effects of 
24R,25(OH)2D3 might be regulated in part by the canonical receptor, ER66, rather than 
the rapid signaling receptor, ER36, thus implying a role for the canonical receptor ER66 
in the rapid signaling of 24R,25(OH)2D3. 
Materials & Methods 
Cell Lines 
MCF7 and HCC38 breast cancer cell lines and C2C12, a muscle cell line, were 
purchased from ATCC (Manassas, VA). Experiments were conducted within 6 months of 
cell purchase.  Cells were maintained in media and passaged following ATCC guidelines 
as previously described1.   
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Caveolin-1 knockdown.  
Stable knockdown of Cav-1 was achieved by transducing wild-type HCC38 cells 
with CAV-1 shRNA lentiviral transduction particles packaged in Mission® shRNA lentiviral 
particles as previously described314. Four shRNAs targeted to the CAV1 gene (Millipore-
Sigma, Burlington, MA, cat#SHCLNV-NM_0001753, clone TRCN0000000310, clone 
TRCN00000000508, clone TRCN 00000008000 and clone TRCN0000008002) were 
cloned into a cassette containing a puromycin-resistance gene and packaged as lentiviral 
particles. Empty control cells were created with MISSION® pLKO.1 puro Empty Vector 
Control Transduction Particles (Sigma MISSION® cat#SHC001V). HCC38 cells were 
transduced with shRNA-containing lentiviral particles according to manufacturer’s 
protocol and a pure population of cells was enriched by using 50g/mL as a selection 
agent. CAV1-knocked down-HCC38 cells were tested for effective Caveolin-1 
knockdown,  and the two clones with the best knockdown, clone TRCN0000000508 and 
clone TRCN0000008002, were chosen for subsequent experiments and labeled “clone 
1” and “clone 2” respectively. Caveolin-1 knockdown was confirmed with western blot as 
previously described 169. Antibodies for all western blots are given in Table 6.1. All 
transduced-HCC38 cells were maintained in full media supplemented with 50g/mL 
puromycin. 
ER isoform overexpression in cell lines 
ER isoforms were overexpressed in HCC38 and C2C12 cells with a commercially 
available ESR1, GFP-tagged open-reading-frame (ORF) plasmid (Origene, cat# 
RG213277) as previously described 315,316. Empty vector controls were created with open 
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reading frame (ORF) control particles (Origene, cat# PS100093) according to Origene 
protocols.  
HCC38 monolayer cultures were transiently transduced for 48 hours with the ESR1 
or control particles according to manufacturer’s instructions. In brief, a solution of 5g of 
plasmid per 1mL of opti-mem serum-free media per 6L turbofectin 8.0 (Origene, cat# 
TF81001) was added drop-wise to T25 (1mL plasmid solution/well), 24W (100L/well) or 
48W (50L/well) monolayer cultures. Transfection was confirmed 48 hours after particle 
addition by visualizing GFP expression in wells with a Zeiss SteroDiscovery.V12 
fluorescence microscope with an AxioCam MRm digital camera. In a representative set 
of cultures, 48 hours after transient transfection a T25 culture of cells was harvested with 
radioimmunoprecipitation assay (RIPA) buffer and ER66 overexpression was confirmed 
by western blot as described previously1.  
C2C12, a mesenchymal cell line derived from myoblasts, were stably transfected 
with ESR1 or empty control cells using the ORF particles described above. 48 hours after 
transfection, cells were selected with full media supplemented with 1mg/mL G418 as 
previously described313. ESR1 overexpression was confirmed by western blot as 
described previously1. 
ERα66 silencing in MCF7 cell lines 
ERα66 was stably knocked down in MCF7 cells with a commercially available short 
hairpin ESR1 lentiviral vector from Sigma MISSION® (cat# TRCN0000003301). 
Scrambled control cells were created with MISSION® TurboGFP® Control Transduction 
Particles (Sigma MISSION® cat#SHC016V). Both vectors included a coding region for a 
puromycin resistance gene. Cells were transduced according to manufacturer’s protocol 
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and a pure cell population was enriched using 50μg/mL puromycin selection media. Cells 
were maintained in 50μg/mL puromycin full media and ERα66 silencing was confirmed 
via western blot as previously described 169.  
 
Table 6.1 Antibodies used in western blots. 
Protein Source Catalog # 
Caveolin-1 Abcam Ab2910 
ER66 Chi Scientific 8-80119 
ER36 Chi Scientific 8-80119 
GAPDH Millipore-Sigma MAB374 
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In Vivo Studies 
 All in vivo experiments were done on female 6-8 week old Nod-Scid-gamma IL2γ 
(NSG) mice obtained from the Virginia Commonwealth University (VCU) Cancer Mouse 
Models Core Laboratory at Massey Cancer Center (Richmond, VA). All animal 
experiments were approved by VCU’s Institutional Animal Care and Use Committee. 
Animals were monitored for signs of hypercalcemia and other health and behavioral 
changes throughout the course of the study.  
Mammary fat pad xenograft model.  
Two mammary fat pad xenograft models were tested for this study. The first study 
was done with un-operated mice. A second study was conducted at a later date with 
ovariectomized mice. 5-6 week old female NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice 
were ovariectomized as previously described 167. Two weeks after ovariectomy, tumors 
were initiated as previously described313. In brief, intact or ovariectomized NSG mice were 
injected twice weekly intraperitoneally with 2.5mg/kg of 17β-estradiol (n=6) (Millipore-
Sigma cat#E8875) or vehicle (n=6) (2% ethanol:1X distilled phosphate buffered saline 
[DPBS]) starting at 1 week prior to tumor initiation and continuing until the end of the study 
10 weeks later. To initiate tumors, 1 million HCC38 cells in 50μL of 1:1 DPBS:BME 
(Cultrex Pathclear basement membrane extract Type 3, 14.5 mg/mL; #3632; RnD 
Systems, Minneapolis, MN) were injected into the lactiferous duct of the right fourth 
mammary gland of 5-6 week old NSG mice as previously described 313.  Tumors were 
measured with digital calipers starting at 2 weeks post cell injection and continued to be 
measured once a week until harvest at 10 weeks.  
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Effect of 24R,25(OH)2D3 on xenograft tumor growth.  
One million HCC38 cells in 50μL of 1:1 DPBS: BME were injected into the 
lactiferous duct of the right fourth mammary gland of un-operated female NSG mice to 
initiate tumors as described in the Error! Reference source not found.. The next day, m
ice were injected with 0, 25 ng, or 100 ng of 24R,25(OH)2D3 dissolved in 2% ethanol:1X 
DPBS. Injections continued 3 times a week for the remainder of the study. Tumors were 
measured with digital calipers, and tumor volume was calculated as previously described 
313. After 8 weeks, mice were euthanized and tumors were harvested as described above. 
Immediately after harvesting, tumors were scanned for μCT analysis and then fixed in 
10% neutral-buffered formalin. CT tumor measurements were normalized to vehicle-
treated tumors and compared to CT measurements taken from MCF7 tumors from a 
previous study 313 and similarly analyzed to assess changes in tumor volume relative to 
their respective controls 313. Animal survival was assessed with a Mantel-Cox logrank 
survival curve analysis, and P-values <0.05 were considered significant as previously 
described 313. 
In vitro Studies 
Response to vitamin D3 metabolites.  
 24R,25(OH)2D3, and 1α,25(OH)2D3 were purchased from Enzo Life Sciences 
(Farmingdale, NY); 24S,25(OH)2D3 was purchased from Millipore-Sigma (cat# 29447). 
Stock solutions were prepared in absolute ethanol and diluted in culture medium as 
previously described 15.  
Confluent cultures were treated with dose-dependent 24R,25(OH)2D3 (10-10-10-7M) 
as previously described 313. To assess specificity of the response to 24R,25(OH)2D3, 
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confluent cultures were also treated with 1α,25(OH)2D3 (10-10-10-8M), 24S,25(OH)2D3 (10-
9-10-7M), or 25(OH)D3 (10-9-10-7M), or a vehicle (10-4M ethanol). All vitamin D metabolites 
were reconstituted in ethanol, as previously described 15. Stock solutions were diluted in 
warm complete media to final treatment concentrations. Media were removed by 
aspiration at 15 min or 24 hours, and cells were incubated with fresh complete media until 
harvest as indicated below.  
Signaling Pathway Inhibition.  
In these experiments, cells were pre-treated for 30 minutes with inhibitors or 
vehicle in warm complete media as previously described 313. In brief, cultures were 
pretreated with 1-10μM 2-bromopalmitate (Millipore-Sigma #21604)269 to inhibit 
palmitoylation, 0.1-1 μM wortmannin (VWR, Radnor, PA, cat# 80055508) 15 to inhibit PLD, 
or 1-10mM methyl β-cyclodextrin (Millipore-Sigma #C4555) in serum-free media to 
deplete cell membranes of cholesterol and inhibit intact caveolae 169,270,271. Cultures were 
pretreated with 10-7M ICI-182780, an inhibitor to cytosolic and nuclear ERs (Millipore-
Sigma #I4409) 272,273, or 1μg of a neutralizing antibody to the membrane-associated 
estrogen receptor (Alpha Diagnostic, San Antonio, Texas, cat#ERA361-A), to assess the 
role of ERα66 or ERα36 respectively on the actions of 24R,25(OH)2D3 55. 
Outcome Measures 
DNA synthesis  
Cells were cultured to 70% confluence, then serum-starved for 48 hours as 
previously described 313. At that time, cells were treated with 24R,25(OH)2D3, 
24S,25(OH)2D3, or 1α25(OH)2D3 for 15 minutes and incubated with fresh complete media 
for 24 hours, harvested, and assayed for EdU incorporation according to manufacturer’s 
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instructions (ThermoFisher Scientific, Waltham, Massachusetts, #C10214) as previously 
described 313.  
Gene expression  
Cells were cultured to confluence, then treated with 24R,25(OH)2D3 or vehicle in 
complete media for 15 minutes as described above. Cultures were then aspirated, 
incubated with complete media for 12 hours. RNA was extracted using TRIzol (Invitrogen, 
Carlsbad, CA) and quantified (Take3 Micro-Volume Plate, Biotek, Winooski, VT) before 
being used to synthesize cDNA libraries (High Capacity cDNA Reverse Transcription kit, 
Promega, Madison, WI) and assessed for gene expression using qRT-PCR as previously 
described 313. Gene-specific primers were designed as previously described and are 
given in Table 6.2 313. HCC38, a triple-negative breast cancer cell line that does not 
express ER66 1 but does express ER36, and MCF7, a luminal breast cancer cell line 
that expresses all ER isoforms 1, were both assessed for hydroxylase enzyme mRNA 
expression. 
  
Modulation of 24R,25(OH)2D3 Tumorigenicity by ER Isoforms in E2-Responsive Cancer • Spring 2019 
Anjali Verma • Ph.D. Dissertation • Biomedical Engineering • Virginia Commonwealth University 161 
 
Table 6.2 Gene expression primers used in quantitative real-time PCR. 
Species Gene Primer Sequence 
Human BAX 
F GACGAACTGGACAGTAACATGG 
R AAAGTAGAAAAGGGCGACAACC 
Human BCL2 Hs_BCL2-1-SG QuantiTect Primer #249900 
Mouse BCL2 
F TTTGAGTTCGGTGGGGTCAT 
R CTGGGGCCATATAGTTCCACAA 
Human CXCL12 
F GCCTCTGAAGCCTATGTATG 
R GACGAACTGGACAGTAACATGG 
Human CXCR4 
F TAGCAAAGTGACGCCGAGGG 
R TGGTTCTCCAGATGCGGTGG 
Human CYP24A1 
F GACATCCAGGCCACAGACAA 
R ACCACCATCTGAGGCGTATT 
Human CYP27B1 
F AGAGTTGCTATTGGCGGGAG 
R AGAACAGTGGCTGAGGGGTA 
Human ERBB2 
F CCGCTGAAGTCCACACAGTT 
R AAAGGTTCTACCCCGCATGG 
Human ESR1 Hs_ESR1-1-SG QuantiTect Primer #044492 
Human GAPDH 
F CTATAAATTGAGCCCGCAGCC 
R TGGCGACGCAAAAGAAGATG 
Human MMP1 
F AGAAAGAAGACAAAGGCAAGTTGA 
R TCCCCAGTCACTTTCAGCCC 
Human OPG 
F GTGTGCGAATGCAAGGAAGG 
R CACTCCAAATCCAGGAGGGC 
Human RANKL Hs_TNFSF11-1-SG QuantiTect Primer #PPH01048F 
Human SNAI1 Hs_SNAI1-1-SG QuantiTect Primer #010010 
 
p53 content  
Total p53 was measured 24 hours post-cell treatment in human cells with 
24R,25(OH)2D3 as described above using a sandwich enzyme-linked immunosorbent 
assay (ELISA) (R&D Systems, cat# DYC1043) and phosphorylated p53 was measured 
using a sandwich ELISA specific to the serine-15 residue (R&D Systems, cat# DYC1839). 
Total p53 content was measured in C2C12 cells with a p53 pan ELISA (Millipore-Sigma 
cat# 11828789001). For all cell types, cells were plated in 24 well plates, treated with 
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24R,25(OH)2D3 for 15 minutes, and incubated for 24 hours in complete media. 
Conditioned media were collected, and cell layers were lysed by sonication (40A for 5 
seconds) in 200μL lysis buffer according to manufacturer’s protocol. Lysates were 
centrifuged at 10,000g for 15 minutes; the supernatant was collected and assayed for 
total protein content (ThermoFisher, Pierce 660 nm Protein Assay) and total p53 content 
following the manufacturer’s instructions. Data are presented as a ratio of nanograms of 
total p53 to total protein content. 
DNA fragmentation  
DNA fragmentation was assessed by colorimetric terminal deoxynucleotidyl 
transferase (TdT)-mediated dUTP nick end labeling (Trevigen, TiterTAC™ in situ 
microplate TUNEL assay). Cells were incubated with vehicle or 24R,25(OH)2D3 for 15 
minutes, followed by incubation in fresh media for 24 hours. Samples were harvested and 
processed for TUNEL staining following the manufacturer’s instructions 313. 
Enzyme-linked immunosorbent assays for secreted proteins  
Confluent cultures cells were plated in 6 well plates, treated with vehicle or 
24R,25(OH)2D3 for 15 minutes as described above, aspirated, and then incubated in 
complete media. After 24 hours, conditioned media were collected in 5mL polypropylene 
tubes, frozen at -80oC and lyophilized (Labconco, Kansas City, Missouri, Freezone 
Freeze Dryer #7740020). Lyophilized samples were reconstituted in 200 μL of filtered 
1XPBS containing 1% BSA and assayed for OPG and RANKL using sandwich ELISAs 
(R&D Systems, Human TRANCE/RANK L/TNFSF11 DuoSet ELISA #DY626, Human 
Osteoprotegerin/TNFRSF11B DuoSet ELISA #DY805) as previously described 313. Cell 
monolayers were lysed in 1mL 0.5% Triton™ X-100. Cell lysates were assayed for total 
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DNA content (Promega, QuantiFluor dsDNA, #E6150). OPG and RANKL content are 
expressed as a ratio of OPG/RANKL.  
Collagenase 
Collagenase content in the cultures was measured using an MMP1 assay kit 
(SensoLyte® Plus 520 MMP-1 Assay Kit *Fluorimetric and Enhanced Selectivity*, 
Anaspec #AS-72012). Cells were plated in 24 well plates and treated with vehicle or 
24R,25(OH)2D3 as described above. At harvest conditioned media were collected; cell 
monolayers were lysed in 500μL 0.05% Triton-X-100 and total DNA content measured. 
Total MMP1 was measured in the media and normalized to total DNA content. Data are 
presented as a ratio of ng MMP1/μg DNA 313. 
Osteoclast Activity  
Osteoclast (OC) activity was measured using a commercially available europium-
conjugated human type I collagen-coated OsteoLyse™ Assay Kit, as previously 
described317. Human OC precursors (OCPs; Lonza Biosciences, Walkersville, MD, cat# 
2T-110) were cultured on a human type I collagen-coated, 96-well OsteoLyse™ Assay 
Kit (Lonza Biosciences). OCPs were differentiated into mature OCs using osteoclast 
precursor growth medium (OCGM, Lonza Biosciences, cat# PT-8001) supplemented with 
33ng/mL macrophage colony stimulating factor (M-CSF) and 66ng/mL RANKL as 
previously described for 7 days317. OCPs were also cultured in OCGM supplemented with 
M-CSF without RANKL for use as a negative control. 
HCC38 cells were plated in 6 well plates. At confluence, cultures were treated with 
vehicle or dose-dependent 24R,25(OH)2D3 for 15 minutes as described above. 24 hours 
after treatment, conditioned media were collected. OC cultures were aspirated and 
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treated with conditioned media. OCs were cultured for another 7 days in conditioned 
media. After 7 days of culturing with HCC38-conditioned media (14 days total), OC activity 
was measured using the OsteoLyse™ Assay Kit, as previously described317. 
Wound closure assay 
A wound closure assay was used to demonstrate metastasis. Confluent cultures 
of HCC38 cells were treated for 15 min with media containing vehicle or 24R,25(OH)2D3. 
Another set of cultures was treated with 10-7M 17β-estradiol as a positive control. 
Following treatment, a scratch was drawn from one end of the well to the other using a 
sterile 1 mL pipette tip. The loosened cells were aspirated along with the treatment media, 
and fresh media added to the cultures. A phase-contrast microscope was used to take 
pictures of each well at 0, 3, 6, 9, 12, and 24 hours after the scratch was made. Wound 
area was calculated using Adobe Photoshop™ 2 software, normalized to the original 
wound closure area, and presented as percent wound closure. Data presented are from 
one of two repeated experiments 313. 
Enzyme Activity Assays 
Cells were plated in 24-well plates and treated with dose-dependent 
24R,25(OH)2D3 as described above for 9 minutes. Immediately after treatment, cells were 
aspirated, washed twice with 1X DPBS, and harvested with 200μL/well of phospholipase 
D (PLD) or protein kinase C (PKC) assay buffer according to manufacturer’s instructions. 
PLD activity was measured using the Amplex Red PLD assay (Fisher Scientific, Hampton, 
NH, cat# A12219)  as previously described55. PKC activity was measured using the PKC 
Activity Kit (Abcam, Cambridge, UK, cat# ab139437) as previously described67. 
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Statistical Analysis 
Data shown are from single representative experiments of two or more repeats 
and are presented as the mean ± standard error of six independent cultures per treatment 
group. Data were analyzed by ANOVA with Tukey’s post-test to determine significance 
between groups. Animal studies were analyzed with a repeated-measures two-way 
ANOVA with  = 0.05. Tumor growth curves were analyzed with linear regression analysis 
to determine whether tumor growth was linear and non-zero. CT data were analyzed 
with a one-way ANOVA within xenograft model types (i.e., MCF7 and HCC38 
experiments were analyzed separately). Animal survival was assessed with a Kaplan-
Meier log-rank analysis. 
 In vitro experiments with two independent variables (DNA synthesis, total DNA 
content, and total p53 time courses) were analyzed with two-way ANOVA with 
Bonferroni’s modification of Student’s t-test post-tests to determine the variance between 
row and column factors. The wound closure assay was analyzed with a repeated 
measures ANOVA test with comparisons between time points. P-values <0.05 were 
considered significant. Treatment over control data were calculated as the mean fold 
change of treated groups as compared to vehicle-treated cultures (dashed lines) from 
three or more experiments and analyzed with Wilcoxon signed-rank non-parametric 
paired t-tests as compared to control. All other experiments were analyzed with a one-
way ANOVA with Tukey’s correction. All statistics were conducted in Graphpad Prism 
6™. For all experiments, P-values < 0.05 were considered significant. 
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Results 
Breast cancer cell lines differentially express 24-hydroxylase enzyme. 
HCC38 expressed both 24-hydroxylase (CYP24A1) and 1-hydroxylase 
(CYP27B1) (Figure 6.1A), while MCF7 did not express CYP24A1. Both HCC38 and 
MCF7 expressed similar levels of CYP27B1 (Figure 6.1B). 
17β-Estradiol supplementation is not required to support HCC38 mammary fat pad 
xenografts in NSG mice.  
HCC38 xenografts were created in the 4th mammary fat pad of un-operated or 
ovariectomized NSG mice given systemic 17-estradiol (E2) or a vehicle. E2 did not 
significantly alter HCC38 tumor burden until week 8 (ovariectomized mice) or week 9 (un-
operated mice) (Figure 6.1C-6.1D). At weeks 9, 11, and 12, E2 statistically increased 
HCC38 tumor burden in un-operated mice. In ovariectomized mice, E2 statistically 
decreased tumor burden at week 8, but did not significantly alter tumor burden at any 
other time point in the study. Tumors grown in mice with intact ovaries (un-operated mice) 
were slightly larger at 3 weeks in un-operated mice (~50-75 mm3) as compared to 
ovariectomized mice (~30 mm3). This slight increase in tumor burden in un-operated mice 
continued throughout both studies, with tumors in un-operated mice being slightly larger 
(~200 mm3) than tumors in ovariectomized mice (~150 mm3) at the end of the study at 10 
weeks (Error! Reference source not found.C-6.1D).  
Tumors grew at a linear rate in vehicle-treated (R2=0.7857) and E2-treated 
(R2=0.7638) un-operated mice with slopes of 2.660  0.1824 mm3/day and 3.206  0.2341 
mm3/day, respectively. The slopes of the vehicle-treated and E2-treated tumors were 
significantly different from each other with E2-treated tumors growing faster than vehicle-
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treated tumors in un-operated mice. In ovariectomized mice, tumors also grew at a linear 
rate with vehicle-treated (R2=0.8257) and E2-treated (R2=0.7916) tumors having slopes 
of 2.579  0.1767 mm3/day and 2.034  0.1539 mm3/day respectively. The slopes of the 
vehicle-treated and E2-treated tumors were also significantly different from each other, 
but E2 treated tumors grew more slowly than vehicle-treated tumors in ovariectomized 
mice. A linear regression analysis found that both vehicle and E2-treated tumors had 
significantly non-zero slopes in both un-operated and ovariectomized mice. 
Treatment with 24R,25(OH)2D3 increased tumor burden in an HCC38 xenograft model of 
breast cancer. 
Mice receiving either 25 ng or 100 ng per injection of 24R,25(OH)2D3 had a greater 
HCC38 tumor burden than mice given a vehicle control injection (Figure 6.1E). This 
increase in tumor volume in 24R,25(OH)2D3 treated mice began at week 6 and continued 
until harvest at week 8. In previous HCC38 mammary fat pad xenograft studies, vehicle-
treated HCC38 tumors reached a final volume of 150-200 mm3 (Figure 6.1C, 6.1D), 
consistent with vehicle-treated HCC38 tumors in this study. Tumors in mice given 100ng 
of 24R,25(OH)2D3 per injection were significantly larger than tumors in mice given 25 ng 
at weeks 7 & 8. At harvest at week 8, tumors in mice given 100 ng were ~33% larger (final 
volume ~400 mm3) than tumors in mice given 25ng of 24R,25(OH)2D3 per injection, which 
reached a final volume of ~300 mm3. As in previous HCC38 mammary fat pad xenograft 
studies, HCC38 tumors were linear with non-zero slopes of 1.635  0.4265 mm3/day 
(vehicle), 5.48  0.4642 mm3/day (25 ng 24R,25(OH)2D3) and 7.575  1.241 mm3/day 
(100 ng 24R,25(OH)2D3). All three slopes were significantly non-zero and different from 
each other. Treatment with high-dose 24R,25(OH)2D3 increased tumor growth rate and 
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tumor burden in HCC38 xenografts by approximately 50%, as compared to a 50% 
decrease in tumor burden by 24R,25(OH)2D3 in MCF7 xenografts as measured by μCT 
(Error! Reference source not found.Figure 6.1F). Signs of hypercalcemia, such as 
anorexia, vomiting, lethargy, fatigue, and polyuria, were not detected in animals treated 
with a vehicle or with either dose of 24R,25(OH)2D3. In the high-dose 24R,25(OH)2D3 
HCC38 xenograft group, only 6 out of 8 animals survived to the end of the study as 
compared to 8 out of 8 animals in the vehicle and low-dose 24R,25(OH)2D3 groups. 
However, this reduction in animal survival was not statistically significant (Figure 6.1G).   
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Figure 6.1 Breast cancer cell lines differentially expression hydroxylase enzymes 
HCC38 and MCF7 breast cancer cells were cultured to confluence and harvested 
after 12 hours for gene expression. Cells were assessed for [A] CYP24A1 or [B] 
CYP27B1 expression and normalized to GAPDH as a housekeeping gene. [C] 
Unoperated female NSG mice implanted with HCC38 xenograft mammary fat pad 
tumors were intraperitoneally injected with 2.5mg/kg 17β-estradiol or a vehicle 
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twice a week for 12 weeks. Tumor burden was measured twice a week throughout 
the course of the study and plotted against time. [D] A similar study was done with 
ovariectomized NSG mice. HCC38 xenografts were treated with the same dose 
(2.5mg/kg) or 17-estradiol) or a vehicle and tumors were measured twice a week 
until harvest at 10 weeks. *indicates statistical significance against week-matched 
vehicle tumors at α=0.05 with two-way ANOVA. [E] NSG mice with HCC38 
mammary fat pad xenograft tumors were intraperitoneally injected with 25 or 100 
ng of 24R,25(OH)2D3 3 times a week for 8 weeks. Tumor burden was measured 
with digital calipers and plotted against time. Animals given 24R,25(OH)2D3 had 
increased tumor burden as measured by digital calipers. *indicates significance as 
compared to vehicle-treated animals within the same time point. O indicates 
significance as compared to animals treated with 25 ng of 24R,25(OH)2D3 within 
the same time point. [F] Animals given 24R,25(OH)2D3 had increased tumor 
burden as measured by μCT as compared to tumor burden in vehicle-treated mice. 
Capital letters were used to indicate significance within HCC38 xenograft tumor 
groups, while lower-case letters were used to indicate significance within MCF7 
tumor groups. Groups that do not share a letter are statistically significant. [G] After 
8 weeks, 8 animals from the vehicle group, 8 animals from the low-dose (25 ng per 
injection) 24R,25(OH)2D3 group, and 6 animals from the high-dose (100 ng per 
injection) 24R,25(OH)2D3 group survived out of an original n of 8. Animals in the 
high-dose group did not have a statistically significant reduced survival rate as 
compared to animals in low dose or vehicle groups.  
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24R,25(OH)2D3 specifically induced proliferation in HCC38 cells in vitro. 
When HCC38 cells were treated for 15 minutes with 24R,25(OH)2D3 proliferation 
increased after 24 hours (Figure 6.2A) as measured by DNA synthesis. However, 
treatment with 24S,25(OH)2D3, an enantiomer of 24R,25(OH)2D3, or 1α,25(OH)2D3 for 15 
minutes did not change proliferation after 24 hours (Figure 6.2B, C). The effect of 
24R,25(OH)2D3 was dose-dependent with the greatest increase at 10-7M 24R,25(OH)2D3. 
The effect of 24R,25(OH)2D3 was also observed in MCF7 cells 313, with both 10-8 and 10-
7 24R,25(OH)2D3 increasing DNA synthesis (Figure 6.2D). In both HCC38 and MCF7 
cells, 10-7M 24R,25(OH)2D3 increased DNA synthesis ~two-fold above vehicle-treated 
cultures. 
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Figure 6.2: 24R,25(OH)2D3 specifically induces proliferation in HCC38 cells. 
HCC38 monolayer cultures were serum-starved for 48 hours, treated with 
24R,25(OH)2D3, 24S,25(OH)2D3, or 1,25(OH)2D3 for 15 minutes and assayed 24 
hours later for EdU incorporation. [A] 24R,25(OH)2D3, but not [B] 24S,25(OH)2D3 
nor [C] 1α,25(OH)2D3, induced proliferation in HCC38 cell monolayers 24 hours 
after a 15-minute treatment. [D] Treatment over control was calculated as the 
average fold-change of treatment as compared to vehicle-treated cultures in three 
or more experiments and analyzed with a paired t-test against normalized vehicle 
controls *indicates significance at P<0.05 as compared to vehicle-treated cultures. 
High-dose 24R,25(OH)2D3 induced proliferation in HCC38 and MCF7 cell 
monolayers 2-fold over control. 
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24R,25(OH)2D3 reduces apoptotic markers in HCC38 cell monolayers, contrary to its 
effect in MCF7 cultures. 
24R,25(OH)2D3 caused a dose-dependent decrease in B cell lymphoma protein 2-
associated X protein (BAX) to B cell lymphoma protein 2 (BCL2) expression ratios 
(BAX/BCL2), which was significant at 10-8M and 10-7M doses (an ~8-fold decrease) 
(Figure 6.3A). 24R,25(OH)2D3 had a similar reducing effect on total p53 levels (Figure 
6.3B) and TUNEL staining (Figure 6.3C), with the 10-7M dose producing the maximum 
decrease in p53 levels (~2 fold decrease) and TUNEL (~.25 fold decrease). 
24R,25(OH)2D3-induced fold-change decreases in apoptosis in HCC38 cultures are 
similar in proportion to 24R,25(OH)2D3-induced fold change increases in apoptosis 
observed in MCF7 cultures (Figure 6.3D-F). However, in HCC38 cells, 24R,25(OH)2D3 
has the greatest effect at 10-7M on BAX/BCL2, total p53, and TUNEL staining; unlike 
MCF7, where maximal effect sizes are observed at 10-8M 24R,25(OH)2D3. 
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Figure 6.3: 24R,25(OH)2D3 prevents apoptosis in HCC38 cells, but induces 
apoptosis in MCF7 cells. 
HCC38 monolayer cultures were treated with 24R,25(OH)2D3 for 15 minutes, and 
harvested 12 hours later for gene expression and 24 hours later for protein and 
TUNEL staining. Cultures were assessed for apoptosis as measured by [A, D] 
BAX/BCL2 gene expression, [B, E] total p53 protein, and [C, F] TUNEL staining. 
[A-C] 24R,25(OH)2D3 reduced apoptosis in HCC38 cells. Groups that share a letter 
are not significant at p<0.05. [D-F] HCC38 or MCF7 monolayer cultures were 
treated with 24R,25(OH)2D3 for 15 minutes and assessed for apoptosis 12-24 
hours later. Treatment over control was calculated as the average fold-change of 
treatment as compared to vehicle-treated cultures in three or more experiments 
and analyzed with a paired t-test against normalized vehicle controls *indicates 
significance at P<0.05 as compared to vehicle-treated cultures.   
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24R,25(OH)2D3 increased epithelial-to-mesenchymal transition, metastatic markers, and 
migration in HCC38 cells in vitro.  
Treatment with 10-8M and 10-7M 24R,25(OH)2D3 significantly increased expression 
of the mesenchymal-associated transcription factor snail family transcriptional repressor 
1 (SNAI1) compared to cells treated with vehicle (Figure 6.4A). Expression of receptor 
tyrosine-protein kinase erbB-2 (ERBB2) and matrix metalloproteinase 1 (MMP1), which 
are associated with tumor aggression and matrix turnover respectively, was also 
increased by similar doses of 24R,25(OH)2D3, with the maximal effect at 10-7M(Figure 
6.4B, 6.4C). 24R,25(OH)2D3 had a biphasic effect on collagenase enzyme protein 
expression, with statistically significant induction of collagenase protein observed in 
cultures treated with 10-8M 24R,25(OH)2D3 (Figure 6.4D), and a non-significant increase 
in cultures treated with 10-7M 24R,25(OH)2D3. 24R,25(OH)2D3 (10-7M) stimulated a 4-fold 
increase in SNAI1 (Figure 6.4E), a 6-fold increase in ERBB2 expression (Figure 6.4F), a 
6-fold increase in MMP1 expression (Figure 6.4G), and a 10-fold increase in collagenase 
protein expression (Figure 6.4H) as compared to vehicle-treated cultures (Figure 6.4E-
H). This is in direct contrast to the effect of 24R,25(OH)2D3 on MCF7 cultures, where 10-
7M 24R,25(OH)2D3 reduced SNAI1, and all doses of 24R,25(OH)2D3 reduced ERBB2 and 
MMP1 transcript expression and reduced collagenase protein expression (Figure 6.4E-
H). 
24R,25(OH)2D3 also increased metastatic markers in HCC38 cultures. 10-7M 
24R,25(OH)2D3 increased chemokine receptor type 4 (CXCR4) to C-X-C- motif 
chemokine 12 (CXCL12) ratios (CXCR4/CXCL12) (Figure 6.4I). 10-8M 24R,25(OH)2D3 
decreased the ratio of osteoprotegerin (OPG) to receptor activator of nuclear factor 
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kappa-B ligand (RANKL) transcripts (OPG/RANKL) (Figure 6.4J) , and both 10-8M and 
10-7M 24R,25(OH)2D3 decreased OPG/RANKL protein expression (Figure 6.4K). 
Conditioned media from 24R,25(OH)2D3-treated HCC38 cells increased osteoclast 
activity more than conditioned media from vehicle-treated HCC38 cells (Figure 6.4L). 
24R,25(OH)2D3 increased osteoclast activity by 100% as compared to vehicle-treated 
cells. 10-7M 24R,25 induced a 10-fold increase CXCR4/CXCL12 ratios (Figure 6.4M), and 
a 2-fold decrease in OPG/RANKL ratios (Figure 6.4N, 6.4O) in HCC38 cells. Both 10-8M 
and 10-7M 24R,25(OH)2D3 decreased CXCR4/CXCL12 ratios and 10-9M and 10-7M 
increased OPG/RANKL transcript and protein expression ratios, respectively in MCF7 
cells. 
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Figure 6.4: 24R,25(OH)2D3 increases epithelial-to-mesenchymal transition and 
metastatic markers in HCC38 cultures. 
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(Figure 4, cont. from the previous page): HCC38 and MCF7 monolayer cultures 
were treated with 24R,25(OH)2D3 for 15 minutes and harvested 12 hours later for 
gene expression. Effect of dose-dependent 24R,25(OH)2D3 on gene expression of 
[A, E] snail, [B, F] her2, [C, G] MMP1, [D, H] collagenase protein, [I, M] CXCR4/ 
CXCL12 ratios, [J, N] OPG/ RANKL ratios, and [K, O] OPG/RANKL protein in [A-
D, I-L] HCC38 cells, but reduces them in MCF7 cells [E-H, M-O]. [L] 
24R,25(OH)2D3 increases osteoclast activity in osteoclasts treated with HCC38 
conditioned media from cultures treated with 24R,25(OH)2D3. Groups that share a 
letter are not significant at p<0.05. Treatment over control was calculated as the 
average fold-change of treatment as compared to vehicle-treated cultures in three 
or more experiments and analyzed with a paired t-test against normalized vehicle 
controls *indicates significance at P<0.05 as compared to vehicle-treated cultures.   
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24R,25(OH)2D3 increased cell migration in a scratch test assay. 12 hours after a 
wound was made on a confluent culture of HCC38 cells, wound size in cultures given a 
vehicle treatment had not significantly altered, while 10-10M 24R,25(OH)2D3 had slightly 
decreased wound size, and 10-7M 24R,25(OH)2D3 had reduced wound size to ~25% of 
its original area (Figure 6.5). 24 hours after the scratch test was initiated, all cultures had 
closed their wounds.  
 
 
Figure 6.5: Effect of 24R,25(OH)2D3 on cell migration in HCC38 cell monolayers. 
HCC38 monolayer cultures were treated with 24R,25(OH)2D3 for 15 minutes and 
incubated with fresh media. A scratch was made across the culture with a 1mL 
pipette tip, and monolayer cultures were observed over 24 hours for wound 
closure.  
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24R,25(OH)2D3 differentially regulates PLD and PKC activity in HCC38 and MCF7 cells. 
24R,25(OH)2D3 dose-dependently increases PLD activity in HCC38 cells, with the 
maximal effect occurring at 10-7M 24R,25(OH)2D3 (~3-fold increase as compared to 
vehicle-treated control cultures) (Figure 6.6A). However, 24R,25(OH)2D3 dose-
dependently decreases PLD activity in MCF7 cells, with 10-7M reducing PLD activity to 
25% that of vehicle-treated control cultures (Figure 6.6A). Treatment with 24R,25(OH)2D3 
did not change PKC activity in HCC38 cells (Figure 6.6B); however, it did slightly increase 
PKC activity in MCF7 cells (Figure 6.6B). Baseline PKC activity in MCF7 cells was ~2-
fold higher in MCF7 cells (~60 μU/μg protein/min) than in HCC38 cells (~30 μU/μg 
protein/min) (Figure 6.6B). 
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Figure 6.6 24R,25(OH)2D3 reduces total p53 levels through a caveolae-associated, 
PLD-dependent mechanism. 
HCC38 or MCF7 monolayer cultures were treated with 24R,25(OH)2D3  for 15 
minutes, and assessed for [A] PLD activity decreases or [B] PKC activity. In a 
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separate set of experiments, HCC38 monolayer cultures were treated with 
inhibitors for 30 minutes before treatment with 24R,25(OH)2D3 for 15 minutes and 
assessed for total p53 content. 24R,25(OH)2D3 reduced p53 levels in HCC38 cell 
monolayers, but this effect was prevented by treatment with [C] wortmannin to 
inhibit PLD activity, [D] 2-bromopalmitate to inhibit palmitoylation of nuclear 
receptors trafficked to the membrane, [E] methyl beta-cyclodextrin to deplete the 
membrane of cholesterol, and [F] short-hairpin RNA to silence caveolin-1. 
 
24R,25(OH)2D3 inhibited apoptosis through a caveolae-associated, PLD-dependent 
pathway.  
PLD inhibition with low-dose wortmannin prevented a 24R,25(OH)2D3-induced 
reduction in p53 (Figure 6.6Error! Reference source not found.C). High-dose 
wortmannin reduced p53 levels in HCC38 cultures, but treatment with 24R,25(OH)2D3 
reversed this effect and increased p53 levels back to baseline p53 levels in vehicle-
treated control HCC38 cultures (Figure 6.6Error! Reference source not found.C). 2-
bromopalmitate (2BP) was used to prevent trafficking of palmitoylated nuclear receptors 
to the membrane. Treatment with all doses of 2BP prevented a 24R,25(OH)2D3-induced 
reduction in total p53 levels (Figure 6.6Error! Reference source not found.D). Methyl 
β-cyclodextrin (MBC) was used to deplete the cell membrane of cholesterol and destroy 
caveolae and lipid rafts. Treatment with 1mM and 10mM MBC prevented a 
24R,25(OH)2D3-induced reduction in total p53 levels (Error! Reference source not 
found.Figure 6.6E).  
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To evaluate the role of the caveolae on 24R,25(OH)2D3 signaling in HCC38 cells, 
HCC38 cells were stably knocked down for caveolin-1 with shRNA (Figure 6.7). Caveolin-
1 knocked down HCC38 cells (shCAV1-HCC38) had <10% of wild-type caveolin-1 
protein, while empty control-transduced cells had >100% of wild-type caveolin-1 protein 
expression (Figure 6.7A). Caveolin-1 levels were similar for both clone #1 and clone #2 
shCAV1-HCC38 cells (Figure 6.7A, 6.7B). 24R,25(OH)2D3 reduced total p53 protein 
expression in wild-type and scramble control HCC38 cells, but did not affect shCAV1-
HCC38 cells. Baseline levels of p53 in shCAV1-HCC38 cultures were lower than wild-
type, and empty-control transduced HCC38 cultures (Error! Reference source not 
found.Figure 6.6F). 
 
 
Figure 6.7 Silencing CAV1 in HCC38 cells. 
Caveolin-1 was stably knocked down in HCC38 using a recombinant plasmid with a 
puromycin antibiotic selection marker. Four short-hairpin clones targeting the CAV1 gene 
were screened for caveolin-1 silencing, and the two best clones (8002, “clone 1”, and 
508, “clone 2”) were sub-cultured and expanded for further experiments. A separate set 
Modulation of 24R,25(OH)2D3 Tumorigenicity by ER Isoforms in E2-Responsive Cancer • Spring 2019 
Anjali Verma • Ph.D. Dissertation • Biomedical Engineering • Virginia Commonwealth University 184 
 
of HCC38 cultures was also transfected with an empty cassette vector as a control. [A] 
Caveolin-1 silencing by shRNA particles and [B] Representative western blot (n=1). 
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Overexpressing and silencing ERα changes the 24R,25(OH)2D3 response.  
ERα was transiently overexpressed in HCC38 cells (Figure 6.8A-D) and stably 
overexpressed in C2C12 (Figure 6.9A-C). ERα66 expression in ESR1-transfected 
HCC38 cells (ovER-HCC38) was 20-times greater than wild-type HCC38 cells and 16-
times greater than empty-control HCC38 cells (Figure 6.8C). ERα36 was 2.3-times 
greater in ESR1-transfected vs. wild-type HCC38 and 3-times greater than ORF-control 
HCC38 cells (Figure 6.8D). In C2C12 cells, ESR1-transfected C2C12 cells (ovER-
C2C12) expressed 11-times more ERα66 protein expression than wild-type C2C12 cells 
(Figure 6.9A), and 2.8-times more ERα36 than wild-type C2C12 (Figure 6.9B, 6.9C).  
24R,25(OH)2D3 induced apoptosis in cells that do not express ERα66 but induced 
apoptosis in cells that express ERα66. In wild-type and ORF-control HCC38 cells, which 
express very low levels of ERα66 (Figure 6.8B, 6.8C), all doses of 24R,25(OH)2D3 
prevented apoptosis as measured by BAX/BCL2 (Figure 6.11A) and total p53 levels 
(Figure 6.11B). However, treatment with 10-8M 24R,25(OH)2D3 induced apoptosis in 
ovERα-HCC38 cells (Figure 6.11A, 6.11B) as measured by both BAX/BCL2 and total p53. 
10-7M 24R,25(OH)2D3 upregulated BAX/BCL2 ratios in ovER-HCC38 (Figure 6.11A). 
24R,25(OH)2D3 had a biphasic effect on total p53 levels in ovER-HCC38. 10-8 
24R,25(OH)2D3 increased total p53 protein in ovER-HCC38, but 10-7M 24R,25(OH)2D3 
did not affect p53 (Figure 6.11). Wild-type and ORF-control HCC38 cells had similar 
baseline ratios of BAX/BCL2 mRNA (Figure 6.11A) and similar baseline levels of total 
p53 protein (Figure 6.11B), but ovER-HCC38 cells had lower ratios of BAX/BCL2 mRNA 
and lower baseline p53 than wild-type HCC38 (Figure 6.11A,  6.11B).  
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Figure 6.8 Overexpression of ESR1 in HCC38 changes ERα isoform expression. 
 [A] ERα and an empty control were transiently transfected in HCC38 using a recombinant 
plasmid with a GFP reporter gene. 48 hours after transfection, cells were assessed for 
ERα isoform expression by [B] western blot (representative image, n=1) and [C] ERα66 
and [D] ERα36 protein expression were quantified (OV = overexpressed; KD = 
knockdown as compared to WT).  
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Figure 6.9 Overexpression of ESR1 in C2C12. 
ERα was stably overexpressed in C2C12 using a recombinant plasmid with a G418 
antibiotic selection marker. ovERα-C2C12 cells were selected for G418 resistance and 
assessed for protein expression via western blot. [A] ERα66 and [B] ERα36 protein 
expression were quantified (n=1) to confirm overexpression of ERα isoforms as compared 
to WT. [C] Representative western blot (n=1). 
 
In C2C12 muscle cells, which express low levels of ERα66 (Figure 6.9A), 
24R,25(OH)2D3 had an anti-apoptotic effect as measured by BAX/BCL2 mRNA ratios, but 
upregulated BAX/BCL2 mRNA ratios in ovERα-C2C12 cells (Figure 6.11C). Wild-type 
C2C12 cultures had higher baseline BAX/BCL2 mRNA ratios than ovERα-C2C12 cultures 
(Figure 6.11C). 24R,25(OH)2D3 did not affect total p53 levels in wild-type C2C12 cells but 
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increased total p53 in ovERα-C2C12 (Figure 6.11D). Baseline total p53 was higher in 
ovERα-C2C12 cells than in wild-type C2C12 (Figure 6.11D). In both C2C12 and HCC38 
cells, transfecting with ESR1 to overexpress the ERα isoforms changed the cell response 
to 24R,25(OH)2D3. 24R,25(OH)2D3 stimulated apoptosis in all HCC38 and C2C12 
cultures that overexpressed ERα66 (Figure 6.11A-D). 
ERα66 was stably knocked down in MCF7 cells (Figure 6.10A, 6.10C). Knocked 
down MCF7 (shESR1-MCF7) cells had approximately one-third the ERα66 expression of 
wild-type MCF7 cells, while scrambled controls had >80% of wild-type MCF7 cells 
expression Figure 6.10A. ER36 levels were similar for wild-type, scramble control, and 
shESR1-MCF7 cells, with the scrambled control and the shESR1-MCF7 cells expressing 
~90% as much ER36 as wild-type cells (Figure 6.10B, 6.10C). 
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Figure 6.10 ERα66 was stably knocked down in MCF7 using a recombinant plasmid 
with a puromycin antibiotic resistant selection marker. 
shESR1 and scramble-control cells were selected for puromycin resistance and assessed 
for protein expression via western blot. [A] ERα66 and [B] ERα36 protein expression were 
quantified (n=1) to confirm silencing of ERα66 as compared to WT. [C] Representative 
western blot (n=1). 
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24R,25(OH)2D3 upregulated BAX/BCL2 mRNA ratios and increased total p53 
levels in wild-type and scrambled MCF7 cells at 10-8M (Figure 6.11E, 6.11F). 
24R,25(OH)2D3 had no effect on BAX/BCL2 mRNA ratios or total p53 levels in shESR1-
MCF7 cells (Figure 6.11E, 6.11F). Baseline BAX/BCL2 mRNA ratios and total p53 were 
the same in wild-type, scrambled, and shESR1 MCF7 cells. In wild-type, MCF7 cells, 10-
7M 24R,25(OH)2D3 also increased phosphorylated p53 but did not increase 
phosphorylated p53 in cultures that were knocked down for ERα66 (Figure 6.12). While 
24R,25(OH)2D3 increased the average amount of phosphorylated p53 in scramble-control 
MCF7 cells as compared to vehicle-treated scramble-control MCF7 cells, this change was 
not statistically significant. Similarly, 10-7M 24R,25(OH)2D3 reduced average 
phosphorylated p53 in shESR1-MCF7 cells as compared to vehicle-treated shESR1-
MCF7 cells; however, this difference was not statistically significant. Baseline 
phosphorylated p53 was not statistically different between wild-type, scrambled, and 
shESR1-MCF7 cells (Figure 6.12). 
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Figure 6.11: Expression and silencing of ERα isoforms change the 24R,25(OH)2D3 
response. 
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(Figure 7, cont. from the previous page):  
Overexpressing all ERα isoforms reversed the 24R,25(OH)2D3 anti-apoptotic 
effect in [A, B] HCC38 cells and [C, D] C2C12 cells. 24R,25(OH)2D3 prevented 
apoptosis as measured by [A] BAX/BCL2 and [B] total p53 levels in wild-type 
HCC38 and HCC38 cells transfected with an empty control vector, but induced 
apoptosis in ERα-transfected HCC38 cells. In C2C12 muscle cells, 24R,25(OH)2D3 
prevented or did not induce apoptosis in wild-type cells but induced apoptosis in 
ERα-transfected cells as measured by [C] BAX/BCL2 and had no effect on 
apoptosis as measured by [D] total p53 levels in wild-type cells. Silencing the 
ERα66 isoform reversed the pro-apoptotic effect of 24R,25(OH)2D3 on [E, F] MCF7 
cells. 24R,25(OH)2D3 induced apoptosis as measured by [E] BAX/BCL2 and [F] 
total p53 levels in wild-type and scramble-control MCF7 cells, but had no effect on 
apoptosis in ER66-knocked down MCF7 cells. 
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Figure 6.12 Silencing the ERα66 isoform reversed the pro-apoptotic effect of 
24R,25(OH)2D3 on MCF7 cells. 
24R,25(OH)2D3 significantly increased phosphorylated p53 levels in wild-type MCF7 cells 
and qualitatively increased phosphorylated p53 in scramble-control MCF7 cells. In MCF7 
cells knocked down for ER66, 24R,25(OH)2D3 qualitatively decreased average 
phosphorylated p53. 
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Discussion 
Vitamin D metabolites may have anti-tumorigenic properties in breast cancer; 
however, many vitamin D3 metabolites are highly calcemic and have narrow therapeutic 
windows (34). Previously we identified an alternative endogenous vitamin D3 metabolite, 
24R,25(OH)2D3, which has anti-tumorigenic and pro-apoptotic effects in the ER66-
positive breast cancer cell lines MCF7 and T47D(21) but, unlike other vitamin D3 
metabolites, 24R,25(OH)2D3 is not calcemic at therapeutic doses (21,35). However, 
recent studies have shown that vitamin D supplementation may not be beneficial for all 
cancer patients (5,6), and some studies have shown that patients with estrogen receptor 
positive (ER66+) breast cancer benefit from vitamin D supplements, but patients with 
estrogen receptor negative (ER66-) breast cancer do not (4,7,36). The dependence of 
the estrogen receptor and its isoforms on the tumorigenicity of vitamin D metabolites is 
an understudied area of breast cancer research, and more investigation into the crosstalk 
between estrogen receptors and vitamin D metabolites is necessary to refine treatment 
protocols and vitamin D supplement regimens.  
In this paper, the effects of 24R,25(OH)2D3 were investigated in vivo in an HCC38 
xenograft orthotopic mammary fat pad model of breast cancer in an immuno-
compromised NSG mouse, and in vitro in cell monolayer cultures of HCC38. The effects 
of 24R,25(OH)2D3 on models of HCC38 (ER66-) breast cancer were contrasted with the 
effects of 24R,25(OH)2D3 in MCF7 (ER66+); the ER66 receptor was overexpressed 
and silenced in HCC38, MCF7, and a third unrelated cell line, C2C12, to understand how 
the expression of ER66 modulates the effect of 24R,25(OH)2D3. Although 
24R,25(OH)2D3 was not calcemic in vivo, treatment with 24R,25(OH)2D3 increased tumor 
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burden and decreased animal survival in mice with HCC38 (ER66-) xenografts. In vitro, 
24R,25(OH)2D3 specifically decreased apoptosis and increased proliferation, metastasis, 
and migration in HCC38 (ER66-) cells. This pro-tumorigenic effect is in direct contrast 
to the pro-apoptotic and anti-metastatic effects of 24R,25(OH)2D3 on MCF7 cells 
(ER66+). Overexpressing and silencing ER66 found that in cells that do not express 
ER66, 24R,25(OH)2D3 does not stimulate apoptosis and may be tumorigenic. In cells 
that express ER66, 24R,25(OH)2D3 is pro-apoptotic and anti-tumorigenic. Our results 
suggest that ER66 directly modulates the apoptotic effects of 24R,25(OH)2D3. 
Our previous work showed that 24R,25(OH)2D3 is anti-tumorigenic in mammary fat 
pad xenografts of MCF7 (ER66+) in NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice. Here, 
we use a similar in vivo model to test the effects of 24R,25(OH)2D3 on tumor burden in 
mammary fat pad xenografts of HCC38 (ER66-) in NSG mice. These models allowed 
us to study the effects of 24R,25(OH)2D3 directly on the tumor, rather than the direct and 
indirect effects of 24R,25(OH)2D3 on the tumor and concomitant immunity. However, it is 
important to note that 24R,25(OH)2D3 has been shown to modulate the immune system, 
and clinically 24R,25(OH)2D3 could also indirectly affect tumor invasion and metastasis. 
Other studies have shown that both 1,25(OH)2D3 and 24R,25(OH)2D3 can alter the 
production of pro-and anti-inflammatory cytokines (16,17). 1α,25(OH)2D3 reduced the 
production of tumor necrosis factor α (TNFα) and interleukin-10 (IL-6) by tumor-
associated monocytes (17). In our lab, we have shown that 24R,25(OH)2D3 reduced 
serum levels of TNFα, IL-6, interleukin-1α, interleukin-1β, and other pro-inflammatory 
factors in Sprague-Dawley rats with surgically transected anterior crucial ligaments (16). 
While studies in this paper with immune compromised animals have shown that 
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24R,25(OH)2D3 is capable of directly modulating tumor growth in vivo, it is possible that 
24R,25(OH)2D3 may also alter the immune-regulation of carcinomas in 
immunocompetent animals, and more studies are required to explore this possibility 
further. 
Previous results by our lab and others have shown that 24R,25(OH)2D3 has anti-
carcinogenic properties, particularly in models of breast, lung, and glandular stomach 
carcinomas (18,19,21). However, high expression of 24-hydroxylase (CYP24A1), the 
enzyme responsible for metabolizing 25(OH)D3 into 24R,25(OH)2D3, is associated with 
increased tumor aggression in several cancers including breast cancer (18–20,37). 
24R,25(OH)2D3 has been shown to act both directly on several cell types such as bone, 
cartilage, kidney, and cancer cells, and indirectly by increasing the production of 1α-
hydroxylated vitamin D3 metabolites in vivo (38,39). Physiologically, 24R,25(OH)2D3 
increases the expression of 1-hydroxylase (CYP27B1) and 1α,25(OH)2D3, in turn, 
increases the expression of 24-hydroxylase (CYP24A1) (40). While HCC38 cells express 
both CYP24A1 and CYP27B1, our results and others have shown that MCF7 cells 
express CYP27B1 but do not express CYP24A1 (37,41). 1α,25(OH)2D3, a product of 
CYP27B1 activity, has been shown to have anti-tumorigenic activity in MCF7 cells in vivo 
and in vitro (42,43). CYP24A1 is a commonly mutated gene in cancers (44), and further 
study is needed to determine whether the tumorigenicity of 24R,25(OH)2D3 is related to 
native CYP24A1 expression within the tumor. It is possible that the MCF7 cells respond 
anti-tumorigenically to 24R,25(OH)2D3 because they are CYP24A1 negative, and this 
point should be explored further in future studies. Previous studies in our lab show that 
MCF7 cells respond with the greatest fold-change to 10-8M 24R,25(OH)2D3 (21), while in 
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this paper we show that HCC38 cells are more sensitive to 10-7M 24R,25(OH)2D3. This, 
coupled with the lack of CYP24A1 expression in MCF7, may indicate that MCF7 cells are 
more sensitive to 24R,25(OH)2D3 than HCC38 cells. This sensitivity may be a result of an 
increase in CYP27B1 and 1α-hydroxylated vitamin D3 metabolite. Furthermore, our 
results with  24R,25(OH)2D3 on MCF7 and HCC38 cells may not be reflective of the direct 
effects of 24R,25(OH)2D3, but could be a result of shifting proportions of other vitamin D3 
metabolites caused by an influx of 24R,25(OH)2D3. 
However, our data on the effect of 24R,25(OH)2D3 on phospholipase D (PLD) and 
protein kinase C (PKC) activity in breast cancer cells suggest that 24R,25(OH)2D3 can 
directly affect breast cancer cells. In male rat resting zone chondrocytes, the rapid actions 
of 24R,25(OH)2D3 are mediated by PLD, while the rapid actions of both 17β-estradiol and 
1α,25(OH)2D3 are mediated by protein kinase C (PKC) (45). Our data show a similar 
effect, with 24R,25(OH)2D3 rapidly changing PLD activity in both HCC38 and MCF7, but 
not affecting PKC activity in HCC38 cells at the same time point. 24R,25(OH)2D3  slightly 
increased PKC activity in MCF7 cells at high doses, but this effect had a smaller fold 
change than the effect size of 24R,25(OH)2D3 on PLD activity in MCF7 cells. The rapid 
effect of 24R,25(OH)2D3 on PLD rather than PKC activity in HCC38 and MCF7 cells 
suggests that in vitro, 24R,25(OH)2D3 acts directly on both HCC38 cells and MCF7 cells 
rather than stimulating the production of another vitamin D3 metabolite which is 
responsible for the effects of 24R,25(OH)2D3 on apoptosis, epithelial-to-mesenchymal 
transition, migration, and metastatic markers in these cells.  
The connection between 24R,25(OH)2D3 and ER66 has implications for many 
different cell types and tissues. Firstly, 24R,25(OH)2D3 has an established 
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chondroprotective effect and may prevent bone resorption by limiting calcium efflux in 
cartilage and bone cells (46). Post-menopausal women have a higher incidence of 
osteoarthritis than men of similar ages (47,48), and the extremely low levels of circulating 
estradiol in post-menopausal women have been implicated in this discrepancy (48,49); 
estradiol has a protective effect on bone, bone resorption, cartilage (48,50). Treatment 
with 24R,25(OH)2D3 has been proposed as a potential therapeutic for osteoarthritis 
patients, as 24R,25(OH)2D3 prevents oxidative damage and apoptosis in chondrocytes 
(16). However, all previous research on the chondroprotective effects of 24R,25(OH)2D3 
has previously been done in male chondrocytes (16), who have higher circulating 
estradiol than post-menopausal women and lower expression of ER66 (48,51,52). 
Further research on 24R,25(OH)2D3 and ER66 should be done to ensure that the 
chondroprotective effects of 24R,25(OH)2D3 are clinically applicable to both men and 
women, and male and female chondrocytes may be an appropriate model to further 
investigate crosstalk between 24R,25(OH)2D3 and ERα. 
Secondly, 24R,25(OH)2D3 is a naturally occurring ubiquitous metabolite of vitamin 
D3. Serum 24R,25(OH)2D3 is present at higher levels in the blood than 1,25(OH)2D3, the 
more commonly studied active metabolite of vitamin D3 (53). Women with breast cancer 
have been reported to take vitamin D3 supplements at a higher rate than the general 
population (4), and some of that supplemental vitamin D3 is undoubtedly getting 
metabolized into 24R,25(OH)2D3 (54). Further investigation into the benefits of taking 
vitamin D3 supplements for patients with ER66+ and ER66- breast cancer needs to be 
conducted, as our results imply that women with ER66- breast cancer may be 
aggravating their tumors by taking excess vitamin D3. 
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Conclusion 
In summary, 24R,25(OH)2D3 modulates apoptosis and tumorigenicity in breast 
cancer cells through an ERα66-associated pathway. In ERα66-negative breast tumors, 
24R,25(OH)2D3 increases tumor burden, migration, and metastasis, and may decrease 
survival. In ERα66-positive tumors, 24R,25(OH)2D3 induces apoptosis and reduces tumor 
burden. Our results show that overexpressing ERα66 in wild-type ERα66-negative 
HCC38 cells reverses the anti-apoptotic effect of 24R,25(OH)2D3 and causes treatment 
with 24R,25(OH)2D3 to induce apoptosis; likewise, silencing ERα66 in wild-type ERα66-
positive MCF7 cells eliminates the pro-apoptotic effect of 24R,25(OH)2D3. Our results with 
C2C12, an unrelated cell line, showed that the regulation of the 24R,25(OH)2D3 effect by 
ERα66 is not limited to breast cancer cells; rather, treatment with 24R,25(OH)2D3 induced 
apoptosis in ERα66-overexpressing C2C12 cells. Our data show that ERα66 is a 
modulator of the apoptotic effect of 24R,25(OH)2D3 in a diverse array of cell lines, and 
should inform diverse research areas such as the implications of vitamin D 
supplementation in breast cancer patients and the potential of 24R,25(OH)2D3 as a 
therapeutic in male vs. female osteoarthritis patients. 
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Chapter 7.  
Conclusions and Future Perspectives 
Although high serum 25(OH)D3 is often associated with improved prognosis and 
reduced risk of tumor recurrence in breast cancer patients, double-blind clinical trials 
investigating the efficacy of vitamin D3 supplementation in cancer have been inconclusive. 
This is in part because breast cancer is a multifaceted disease with genetic and 
phenotypic variations. As such, the idea of making blanket treatment recommendations 
on vitamin D3 supplementation may be as impractical as suggesting a single, defined cure 
for all types of breast cancer. Preliminary research on vitamin D3 supplementation in 
breast cancer suggests that ER+ patients may benefit from vitamin D3 supplementation, 
but ER- patients may not. This thesis demonstrates that 24R,25(OH)2D3 is functionally 
active in breast cancer cells and that the tumorigenicity of 24R,25(OH)2D3 is regulated in 
part by ERα66.Furthermore, this work suggests that crosstalk between 24R,25(OH)2D3 
and ERα66 may not be cell-type specific, and the actions of 24R,25(OH)2D3 on apoptosis 
may have implications for other disease states.  
Like other steroid hormones, 24R,25(OH)2D3 has been found to initiate multiple 
rapid signaling pathways from the cell membrane in chondrocytes, and a membrane 
receptor has been implicated, which remains the subject of active investigation. Here, we 
show evidence that the rapid actions of 24R,25(OH)2D3 are conserved across cell types, 
with 24R,25(OH)2D3 regulating proliferation and apoptosis in MCF7, HCC38, and C2C12 
cells – three unrelated cell lines from different species, tissues, and with different ERα 
profiles. Furthermore, the regulation of proliferation and apoptosis by 24R,25(OH)2D3 was 
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specific to the ‘R’ enantiomer. 24S,25(OH)2D3 did not have an effect on apoptosis in either 
MCF7 or HCC38 cells.  
Our results also demonstrated that in MCF7 and HCC38 cells, 24R,25(OH)2D3 
stimulates PLD at 9 minutes. Extensive studies in chondrocytes have shown that 
24R,25(OH)2D3 also stimulates PLD after 9 minutes15.  In proliferative chondrocytes, 
24R,25(OH)2D3 has been shown to prevent apoptosis through a PLD-dependent 
mechanism by promoting p53 degradation via ubiquitination. This is similar to the 
mechanism we observed in HCC38 breast cancer cells, where 24R,25(OH)2D3 prevented 
apoptosis by decreasing p53 production. This suggests that 24R,25(OH)2D3 regulates 
apoptosis in proliferating chondrocytes and ERα66-negative breast cancer cells through 
the same PLD, p53-dependent mechanism.  
Many of the second messengers of the rapid signaling pathway of 24R,25(OH)2D3, 
such as PLD and PKC, are also implicated in 17β-estradiol (E2) signaling through the 
membrane receptor ERα36. Our results show that E2 signaling through ERα36 is 
tumorigenic in laryngeal cancer as well as breast cancer, suggesting that E2 signaling 
through ERα36 might also regulate apoptosis in other disease states. We also show that, 
as in breast cancer, ERα66-, ERα36+ laryngeal cancer is more aggressive than its 
ERα66+, ERα36+ counterparts.  
Many of the rapid signaling pathways activated by E2 binding to ERα36 in laryngeal 
cancer are also activated by 24R,25(OH)2D3 in breast cancer. Our results suggest that 
the rapid actions of 24R,25(OH)2D3 in MCF7 (ERα66+, ERα36+) breast cancer cells may 
be modulated by a membrane-mediated, caveolae-localized pathway employing a 
palmitoylated nuclear receptor to stimulate PLD with downstream regulatory effects on 
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apoptosis, proliferation, migration, and metastasis. In MCF7 (ERα66+, ERα36+), 
24R,25(OH)2D3 confers a chemoprotective effect against breast cancer cells in vitro and 
in vivo to prevent tumorigenesis and reduce metastasis. 
Our work with MCF7 (ERα66+, ERα36+) showed that the chemoprotective effects 
of  24R,25(OH)2D3 were dependent upon activation of isoforms of ERα in this cell line. 
This suggested that ERα isoforms may modulate 24R,25(OH)2D3 in breast cancer cells. 
The effects of 24R,25(OH)2D3 on tumorigenicity were examined in a second cell line, 
HCC38, which does not express ERα66 (ERα66-, ERα36+). 24R,25(OH)2D3 was 
tumorigenic in HCC38 (ERα66-, ERα36+), and this tumorigenicity was initiated by a PLD-
dependent signaling mechanism. Overexpressing ERα66 in HCC38 (ERα66-, ERα36+) 
reversed the tumorigenic effects of 24R,25(OH)2D3, suggesting that ERα66 may 
modulate the rapid actions of 24R,25(OH)2D3. We also overexpressed ERα66 and ERα36 
in an unrelated cell line, C2C12, and found that 24R,25(OH)2D3 increased apoptosis in 
C2C12 cells that overexpressed ERα66 and ERα36. And wild-type MCF7 (ERα66+, 
ERα36+)  and ERα66-silenced MCF7 (ERα66-, ERα36+) were tested for 24R,25(OH)2D3-
induced apoptosis, and we found that in wild-type and scramble-transfected MCF7 cells, 
24R,25(OH)2D3 induced apoptosis; however in ERα66-silenced MCF7 cells, 
24R,25(OH)2D3 did not stimulate apoptosis. This demonstrates that the pro-apoptotic 
effect of 24R,25(OH)2D3 is dependent upon the ERα66 isoform across cell lines. 
The implications of this in the wake of similarities between 24R,25(OH)2D3 
signaling in chondrocytes, MCF7, and HCC38 cells are interesting. The 24R,25(OH)2D3 
signaling pathway was discovered and tested in male rat chondrocytes, where 
24R,25(OH)2D3 was found to prevent apoptosis. Male rat chondrocytes express all 
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isoforms of ERα, including ERα66 and ERα36. However, female rat chondrocytes 
express roughly equal amounts of ERα66 in the plasma membrane, caveolae, and 
nucleus324. Male rat chondrocytes expressed more ERα66 in the plasma membrane and 
caveolae fraction than in the nucleus. Furthermore, ERα36 was found at similar levels in 
the plasma membrane and nucleus of female rat chondrocytes. However male rat 
chondrocytes only expressed ERα36 in the nucleus, and did not express detectable levels 
of ERα36 in the plasma membrane or the caveolae324. It is worth noting that ERβ levels 
were the same in female and male rat chondrocytes324. Similarly, MCF7 cells express 
high levels of ERα isoforms in the plasma membrane and nucleus, while HCC38 cells 
only express ERα isoforms in the membrane1,27. Perhaps the pro-apoptotic effects of 
24R,25(OH)2D3 are regulated not by ERα66 itself, but by an abundance of nuclear ERα 
isoforms rather than an abundance of membrane ERα isoforms. 
This work provides a foundation for the further investigation of 24R,25(OH)2D3 as 
a modulator of tumorigenicity in breast cancer, and suggests that vitamin D3 
supplementation should only be considered for patients with ER+, or ERα66+, breast 
cancer. Our lab has begun developing a means of assessing 24R,25(OH)2D3 metabolite 
expression by HPLC. We plan to use this technique to measure the local production of 
24R,25(OH)2D3 in breast tissue. Later on, we plan to assess 24R,25(OH)2D3 metabolite 
levels in banked serum samples from breast cancer patients. A meta-analysis can be 
conducted to assess correlations between circulating 24R,25(OH)2D3 metabolite 
expression and ERα66 and ERα36 expression in breast cancer.  
Preliminary results from these studies also suggest that 24R,25(OH)2D3 can alter 
markers of osteoclast activation in breast tumors. In MCF7 (ERα66+, ERα36+) 
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24R,25(OH)2D3 reduced markers of osteoclast activation and in HCC38 (ERα66-, 
ERα36+) 24R,25(OH)2D3 enhanced markers of osteoclast activation and osteoclast 
activity in HCC38. Stage 4 ER+ breast cancer commonly metastasizes to the long bone 
and spine, and 5-year survival rates for patients with late-stage bone metastasis are 
around 22%. 24R,25(OH)2D3 may have potential as a therapeutic for these patients. Our 
lab has established a model of breast tumor osteolysis in murine femurs, and we are 
planning to examine the effect of 24R,25(OH)2D3 on models of ER+ and ER-breast cancer 
metastasis in mice. If these pre-clinical studies show that 24R,25(OH)2D3 is efficacious 
against ER+ breast cancer metastasis, we would suggest a clinical trial on the use of 
24R,25(OH)2D3 supplementation in breast cancer patients.  
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